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SUMMARY.
Micro and macro peripheral blood cultures were set up from 
185.test (mothers who had taken oral contraceptives) and 181 control 
mothers. Cord bloods were collected from infants of these mothers at 
the time of delivery. In a pilot study, mitotic indices were used to 
determine the best culture technique.
The cytogenetic characteristics of the peripheral lymphocytes from the 
mothers and babies were then evaluated. It was found that there was 
’no significant difference in the frequency or type of chromosome 
abnormalities between the test and control mothers. However, there 
was found to be an increase in the numbers of triploid cells and 
structural aberrations in the test babies group compared to the 
control group.
Maternal age, previous obstetric, history, menstrual history, 
present pregnancy history, length of time the test mothers had been 
taking oral contraceptives, the interval between discontinuation and 
pregnancy, and the constituents of the contraceptives were not found 
to significantly affect the numbers and types of chromosome abnormalities. 
No increase in chromosome abnormalities was observed in the mothers 
who had been exposed to various additional hazards, such as X-rays, 
illnesses and drugs.
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INTRODUCTION
1. Brief History and Development of the Oral Contraceptive.
Although it was known since early 1939 (Sturgis and Albright 1940) 
that oestrogens were useful in inhibiting ovulation in women, oral 
contraceptives have been available for general use only within 
the last decade. Hamblen and colleagues had investigated the 
anti-ovulatory effect of oestrogens in 1941 and finally concluded 
that these compounds were not effective in consistently inhibiting 
ovulation. However, earlier work carried out by Makepeace and 
workers in 1937 had demonstrated that progesterone can inhibit 
ovulation in rabbits. The latter observation was subsequently 
substantiated by Pincus and Chang (1953) who, using synthetic 
progestagens obtained from Searle and Syntex Laboratories, U.S.A., 
showed that these compounds were orally active steroids with 
biological properties of progesterone.
The studies of Pincus and coworkers (1956) further demonstrated 
that norethynodrel, norethisterone and 17 cC-ethinyl-19-norethisterone 
were much more effective than progesterone alone in inhibiting ovulation 
in rabbits. These tests were carried out in oestrous rabbits which 
do not ovulate normally until, approximately 10 hours after 
mating. Progesterone and the synthetic progestagens were injected 
at a dose of 1 - 2 mg per rabbit, 24 hours before mating and 
ovulation was inhibited in 50 - 100% of the animals. The 
progestagens tested proved to be more powerful inhibitors of 
ovulation than progesterone (Pincus and coworkers 1953 and 1956). 
Similarly, Hertz and colleagues (1954) reported from their studies 
that 17-ethyl-19-nortestosterone was an orally effective progestagen, 
and norethynodrel, a related progestagen, was subsequently 
synthesized and used in the first oral contraceptive.
Although much valuable preliminary information can be obtained 
by studying the effects of oral contraceptive compounds in 
experimental animals, the potency of these compounds, as assessed 
by animal studies, may not always be relevant to their effectiveness 
in the human. The initial results of a clinical trial in Puerto 
Rico were reported at a Symposium in 1957 by Pincus (1957) and 
Rice-Wray (1957) with favourable results and, as a consequence, 
the contraceptive Enovid, was released. This was done firstly 
for menstrual disorders in 1957* and then as an oral contraceptive 
in I960.
A number of surveys have since been carried out to test the
efficacy of these preparations. Swyer and Little (1968) compared
a number of progestagens at different dose levels, with and without
oestrogen, with respect to their ability to postpone menstruation
in normal women given 20 day courses of progestagen. It was found
that higher doses of progestagen were associated with scanty
withdrawal bleeding, while lower doses resulted in breakthrough 
%
bleeding. It has been suggested that a higher dose of oestrogen 
(80 yug) instead of 50 yug mestranol may be needed in some women 
to avoid this spotting and breakthrough bleeding.
The variations of oestrogen doses have also been studied from 
the point of view of contraceptive effectiveness. A number of 
investigators (Jackson and workers, 1968; Miyamoto, 1970;
Goldzieter and colleagues, 1964)* studied the effectiveness of 
various doses of either ethinyl oestradiol or mestranol, in the 
initial portion of a sequential regimen or in combination with a 
progestagen. The results of a study by Martinez-Manautou and 
Rudel (1966) implied that a dose of 80 yug mestranol was necessary 
to produce the same and acceptable degree of ovulatory inhibition 
as 50 ng of ethinyl oestradiol.
The results of a subsequent study (Jackson and workers, 1968) 
showed that a daily dose of 100 yug ethinyl oestradiol was necessary 
to inhibit ovulation consistently, and subsequent work by Miyamoto 
(1970) has substantiated these findings.
The sequential system consists of 21 to 23 oestrogen tablets 
supplemented during the last 5 or 7 days by the addition of a 
progesta^n. The serial system from which continuous combination 
regimens evolved, includes 7 placebo tablets to make up a 28-day 
cycle of treatment (Liggins 1964). Sequential products contain 
-either 75 or 80 yug of oestrogen. Unlike combination preparations 
this dose cannot be reduced to 50yug without loss of effectiveness. 
Since the pregnancy rate during sequential contraception is marginally 
greater than that with the combination therapy it is unlikely that 
new formulations containing lower doses of oestrogens will be 
marketed.
2. Chemistry of the Oral Contraceptive.
The chemical structure of the two oestrogens and eight 
progestagens present in the commercially available oral 
contraceptives are shown in diagrams 1 - 10. Oestradiol is not 
active orally; but addition of the 17©^-ethinyl radical however, 
as in ethinyl oestradiol and it%£r- 3-methyl ester which is 
mestranol, renders the molecule active orally (Allen 1970).
On the basis of chemical structure, there are two classes 
of steroids used as progestagens in oral contraceptives. The 
first group, shown in diagrams 3 - 8, is structurally related to 
19-nortestosterone, norethisterone, norethisterone acetate and 
norgestrel, all of which possess some androgenicity while 
norethynodrel has oestrogenic activity. The other group of 
progestagens is structurally related to 17°^-hydroxyprogesterone.
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This steroid has no activity when administered orally and further- 
more, the derivatives of the progesterone molecule are not easily 
obtainable (Allen 1970). However, 17-acetoxy-progesterone is quite 
active orally and is a potent progestagen. Both megestrol and 
chlormadinone acetate can be derived from this compound. The 
various constituents and brand names of some of the most'commonly 
used oral contraceptives are shown in Table 1.
3. Mechanism of Action.
The biological activities of the oral contraceptives have 
been studied in some detail by Saunders in 1970* He postulated 
that in untreated women, certain factors are released from the 
hypothalamus and as a result stimulation of follicle stimulating 
(FSH) and luteinising hormones (LH) from the pituitary is brought 
about. These hormones act on the ovary to produce follicle growth 
and maturation, ovulation, and corpus luteum formation. They also 
stimulate ovarian secretion of oestrogens and progesterone which 
in turn act on target tissues, for example the uterus and mammary 
gland.
When oral contraceptives are ingested, the steroid acts on the 
hypothalamus and inhibits the production of FSH and LH and there­
fore, follicle stimulation does not occur. Ovarian steroid 
production is essentially eliminated and follicular maturation 
does not occur. However, the oestrogen and the progesterone 
present in the oral contraceptive serve to develop and maintain 
the uterus and other target organs and thus a simulated cycle 
is still observed. This is because the synthetic hormones 
exert a negative feedback on the hypothalamus in a manner similar 
to that by which naturally occuring hormones act. The major
Table 1 : Information of various Oral Contraceptives.
BRAND NAME OF 
ORAL 
CONTRACEPTIVE
MANUFACTURER CONSTITUENTS OF THE 
ORAL CONTRACEPTIVES
m.g.
COMBINATION1
Anovlar Schering Norethisterone acetate 
Ethinyloestradiol
4.00
0.05
Conovid Searle Norethynodrel
Mestranol
5.00
0.075
Conovid E Searle Norethynodrel
Mestranol
2.50
0.10
Eugynon Schering Ethinyloestradiol 
d 1 norgestrel
0.05
0.50
Gynovlar Schering Norethisterone acetate 
Ethinyloestradiol
3.00
0.05
Lyndiol 2,5 Organon Lynestrenol
Mestranol
2.50
0.075
Minovlar Schering Norethisterone acetate 
Ethinyloestradiol
1.00
0.05
Norinyl Syntex Norethisterone
Mestranol
1.00 
0.0 5
Norlestrin Parke Davis & 
Co.
Norethisterone
Mestranol
2.50
0.05
Nuvacon B.D.H. Megestrol acetate 
Ethinyloestradiol
2.00
0.10
Ortho - Novum Ortho Norethisterone
Mestranol
1.00
0.05
Ovulen Searle Ethynodiol diacetate 
Ethinyloestradiol
1.00
0.05
Volidan B.D.H.
SEQUENTIAL
Megestrol acetate 
Ethinyloestradiol
4.00
0.05
Serial 28 B.D.H. Mestranol —' I6days 
Megestrol acetate _ , - 
Ethinyloestradiol ” a^s
0.10
1.00
0.10
Sequens Lilly 
PROGESTAGEN ONLY
Mestranol
Chlormadinone acetate 
>RAL CONTRACEPTIVES.
0.08
2.00
Normenon Syntex Chlormadinone acetate 0.05
difference however, is that oral contraceptives provide a constant 
(inhibitory) dosage, a steady supply of synthetic ovarian hormones, 
in contrast to the changing levels of naturally occuring steroids 
provided during the normal untreated cycle (Bingel and Benoit 1973)• 
It is established that the long term usuage of combined oral 
contraceptive preparations results in the inhibition of ovulation 
and evidence for this is seen by the appearance of the ovaries 
at laparotomy. The ovaries are reduced in size and acquire a 
smooth surface and, it is likely, that similar changes take place 
in the ovaries of women on long term sequential contraceptives 
(Diczfalusy 1968). However, no such changes occur in a 
considerable proportion of women on continuous progesterone 
medication.
The mode of action of contraceptives is made more complex 
because the pharmacological effects of seemingly close structurally 
related compounds are often different and even the same compound 
at different dose levels may have different modes of action; when 
such compounds are used in combination with others they may have 
multiple modes of action (Seddon 1971)
4. Clinical Aspects.
In a review concerned with the side effects produced in women 
who were taking oral contraceptives Hellman(1969)5 pointed out 
the concern about the immediate and long .range side effects 
of hormonal contraceptives. These have been seen to increase as 
further scientific investigations have uncovered a host of 
diverse biological effects.
(a). Thromboembolism
An increased risk of thromboembolic disease attributable to 
the use of hormonal contraceptives has now been defined in both 
Gt. Britain and America, and there is still a great deal of
controversy between the association of thromboembolism and oral 
contraceptives (Inman and Vessey 1968). Other risks such as 
hypertension, liver diseases and reduced tolerance to carbo­
hydrates have not been quantitated with the same precision. 
Controversy has also centred around the following two areas;
(i) the scientific data required to establish an aetiologic 
relation and (ii) the.balance between acceptable and potential 
benefit.
In 1967  ^ the Royal College of General Practitioners in 
Gt. Britain undertook interviews of young women with vascular 
diseases and, by comparing patients with superficial 
thrombophlebitis with a suitably matched series of controls, 
it was shown that the risk of developing thrombophlebitis was 
tripled in women using oral contraceptives. After two further 
studies, Vessey and Doll (1968) following the same lines, 
concluded that the risk of developing deep vein thrombosis, 
pulmonary embolism or cerebral thrombosis increased about eight 
times by the use of oral contraceptives, whilst the risk of 
developing coronary thrombosis was apparently unchanged.
Since there is a relationship between thromboembolic disease 
in patients and the oestrogen content of oral contraceptives, 
(Inman 1970), their effect on platelet behaviour has also been 
studied (Adams 1970). He showed in a study totalling 28 women 
that the post heparin lipolytic activity was significantly 
depressed and platelet adhesiveness significantly increased.
This observation may provide a link between thrombolic and 
metabolic effects of oral contraceptives in that oestrogen 
induces a platelet abnormality similar to that found in patients 
with arterial occlusion.
(b)o Nitrogen and Electrolyte Metabolism.
There are also many other effects produced by hormonal 
contraceptives on major organs of the body (Preston 1971)j 
for example the liver, (Rannevik and coworkers, 1972; Sherlock 1968) 
the thyroid, (Wheeler and colleagues, I96O; Alexander and 
Marmoston, 1961) and the adrenal, (Layne and colleagues, 1962;
Dodek and workers, 1965). They also affect some of the body^ 
homeostatic mechanisms by producing changes in salt and water 
metabolism thereby inducing hypertension (Heilman 1969).
In a review, Goldzieher (1970) wrote that the prolonged 
use of steroidal contraceptive agents by numerous women poses 
a problem of the utmost gravity to clinical pharmacology. The 
possibility that these agents will be greatly modified, if not 
superseded in the next decade, in no way diminishes the need 
to examine their short and long term effects in the greatest 
details. In some of the experiments on the electrolyte 
and nitrogen metabolism, the results showed an increase in 
lean*body mass associated with nitrogen retention. There was 
also a positive sodium balance and a negative phosphorous 
balance during exposure to the progestational agent.
Another side effect produced by the oral contraceptive, the 
Carpal Tunnel Syndrome, was looked at by Sabour and Fadel (1970). 
During the years 1965-68,theylooked at those patients who had 
the following symptoms; numbness and tingling of hands and 
clinical evidence of fluid retention. The patients were asked 
to stop taking oral contraceptives as the sole therapeutic 
measure. Within a month, all patients returned with marked 
improvements in their symptoms. After a few further months,
15 of these patients resumed the use of the oral contraceptives 
and had their symptoms exacerbated once again. It is agreed
by most workers in this field that fluid retention is maximal 
in the early treatment cycles and those that still have it 
are destined to develop the syndrome. It is the oestrogen 
component of the contraceptive which is thought to be responsible 
for the natriuretic action and, therefore, people with this 
complaint are advised to have a predominantly progestational 
oral contraceptive.
(c). Carbohydrate Metabolism.
Changes in carbohydrate tolerance in patients using 
combination type oral contraceptives were first reported 
by Waine and coworkers (1963). Initially, there was a great 
deal of controversy over the agents that incorporate two potent 
ingredients, differences of dosage, duration of use and other 
variables. The situation is now being clarified as Javier and 
colleagues (1968) have shown that mestranol itself is capable 
of decreasing glucose tolerance promptly. A.recent study was 
carried out by Spellacy and workers (1970) who examined the 
long term effects of progestagens and oestrogens. They compared 
patients who had taken sequential preparations for periods 
exceeding six years. A marked difference was found, as 3$ of 
the sequential contraceptive users showed clearly abnormal 
glucose tolerance and elevated insulin levels, whereas 39$ of 
the combination users showed the same type of disturbances.
It is therefore evident that both steroidal agents have an 
adverse effect on carbohydrate metabolism, but the effect of 
oestrogen appears to be less. In most individuals terminating the 
use of oral contraceptives, menses and fertility return promptly. 
Of the combination users, 5 - 6$ had a menstrual delay of 
70 - 390 days, and of the sequential users only 2.5$ had cycles
delayed longer than 70 days. The difference was found to he 
statistically significant.
Kalkhoff (1972) reviewed the situation of the oral 
contraceptive and its connection with diabetes. Initial 
studies of women taking oral contraceptives revealed an 
incidence of diabetes mellitus from 15 - 40$ (Gersberg and 
colleagues, 1964; Hailing and coworkers, 1967)5 which was 
considerably above the accepted figure (2 - 4$) for the 
general population. The majority of prospective studies do 
not support these earlier findings. Other results suggest that 
oral contraceptive agents induce an acquired form of subclinical 
diabetes mellitus in nondiabetic subjects and this condition 
was found to be reversible (Kalkoff and colleagues 1969).
(d). Liver Dysfunction and Jaundice.
During the past few years the use of oral contraceptives 
has been reported to be associated with an increasing frequency 
of liver dysfunction, usually with jaundice, (Westerholm, 19705 
and‘Boake, 1967). Rannevik and colleagues (1972) have 
investigated the possible effects of oestrogen and progesterone 
separately to see whether they are responsible for abnormal 
hepatic function. It was found that chlormadinone acetate 
and lynestrenol (both constituents of several contraceptives) 
produced little or no increase in the serum enzyme activity.
With the combined preparation of mestranol and chlormadinone 
acetate, an increase of the serum enzyme activity was found 
but this soon returned to the normal level.
Many tests have been performed on the serum of women who 
have taken oral contraceptives. Thirty healthy women were 
examined before and after three months treatment with oral 
contraceptives in order to ascertain whether or not the treatment
affected the serum acid content (Castren and Rossi 1970). No 
difference was noted between drugs containing different oestrogen- 
progesterone components. Also, treatment of a longer duration 
(5 - 32 cycles) did not affect serum folic acid levels significantly. 
The serum cholesterol and triglyceride levels were estimated 
in subjects taking oral contraceptives by Barton and Freeman 
(1970)* Tests were made at three monthly intervals for two years 
and a rise of serum cholesterol and triglycerides were seen 
in those talcing oral contraceptives containing both oestrogen 
and progesterone, but this was not the case in those receiving 
progesterone alone. The results therefore show that the adverse 
effect of oral contraceptives on lipid metabolism is due to the 
oestrogen component and not progesterone.
(e). Hypertension.
Another side effect of oral contraceptives is hypertension 
although it is not clear as yet, how oestrogen - induced hyper­
tension is mediated. Sodium retention is a common effect 
of oestrogen therapy but it has not been shown to predispose 
to hypertension in this situation. Estimates of the incidence 
of hypertension in association with oral contraceptives vary 
widely. Two prospective studies yielded figures as high as 
15$ (Tyson 1968) and 18$ (Saruta and colleagues 1970)•
A review of the literature by Spellacy and Birk (1972) 
reported an incidence of hypertension in 0 - 15«5$ of oral 
contraceptive users. Fuertes de la Laba and coworkers (I97I) 
found an incidence of 11.3$ of hypertension in long term users, 
of oral contraceptives in Puerto Rico. The reports of Goodlin 
and Waechter (1969)5 Carmichael and associates (1970) and 
Weir and coworkers (1971) in cross sectional studies on blood
pressures suggest that hypertension is just as frequent in women 
not taking oral contraceptives. Since these results are 
conflicting, Spellacy and Birk (1972) conducted a study pertaining 
to 415 women who had normal initial blood pressures before 
entering the study. They were given either individual 
progestagens, individual oestrogens or oral contraceptives 
(combination). The results showed that an increase in blood 
pressure occurred with oral contraceptives (5%), mestranol (6$), 
and ethinyl oestradiol (7$)<> This increase was not found in 
women taking progestagens or conjugated oestrogens. However, 
the differences were not significant at the 5% level.
(f). Depression.
Lewis and Hoghughi (1969) using a standardised questionnaire 
in 50 women found that 6$ of the women on oral contraceptives 
and 1$ of their control group showed symptoms of severe 
depression. Herzberg and coworkers (1970) also found 6$ of 
women suffering from depression whilst taking oral contraceptives 
whereas only 2% of the control group had similar symptoms.
Women taking Lyndiol 2.5 showed increased feelings of 
dissatisfaction, crying and tension; but this may be due to 
the fact that; their General Practioners had selected Lyndiol 2.5 
for the patients they considered to be depression prone. The 
Committee on Safety of Drugs recently recommended that women 
should take oral contraceptives containing only 50yug or less 
of ethinyl oestradiol or mestranol. This has resulted in a decrease 
in the number of products and consequently should make evaluation 
of the side effects produced in individuals easier.
(g)• Tumour Formation.
It is known that oestrogens can cause tumours of the testes, 
ovaries, pituitary, kidney and bone marrow in certain animal 
species (Gardner 19375 Dunn 1969; and Hertz 1968). This very
diversity suggests the existence of species-specific phenomena 
which may be of great interest in themselves, but maybe totally 
unrelated to the clinical problem. At one time it was thought 
that individuals with a late age of menopause were more prone 
to develop endometrial carcinoma (Lindell 1952); this was 
attributed to the relatively longer exposure to endogenous 
oestrogens. However, Larson (1954) has shown that no association 
between endometrial carcinoma and age of menopause exists. It 
has been observed that oestrogen therapy is harmful in breast 
cancers of a certain type (James and associates, 1970) and 
beneficial in others (Forrest 1971); hut it seems to be a 
property of malignancy, rather than any intrinsic features of 
oestrogens, which is responsible for these effects.
t
Fechner (1970) studied 5 women under the age of 35 with 
carcinoma of the breast who were taking oral contraceptives 
at the time the lesion was discovered and found no evidence ' 
of an unusual response morphologically. Further, this study 
did net provide additional proof of an association between 
hormones and the development of carcinomas. The fact that oral 
contraceptives may modify the course of metastatic cancer 
does not provide information concerning their effect on the 
induction of cancer.
In 1972, Gould and colleagues repeated this work with other 
patients and concluded that oestrogens and progesterones are 
sometimes capable of stimulating metastases of carcinomas of 
the breast and they might play a part in the development of the 
primary lesion. All this suggests a caution in their administration 
especially to those women with previous breast carcinoma history.
Several short term studies on pre-clinical carcinoma of the 
cervix and cytological abnormalities associated with the use of
oral contraceptives have been reported, with conflicting results.
In one large cytological study (Weid and colleagues 1966), there 
was no statistical increase in cellular atypia in women using 
oral contraceptives for more than one year. However, Pincus 
and Garcia (1965) reported a lower rate of atypia in women taking 
combined preparations of oral contraceptives in comparison to 
those using other forms of contraception. Contradictory findings 
were reported by Dougherty (1970) who found an increased 
incidence of cytological atypia with the use of sequential 
preparations; Melamed and coworkers (1969) also described a significant 
elevation of the prevalence rates of carcinomas of the cervix 
in those women who had taken oral contraceptives. Worth and 
Boyes (1972) undertook a study to adjudge the possible effects of 
the oral contraceptive on pre-clinical carcinoma of the cervix 
by using 310 test subjects with 682 matched controls. Their 
results supported those previously obtained in which no positive 
relationship between the ingestion of oral hormonal contraceptive 
agents and pre-clinical carcinoma of the cervix was demonstrated.
Boyce and colleagues (1972) and Thomas (1972) did similar surveys 
and substantiated the findings of Worth and Boyes in that oral 
contraceptives were not linked with cervical cancer.
Much work has been carried out to ascertain the effect of 
various oestrogens, administered in high doses to adult mice over 
prolonged periods of time. Carcinomas in situ of the cervix 
were produced although it was found that progesterone delayed 
the development of chemically induced cervical carcinomas• It 
was further shown however, that cervical carcinomas did develop 
in mice given oral contraceptives containing both the oestrogen, 
mestranol and the progestagen norethynodrel for prolonged periods.
(h)• Safety Evaluation of the Oral Contraceptive.
The Committee of Safety of Drugs considered the safety problems 
•which might be associated with the long term administration of 
oral contraceptives to healthy women. In 1966, they investigated 
the effect of mestranol on rats and concluded that this oestrogen, 
when administered in high doses and over prolonged periods of 
time to these animals, caused liver damage which can sometimes 
be severe. On these findings the Committee insisted that all, 
new oral contraceptives and their active constituents should 
be investigated for carcinogenic properties before they are> 
made generally available to the public. It was agreed that the 
work must be carried out in both sexes of rats and mice at three 
dose levels. The studies lasted for 2 years, with the experiments 
on mice continuing for 80 weeks and those in rats for 104 weeks, 
and included 13,000 animals. The constituents of the oral 
contraceptives were administered daily in the animals1 diet at 
doses, 2-5, 50-150 and 200-400 times the human contraceptive 
doses. At the end of the experimental period full postmortem 
examinations on the killed animals were carried out.
The results of the extensive tests reported do not support 
the previous work showing liver damage and increased incidence 
of hepatomas from prolonged administration of oral contraceptive 
preparations to rats. The results are in conformity with the 
clinical evidence that no constant or persistent disturbance 
of liver function occurs. The incidence of breast tumours, 
including carcinomas, was found to follow the pattern expected 
from other published studies. With the latter types of tumours 
the effects are predominantly related to oestrogenic activity 
of the compounds and the amount required to produce them is
several hundred times the human contraceptive dose.
The Committee (1972) finally concluded that, although a 
carcinogenic effect can be produced when some of the preparations 
are used in high doses throughout the life span of certain strains 
of rats and mice, this evidence cannot be interpreted as 
constituting a carcinogenic hazard to women when these 
preparations are used as oral contraceptives.
5- Chromosomes and Oral Contraceptives.
(a). Constituents.
Various constituents of the oral contraceptive have been 
tested in in vitro systems in order to detect any induced 
chromosome abnormalities (Stenchever 1969)* The oestrogens 
evaluated were oestradiol, ethinyl, oestradiol and mestranol; the 
progestagens were progesterone, megestrol acetate, norethisterone 
acetate and chlormadinone acetate. Four different final 
concentrations of 0.1, 1.0, 10.0 and 100.0 ^ ug/ml.. of each 
constituent were used in the blood cultures and then over 200 
metaphases were examined from each culture. No significant 
chromosome abnormalities were-, found in any of the cells at the 
concentrations studied.
(b). Abortion Studies.
A preliminary study of 394 spontaneous abortions (Medical 
Tribune Report 1969) provided no evidence that prior use of 
oral contraceptives increased the incidence of abortions, but 
it appeared, that the aborted foetuses had a higher ratio 
of *growth disorganisation*. Extrapolation of information from 
animals suggests that one of the factors responsible for this 
phenomenon might be the ageing of the ovum due to delayed ovulation. 
As the mechanism of ovulation may take up to 4 months to return
to normal in patients who have discontinued oral contraceptives, it 
is possible that the blighted ova are associated with delayed 
ovulation (Poland.1970)«
Chromosome studies were undertaken by Carr (1970) on aborted 
foetuses from women who had conceived within 6 months of 
discontinuing oral contraceptives indicating a highly 
significant increase in triploidy (cells with 69 chromosomes) in 
the test compared to the control foetuses. Tetraploidy (92 
chromosomes) was also increased, but the numbers concerned were 
too small for analysis. Carr then suggested that there was 
a temporary hormonal imbalance in some women after they had 
discontinued oral contraceptives and that this could affect 
the timing of fertilisation and, therefore, triploidy could arise 
at the first or second meiotic division of the ovum or at 
fertilisation.
(c). Chromosome Studies.
Before this project was initiated, some workers had 
investigated the chromosome breaking effects of oral contraceptives 
in women who had taken them for any length of time and also their 
children. Rice-Wray (1970) looked for possible chromosomal 
anomalies in the leucocytes of 61 children whose mothers had 
taken oral contraceptives, and failed to find any. Shapiro 
and colleagues (1972) set up blood cultures from 7 women prior 
to, and after 1 or 2 months, taking oral contraceptives and 
found no significant change in their chromosomes. Timson (1969) 
also looked at the effect of Lyndiol 2.5 on the lymphocytes of 
19 women and found no structural or numerical abnormalities 
in their chromosomes. However, he observed a decrease in the 
mitotic indices•
Reports which are in complete disagreement with the above
findings were published by McQuarrie and coworkers (1970) and 
Goh (1967)* McQuarrie and coworkers (1970) looked at the 
metaphase spreads of 50 babies born to mothers who had been 
taking oral contraceptives, and found an increase of chromosome 
breakage and other abnormalities in the test compared to the 
control groups-. Goh (1967) had also found a variety of complex 
structural rearrangements of chromosomes from the blood leucocytes' 
of women taking oral contraceptives. These studies provide only 
a small amount of data on the chromosome breaking effects of 
, oral contraceptives. Also , the majority of studies only dealt 
with one aspect (chromosome aberrations) of abnormalities. It 
is therefore hoped that the present study would provide further 
useful information regarding the biological aspects of the oral 
contraceptives.
6. Cytogenetic Testing of Commonly Used Compounds.
During the last five years there have been many reviews 
written concerning various aspects of mutagenesis. This is due 
mainly to the increasing awareness of this problem and the
r
technical advancements in tissue and chromosome preparations.
As a result, many classes of exogenous agents, for example, 
radiation, viruses and chemicals capable of producing chromosome 
damage, have been assessed (Hirschhorn and Cohen 1968).
Nowadays, man is exposed to a great number of substances, 
not encountered by his ancestors and to which he has not been 
specifically adapted. Among these substances are food additives, 
drugs, narcotics, antibiotics, pesticides, cosmetics, contraceptives 
and air and water pollutants. Present information would indicate 
that these chemicals mentioned may be far more dangerous to the 
population in terms of genetic defects than radiation and as a
result it is important to determine their mutation frequency in 
mammalian cells (Muller 1963).
In 1971 a- WHO Conference was held in Geneva to discuss 
the evaluation and testing of drugs for mutagenicity due to the 
potential hazard of these drugs to mankind in causing gene 
mutations and chromosome aberrations. In man, significant 
frequencies of chromosome aberrations have been observed in 
spontaneous abortions and newborn infants, and since it is not 
known what part drugs might play, there is a strong possibility of 
-the existence of a potentially serious mutagenic problem.
Two main types of genetic damage are recognised, chromosome 
aberrations and gene mutations. These may affect either somatic 
or germ cells, although damage to either cell population may 
have serious consequences from the public health standpoint.
However, mutations in germinal cells are of paramount importance 
as they present a hazard to future generations.
A mutation can be conveniently defined as an abrupt inherited 
variation that is not due to recombination of the existing genetic 
material (Legator 1972). This definition would include extremely 
localised alterations in chromosomes, point mutations or alterations 
extending over a significant part of the chromosome causing 
abnormalities, The chromosome aberrations are most frequently 
classified as numerical or structural. These are thought to be 
based on independent events, that is, numerical mutations may 
result from nondisjunction and anaphase lag, while structural 
mutations result from breakage and reunion. It is becoming 
increasingly likely that numerical aberrations are based on 
underlying structural re-arrangements (Shaw 1970).
There seems little doubt that a drug or chemical can produce 
cell death due to chromosomal damge during the organogenesis
period of embryogenesis. This results in an abnormal or dead 
foetus. Therefore any agent that is capable of crossing the 
placental barrier and produces chromosome abnormalities in the 
foetus can produce abnormal offspring (Nichols 1972).
The recent introduction of oral contraceptives into the lives
of child bearing members of the population exacerbates the problem
since these hormones are taken continously for a relatively long
A
time. Obviously, since the mechanism of action of these agents is 
not fully understood, it is of the greatest importance that the 
long term genetic effects of taking oral contraceptives be fully 
and thoroughly investigated. The result of these researches 
could affect the healthy propagation of this generation. The 
commercial market has recently been flooded with a number of 
oral contraceptives which are mainly steroidal, the biological 
side effects of which are not fully elucidated. In view of this, 
and the long term biological and socio-economic implications, it 
is important to establish through carefully planned and controlled 
investigations the cytogenetic effects of oral contraceptives
L
taken as a means of contraception.
7* Methodology.
Over the last several years there has been considerable 
technical activity in an attempt to develop reliable methods for 
screening chemicals for alterations in genetic material, for 
example, mutagenesis. In the report of WHO (1971) Scientific 
group on the evaluation and testing of drugs, it is stated that 
drugs that are often used over a period of years by a large 
population of people should be given a high priority in 
mutagenic testing.
The methodologies which are available at the present time are
(i) host mediated assay, (ii) dominant lethal and (iii) cytogenetic 
testso In the host mediated assay, the mammal, during treatment 
with a potential chemical mutagen, is injected with an indicator 
micro-organism in which the mutation frequency can be measured*. 
After a sufficient time period, the micro-organisms are with­
drawn from the animal and the induction of mutants is determined.
The dominant lethal test is a measure of the amount and the . 
type of foetal wastage which may occur following administration of 
a potential mutagen. Dominant lethal mutations are indicators 
of major genetic damage. The effects of mutagens on the meiotic 
chromosome complement in germ cells may result in the production 
of non viable zygotes, early and late foetal deaths, abortions 
and congenital malformations.
The third method available for testing compounds is the 
cytogenetic test, in which gross chromosomal morphological changes 
can be observed. Alterations in chromosome number and structure 
is observed when a mutagen is added to cells in vitro or injected 
into animals (in vivo). It is clear that some test systems 
have distinct advantages over others. Cytogenetic systems are 
preferable to the host mediated assay and dominant lethal tests 
since the former demonstrate damage at above the molecular 
level (chromosome alterations). On account of this, the former 
system was chosen for this project, especially since the host 
mediated assay and the dominant lethal tests cannot be usefully 
performed on humans.
In selecting the cytogenetic test to be used for evaluating 
chromosome potentials of a drug, it is necessary to be aware 
of the shortcomings of the different systems involved. In the 
cases where animal systems and in vitro cultures are used, one 
must be careful in extrapolating the results from these systems
to human systems. This is because observations on non human 
systems cannot duplicate the unique metabolism of man or the 
. variety of environmental components to which he is exposed 
(Sutton 1972). The ideal system of course, would be to examine 
cells of human individuals before and after exposure to named 
drugs, but, because of its impracticability the next best method 
available is to use peripheral leucocytes from humans who have 
been subjected to these drugs, using untreated individuals as 
controls. The versatility of the blood culture method and the 
rapidly advancing techniques make cytogenetic analysis in order 
to screen chemicals to assess their potentiality for inducing 
abnormal growth, one of the most promising systems.
(a). Blood Culture Technique.
Peripheral blood is the most easily obtained tissue and 
the development of techniques for the in vitro culture of 
circulating lymphocytes has • proved to be a very useful tool 
to cytogeneticists. The gradient method used to separate 
white blood cells described by Osgood and Brooke (1955)* was 
later modified for cytogenetic studies. Nowell and colleagues 
(1958) , Moorhead and colleagues (i960) and Hungerford and 
coworkers (1959) published modifications of the then known 
techniques using Nowell's method for the cultivation of 
peripheral blood leucocytes with the advantages inherent in the 
air drying methods of Rothfels and Siminovitch (1958). They 
were able to prepare good metaphase plates from the cultured 
cells having used heparinised and cooled blood from which the 
red blood cells were sedimented by centrifugation. The supernatant 
plasma containing the white cells was introduced into culture 
flasks with growth medium containing human AB serum. This method 
of culturing blood cells had been shown to have three great
advantages; firstly there is a relative ease of obtaining blood 
and only a small volume is required; secondly, an adequate mitotic 
yield is obtained from the short term culture of the leucocytes 
and thirdly, a high number of good metaphase spreads are available 
for permitting a critical analysis of the chromosome morphology.
Following these developments many other techniques have been 
described. Arakaki and Sparkes (1963) used small amounts of 
whole blood for cytogenetic investigations in man and animals.
They added 0.05 - 0o25ml heparinised blood into culture medium 
containing 15% foetal calf serum and phytohaemagglutinin (PHA).
Since this publication, many modifications of the original 
techniques have been recorded on account of the discovery that 
PHA will stimulate leucocytes to divide in vitro (Froland 1962; 
Robinson and colleagues, 1964; and McGuire 1966). These 
modifications have resulted in newer and improved techniques, 
some of which have been used in the present study to culture the 
blood cells.
(b)• New Methods.
Within the last year or so several techniques have become 
available to identify each chromosome pair in the human complement 
(Evans and colleagues 197l)« These techniques reveal specific 
banding patterns within chromosomes so that not only whole 
chromosomes, but parts of chromosomes, can be readily identified.
The new techniques have been used to distinguish certain chromosomes 
involved in specific diseases (Caspersson and colleagues 1970$> 
to differentiate human/animal cells (Caspersson and coworkers 1970$, 
and to characterise chromosome structural changes in continously 
cultured cells of both normal and malignant origin (Steele 1971)*
In 1971 a Conference was held in Paris to discuss the proposed 
banding of the chromosome nomenclature. Each chromosome in the
human somatic cell complement is considered to consist of a 
continuous series of bands with no unbanded areas. The bands are 
allocated to various regions along the chromosome arms and the 
regions to which they belong are identified by numbers, with 
the centromere serving as the point of reference for the numbering 
scheme. A chromosome banding diagram has been constructed based 
on the patterns observed in different cells stained with giemsa 
or quinacrine. Also, systems for designating structural 
abnormalities by breakage points and band compositions were 
presented using additional nomenclature symbols.
When the present study was initiated, the newer techniques 
for identifying chromosomal abnormalities had not been perfected. 
Consequently, chromosomal banding was not included in the 
results• Table 2 shows a resume of the techniques available 
and comments thereof.
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AIMS OF THIS PROJECT.
To investigate the cytogenetic characteristics of peripheral 
blood leucocytes from women who have taken oral contraceptives
To establish whether or not chromosomal abnormalities were 
produced in any of the offspring of the mothers who had taken 
oral contraceptives.
To establish whether the chromosomal aberrations (if any) 
were related to:
(a). Maternal age•
(b). Number of previous miscarriages.
(c). Length of time that the oral contraceptive was taken.
(d)• Time between discontinuation of oral contraceptives 
and the onset of pregnancy.
(e). Type of oral contraceptive which was used (constituents 
. of the various oral contraceptives).
t
To establish whether or not any chromosome abnormalities 
in the mothers and babies are exaggerated when taken in 
conjunction with other drugs or associated with serious 
illnesses or other exogenous agents.
To establish whether any chromosome abnormalities found 
in the offspring are similar to those found in their mothers.
MATERIALS AND METHODS.
1. Choice of Subjects.
The subjects chosen for this project were from the maternity 
ward of a large general hospital in Sussex. The subjects were 
one of two types:
(i) those who had taken one or more type of oral contraceptive 
at some time during their reproductive life (henceforth 
referred to as test mothers),
(ii) those who had never practised any form of oral contraception, 
(subsequently referred to as control mothers).
Both groups of mothers had entered hospital for the imminent birth 
of their babies, which were included in the survey as test and 
control^babies respectively.
Six months before the predicted birth of their babies, the 
women who attended the antenatal clinic to arrange their eventual 
admission to hospital for the delivery of their babies were asked 
if they had ever taken any form of oral contraception. If the 
answer was in the affirmative, a small white circle was stuck to 
their medical files. When these women entered hospital for their 
deliveries it was known that they were part of the trial and therefore 
blood was to be obtained from them and their newborn babies 
automatically and without exception. Approximately 25% of the 
women who were admitted to Cuckfield hospital during the period of 
the trial which lasted for 9 months (1970/71)s were therefore 
included in the series of test mothers. The number of test mothers 
investigated during this period amounted to l85> similarly 185 
test babies were involved.
The selection of the control mothers was performed at the time 
of delivery and not at the !bookingT clinic. A number of control 
mothers, identical to the number of test mothers delivered on that 
day, were chosen by the medical social worker at random and without 
reference to their medical circumstances or histories. Apart from 
excluding mothers who miscarried, there was no selection against 
parameters such as difficult labour or abnormal pregnancy. The 
control mother and baby series therefore consisted of approximately 
33% of all the women who had never taken oral contraceptives 
(control) who entered hospital for their deliveries. Altogether 
181 control mothers and 181 control babies were included in the 
investigation.
After the delivery of the baby, 10 ml peripheral venous blood was 
collected from the mothers and 5 ml cord blood was collected from 
their babies. The bloods were aspirated into tubes containing 
heparin (0.1ml of 5000 i.u./ml), to prevent the blood coagulataing.
These tubes were collected from the hospital on Mondays, Tuesdays 
and Fridays for convenient harvesting procedures, which took place 
three days after the cultures were set up.
The tubes were coded with a hospital number, and thereafter 
transported to the laboratories where they were given a laboratory 
code number. These latter numbers were given in the order of the bloods1 
-arrival and even numbers were assigned to the mothers and odd numbers 
to the babies with only a few exceptions. It was performed on a 
completely blind basis and not until all the results were obtained 
were they partitioned into test and control groups.
2. Blood Culture Technique.
Two methods, micro and macro methods, were employed in the 
setting up of blood cultures for chromosome preparations. In the 
attempt to establish a workable micromethod, various amounts of
whole blood were added to the culture media with different 
combinations of media constituents. Different concentrations 
of colcemid, which was used to arrest cell division at metaphase, 
were also used.
(a). Micromethod.
The best results for a workable micromethod were obtained 
when the following constituents were used; 0.5 ml whole blood 
together with 3«0 ml Eagle’s Minimal Essential Medium (Wellcome’s) 
with added penicillin and streptomycin and 0.1 ml phytohaemagglutinin 
(Difco). These various constituents were injected into a 
sterile McCartney bottle and shaken well. The culture was left 
in an incubator at 37°C for three days with periodic agitation.
Three hours before the blood was harvested, 0.2 ml colcemid 
(lOOyUg/ml) Ciba was added to arrest the cells at metaphase.
In addition to this technique, special chromosome kits 
were obtained from Gibco (Grand Island Biological Company,
New York). These tubes contained 10 ml medium and in a 
preliminary set of experiments the number of ’drops1 of whole 
blood added to these tubes was varied, until the best results 
were obtained. This number was found to be eight (roughly 0.1 ml) 
in the trial. The tubes were incubated with 0.1ml phytohaemagglutinin 
for 72 hours and colcemid 0.3 ml (100 jug/ml) added three hours 
before harvesting.
(b). Macromethod.
Three modifications of a macromethod were tried primarily 
in order to produce a good leucocyte-rich supernatant. Firstly,
1.0 ml Dextran in 0.9% sodium chloride (Dextraven) was added 
to 10 ml whole blood from the mother or to 5 ml cord blood from 
the baby and left in the incubator at 37°C to sediment.
Secondly, the blood was left at room temperature (23°C) to sediment,
and thirdly , Oel ml PHA. 'added to the whole blood which was 
placed in a bucket containing ice for half an hour and then 
centrifuged at 1000 r.p.m. for ten minutes. The supernatants 
were aspirated from the tubes into sterile McCartney bottles 
into which an equal volume of Eagle’s M.E.M. and 0.1 ml PHA 
were added, except in the third method. These cultures were 
placed in the incubator and left for three days with periodic 
shaking, before co]cemid (0.2 ml of 100 ^ ug/ml solution) was 
added three hours before harvesting.
It was found that the third method, that is, adding the 
PHA to the blood and the subsequent cooling, was superior 
to the other two preparations, and was employed together 
with the suitable micromethod already described. Every blood 
sample which came into the laboratory was set up in culture 
using both the micro and macro methods. Firstly 0.1 ml whole 
blood was removed from the heparinised tube for the micromethod, 
and then the remainder was allowed to sediment on ice for the 
macromethod. As the micromethod was found to be more 
successful, the macromethod was later discontinued. . r
(c)• Mitotic Indices.
Blood cultures from 50 control mothers and 60 control babies 
were utilised to assess the mitotic response of newborn cord 
blood to PHA stimulation, to compare with the mothers’ venous 
blood. Also, this method was chosen to compare the two techniques, 
the micro and macro methods. The mitotic indices which are 
defined as the percentage of mitotic figures present in the total 
number of cells examined, were calculated after the examination 
of 1000 cells from each blood culture. (See Plate 1).
Similarly the mitotic indices were calculated from 70 test 
mothers who had taken various types of oral contraceptives and
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Plate 1 : Photograph of a micro culture showing mitotic figures. 
Magnification x 300.
their babies, and. their means were compared with 70 control 
mothers and babies. The time interval between discontinuation 
of the oral contraceptive and pregnancy was also noted to ascertain 
if the varying lengths of time had an adverse effect on the 
mitotic activity of the blood cultures. Five hundred cells 
were examined from each micro culture.
(<!)• Harvesting the Blood Culture.
Harvesting the blood was identical in both techniques. The 
bottles or tubes of blood were emptied into clearly marked 20 ml 
centrifuge tubes, and spun for 10 minutes, at 1000 r.p.m. on a 
M.S.Eo centrifuge. The supernatants were removed, using Pasteur; 
pipettes, one for each blood, and 5 ml of sodium citrate 
(0.85%, solution) was slowly added to the precipitate of cells. The 
tube was left for 30 minutes in an incubator at 37°0, which was 
followed by centrifugation for another 10 minutes at 1000 r.p.m. 
After the supernatant was discarded 5 ml Clark’s fixative solution, 
which was composed of 3 parts of absolute alcohol to 1 part 
glacial acetic acid, was slowly added to the pellet of cells in 
the bottom of the centrifuge tube and agitated gently. This /•
was placed in a refrigerator at 4°C for 30 minutes and the 
suspension was centrifuged as before, the supernatant aspirated 
and the cells were resuspended twice again in the fixative. About
0.5 ml 45% acetic acid was added to the pellet of cells to render 
the cell membranes fragile in order to facilitate spreading of the 
chromosomeso
(e)• Slide Preparation.
The slides were well cleaned by soaking in an acetone/ether 
(50/50) mixture and then drying with a dust free anti-static 
cloth. After this process, the slides were placed on a block 
of cardice until they had a frosty appearance. Then 5 drops 
of the cell suspension were dropped onto the slide, which was
tilted in order to affect maximum spreading of the cells, and 
then held over a gentle flame. The excess water was removed 
by placing the edge of the slide onto blotting paper. Three 
slides were made from the micromethod culture and two from the 
macromethod, for every culture. The slides were stained 
by adding two drops of lacto-acetic orcein, a coverslip then 
laid and the whole left overnight in order that the cells might 
take up the maximum amount of stain.
These temporary slides were mounted permanently, by firstly 
removing the excess stain with 45% acetic acid (for not more 
than 5 minutes), then transferring them to cellosolve 
(2 ethoxyethanol) for dehydration for 10 minutes, and finally 
placing them in euparal essence for at least an hour before 
mounting in euparal.
The slides were scrutinised systematically on a mechanical 
stage using a Leitz Orthomat microscope under a low-powered 
lens <10 x magnification). When a suitable metaphase was 
located, a higher magnification was used (100 x oil lens) 
for further detailed study. A suitable metaphase was defined 
as one that appeared intact and in which the chromosomes 
could be easily counted. At the beginning of the project 
25 met?tphases were counted from each specimen using the 
micromethod studies only. However, if too few spreads were 
found in the former group, then the slides from the macromethod 
were used. Later in the series 50 spreads were analysed and 
counted from each blood culture.
(f). Scoring System.
Each metaphase was examined carefully and the following 
scoring procedure was undertaken; firstly, a chromosome count 
was done and repeated twice for confirmation; secondly, each
chromosome was scrutinised to ascertain whether or not there 
were any gaps or breaks along its length. Also, all numerical 
or other structural disorders were recorded, the former being 
mainly tetraploidy or hypodiploidy, and the latter being gaps, 
breaks or translocations.
Structural aberrations were only scored as single breaks if 
there was a clear discontinuity of the chromatid with a dis­
placement of the distal portion. Structural re-arrangements, 
for example quadriradials, were scored as two breaks. Gaps 
were defined as attenuated pale staining areas without 
displacement of the distal portion (See Diagram 11).
These breaks and gaps were only scored from cells which 
had the full complement of chromosomes present. It was judged 
to be important to count breaks and gaps in intact metaphases 
only, because there might be an increase of abnormalities 
occuring in broken cells, due to the vigorous disruption 
’of the cells•
Numerical chromosome abnormalities were scored as follows: 
triploid cells were defined as those cells with 6 9 - 5  chromosomes 
tetraploidy as those cells with 92 - 10 chromosomes$ and 
polyploidy as any chromosome count above tetraploidy. Endo- 
reduplication was scored if more than six chromosomes had 
replicated and remained unseparated at metaphase.
Each metaphase counted under the microscope was sexed, hy 
specifically ascertaining the absence or presence of a Y 
chromosome. This, process was facilitated by counting and 
identifying the small acrocentric chromosomes.
gap^
quadriradial
3. Photography and Karyotyping.
Any abnormal metaphases and at least one metaphase of good 
quality from each specimen were photographed using a Leitz 
Orthoplan microscope with an automatic camera attachment 
(1250 x magnification). Ilford Pan F film of slow to medium 
sensitivity was used, and each photograph taken was entered into 
a notebook so that a record was kept of its: origin. The film 
was then developed in I.D.ll (Ilford) for 72 minutes, agitating 
for 5 seconds every minute, fixed in Ilfofix (ilford) for 
10 minutes and then washed for 30 minutes in running water.
A Leitz enlarger in conjunction with an automatic printer was 
used, to produce good quality prints for the records and 
karyotyping.
Selected metaphases were karyotyped according to the 
Denver classification (Denver 1966), shown in Plate 2, 
especially those where 47 chromosomes were present in order to 
assign the aberrant chromosomes to a specific group. One 
large photograph was cut up into the individual chromosomes 
and a second large photograph was kept for reference. The 
initial karyotype arrangement was made on a piece of paper, 
afterwhich the groups were transferred to a piece of white card, 
each chromosome was stuck on the card with a clear glue. The 
small photograph was stuck onto the card as shown in Plates 3> 6 and 8
4. Patients1 History Information.
Using the information given by the test and control mothers, 
clinical history forms were duplicated (see form on next page), 
and filled in by a social worker based at the hospital.
These forms were divided into five main groups which were
AVERAGE MEASUREMENTS OF HUMAN CHROMOSOMES 
-DENVER SYSTEM
Metacentric
Sub-metacentric
Acrocentric
•1. Short arm
2. Centromere
3. Long arm
i|i iiii i
13 14 15
♦  —  p -------►
■4. Satellite
XIIXX XX xx XX u fu\ A1
to ff 18 19 20 21 22 Y
Plate 2 : The Denver classification of chromosomes, subsequently 
altered in 1966 (Chicago).
CHROMOSOME SURVEY
PATIENT1 S NAME & ADDRESS CASE NO*------ HOSPITAL NO.
________________________________  NAME & ADDRESS OF GENERAL
HOSPITAL & WARD PRACTITIONER.
NAME & ADDRESS OF HOSPITAL 
CONSULTANT.
PATIENT * S HISTORY (prior to this pregnancy)
AGE_______  DATE OF BIRTH    MARITAL STATUS S M W D ?
MARRIED SINCE  ____________ OR LENGTH OF RELATIONSHIP  _______________
HEIGHT CM. WEIGHT __ KG.
ORIGINAL HAIR COLOUR RED__ BLOND_  DARK_
RACE CAUC.  NEGRO  BROWN YELLOW COUNTRY OF ORIGIN ________ _
RELIGION CATH.  PROTEST.  JEWISH ISLAM OTHERS UNKNOWN _____
BLOOD GROUP 0 A B AB RH: POS. NEG. UNKNOWN
RH. INCOMPATIBILITY NO YES_ UNKNOWN____
OCCUPATION OF FATHER______________  MOTHER___________
SOCIAL GROUP ___________ __
SMOKING NO  YES_ IF YES ______ CIGARETTES / DAY
ALCOHOL NO  YES______IF YES, SPECIFY__________ ____________
HAZARDOUS OCCUPATION MOTHER ' NO YES FATHER NQ_ YES__
IF YES, RADIATION MOTHER ___   FATHER
INDUSTRIAL CHEMICALS________ _____  ______
DUST_______________________ ______ _____
AGRICULTURAL CHEMICALS   -___________
CYTOTOXIC DRUGS_____________ ______ ______
OTHERS______________________ _ ____  _ ____
SPECIFY ________ _____________________
FAMILY HISTORY OF DIABETES NO YES  UNKNOWN ________
IF YES, FURTHER DETAILS _______      ■
FORM FILLED IN BY _ _ _  
DATE OF REPORT / /'
LIVE BIRTHS 
STILL BIRTHS
ANY MULTIPLE BIRTHS 
SPONTANEOUS MISCARRIAGES 
INDUCED ABORTIONS 
PREVIOUS FOETAL ABNORMALITIES 
SIBLINGS : ANY ABNORMAL
DATE OF LAST 
DATE OF LAST 
NO YES  SPECIFY
NO_YES _  DATE OF LAST
NO__YES_DATE OF LAST
NO__ YES_SPECIFY____
NO YES SPECIFY_____
ARE ANY OTHER MEMBERS OF FAMILY ABNORMAL 
OR HAVE ANY ABNORMAL CHILDREN NO
IF YES PLEASE SPECIFY
YES
MENSTRUAL HISTORY 
AGE OF MENARCHE _  
LENGTH OF CYCLE __
CYCLE REGULAR IRREGULAR
AMOUNT OF MENSTRUAL LOSS 
INTRAMENSTRUAL BLEEDING 
AMENORRHEA
DURATION OF BLEEDING  ___
LIGHT  NORMAL____
NONE  RARE_____
NO_   YES  SPECIFY
HEAVY
CYCLE INFLUENCED BY HORMONAL CONTRACEPTION
CONTRACEPTIVE METHOD USED IN LAST 6 MONTHS
IF YES, METHODS:
RHYTHM METHOD _____________ __
COITUS INTERRUPTUS  ________
CONDOM
NO.
FREQUENTLY
YES
NONE YES
DIAPHRAGM PLUS CHEMICALS 
CHEMICALS
I.U.D.
COMBINATIONS THEREOF
HORMONAL CONTRACEPTIVES 
SEQUENTIALS
NO YES IF YES
COMBINED PREPARATIONS 
MINI-PILLS
INJECTABLE PREPARATIONS 
OTHERS
PRODUCT
DATE OF LAST PRACTICE OR INTAKE
DATE OF ABORTION OF DELIVERY _______!______________________
LAST MENSTRUAL PERIOD __________ ___________________
WEEKS' OF GESTATION ________ ___________________
METHOD OF PREGNANCY DIAGNOSIS:
PHYSICAL EXAMINATION _________________ ________
NON-HORMONAL PREGNANCY TEST ____________ __________
HORMONAL PREGNANCY TEST  SPECIFY PRODUCT_________________
DURING PREGNANCY:
X-RAY EXAMINATION NO  YES. IF YES CHEST ____________
ABDOMINAL _ _ _ _ _  
OTHERS ____ SPECIFY
IF YES,   WEEKS BEFORE ABORTION
OR UNKNOWN
SURGERY NO  YES_____ SPECIFY _______________
ANAESTHETIC USED ________ ________ _____
ILLNESSES BEFORE PREGNANCY NO YES___ UNKNOWN______
IF YES, SPECIFY  ___________  • ' ___________
ILLNESSES DURING PREGNANCY NO  YES  UNKNOWN
IF YtfS, SPECIFY _______________ _________________
COMPLAINTS DURING PREGNANCY NO YES UNKNOWN_______
IF YES, FEELING SICK _ _ _ _ _ _ _
PYREXIA '
NAUSEA/HYPEREMESIS _ _ _ _ _
OTHERS _ ^ _ _ _ _  SPECIFY ■__ __________ _
EVIDENCE FOR OXYGEN DEFICIT NO  YES  UNKNOWN_________
IF YES, SPECIFY  _________ ___________________    .
EVIDENCE FOR ABNORMAL OR UNUSUAL HABITS NO___  YES___ UNKNOWN
IF YES, SPECIFY _______ _______________________ ;______________ _
V J I Y t i i J  O U iN  X X U X O X jX  J . 1 V D D
TYPE * _________
1NVJ xx io  -------  xx' iL iO j  o rx ix ix x  x
N A M E ___________________________
TOTAL DURATION OF THERAPY (months) _______________________
CONTINUOUSLY OR DISCONTINUOUSLY ______________________-
* LAST INTAKE (date) _________________________
INTAKE DURING PREGNANCY NO  YES ____ DAYS-------
INTERVAL BETWEEN DISCONTINUATION AND ONSET OF PREGNANCY (weeks)
INTERVAL BETWEEN DISCONTINUATION AND ONSET OF ABORTION (weeks)
* Use Code No. Combined preparations -1, Sequential prep - 2
mini - pills - 3> Others - 4
OTHER HORMONE THERAPY NO YES TF YES., SPECIFY
TYPE *
NAME
TOTAL DURATION OF THERAPY (months)
NO. OF INJECTIONS
LAST INTAKE OF INJECTION (date)
INTAKE/INJECTION DURING PREGNANCY NO YES DAYS
INTERVAL BETWEEN DISCONTINUATION AND ONSET OF PREGNANCY (weeks)
INTERVAL BETWEEN DISCONTINUATION AND ONSET OF ABORTION (weeks)
* Code Androgenic or anabolic steroids - 1; Progestogen - 2;
Steroidal Oestrogens - 3; Progestogen-Oestrogen comb.-4 
Nonsteroidal Oestrogens - 5j Androgen-Progestogen-Oestrogen 
Comb. - 6; ' Androgen - Oestrogen Comb. - 7; Corticoids - 8; 
Trophins - 9; Insulin - 10; Thyroids - 11; Others - 12.
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NEONATAL RECORD
NAME ,__________________  WARD      DATE OF BIRTH
S E X ___________________
STATE AT BIRTH WEIGHT
GENERAL CONDITION _________ _
LENGTH .___________________
SKIN
COLOUR ________________________
MALFORMATIONS __________________ _
WEIGHT ON DISCHARGE 
METHOD OF FEEDING_
GENERAL CONDITION
PROGRESS AND SUMMARY 
AGE ON DISCHARGE _  
DATE OF DISCHARGE __ 
ANY SPECIAL POINTS
DATE PROGRESS NOTES AND TREATMENT
the patients1 history, obstetric? history, menstrual history, 
any previous drug therapy including hormones and oral contra­
ceptives, and finally the history of their present pregnancy.
All these groups were subdivided and covered a wide range of 
questions.
When all the slides had been read and the results decoded 
into test and control groups, the clinical sheets were studied 
and the relevant information extracted. The following information 
was considered necessary for the project; age of patient, 
hazardous occupation of both mother and father, number of 
recorded still births and miscarriages, any foetal or familial 
abnormalities, any illnesses during pregnancy which resulted in 
drug therapy, hormone therapy prior to pregnancy either taken 
for menstrual or reproductive disorders, for example, infertility, 
and if oral contraceptives were taken at any time. Any patient 
in this latter group was classed as a test subject, even if 
they had only taken oral contraceptives for 1 month during 
their reproductive life. The type of oral contraceptive, it§s 
brand name and constituents and the proportions of oestrogen to 
progestagens were noted. When the information had been 
extracted, it was tabulated for easier reference and then 
grouped with the chromosome results, in order to ascertain 
if any of these variables have an adverse effect on the 
chromosomes.
5. Statistical Methods.
The majority of the statistical tests employed in this project 
were carried out with an Olivetti 101 programma. Pre-programmed 
cards were utilised and fed into the calculator with the chromosome 
results from the various groups.
Three different statistical tests were applied to the results; the 
!t! test; the Chi-squared test and correlation coefficients, and were 
used depending upon the expression of the results.
*tT test.
xr
t =
(s\)
(Nj)
+ (s |)
(n2)
x - mean 
c2S - variance 
N - number
Chi-squared test.
X  = \  (0 - E-») 0 - observed value 
E - expected value
Correlation Coefficient
- I
(x - x) (y - y)
y[[(x - x)2 l (y - y)2_
x - one variable 
y - another variable
x - mean of x
y - mean of y
When the chi-squared tests were applied to the results, the
\
chromosome readings were divided into 4 groups; 44> 45 46 and over 
46 chromosomes. The latter group included triploid, tetraploid 
endoreduplicated and polyploid cells. Structural aberrations were 
not included in these tests, although a block chi-squared test was 
carried out on the number of gaps and breaks observed in the test 
and control groups.
RESULTS.
1. Mitotic Indices.
(a.). Comparison of Micro and Macro Cultures.
In order to assess the suitability of the techniques at the 
beginning of the survey, a preliminary study was carried out 
to investigate the mitotic response of the lymphocytes of 50 
mothers1, and 60 babies* blood to PHA using both micro and macro 
methods. These results are shown in Table 3* The differences 
in mitotic indices in both blood culture methods between the 
mothers and newborns were statistically significant; (0.02> P> 0.01) 
the mean mitotic indices from the micromethod were 2.11$ and 
5.4% from the mothers and babies* cultures respectively. The 
mitotic indices from the macromethod were M*34% and 2.43% 
from the mothers and babies respectively. These results 
are statistically significant when the *t* test is applied;
(o.02>P >0.01).
Dividing cells were obtained from all the micro cultures 
set up from the newborn infants, whereas some cultures from the 
mothers failed to give any readable results. The mitotic indices 
were lower in the mothers when the macro cultures were employed,
.1.34% compared to 2,(11% in the micro cultures.
Although the ranges of mitotic indices were approximately the 
same in all of the cultures in both groups of subjects, there 
were considerable differences in their means. However, in the 
babies, there was a greater uniformity in the distribution of the 
results obtained in both the micro and macro cultures (Bishun 
and coworkers 197la)•
Table 3 • Comparison of the Mitotic Indices from the Micro and
Macro Methods.
METHODS MOTHERS NEWBORNS
MICROMETHODS
Range•. 1 - 17$ 1 - 16%
Mean. 2.11% 5.40$
Standard + 2.3 + 2.8
Deviation.
MACROMETHODS
Range. 1 - 1 5 % 1 - 1 9 $
Mean. >1.34$ 2.43$
Standard + 2.1 ' + 2.2
Deviation. i
1
(b). Comparison of Test and Control Subjects.
Further, the mitotic indices were calculated from 70 test 
mothers and babies and 70 control mothers and babies to ascertain 
whether the response of their lymphocytes to PHA was depressed 
in those patients who had taken oral contraceptives. The ranges 
and means of the mitotic indices in each type of oral contraceptive 
are shown in Tables 4 and 5 for both mother and baby. The controls 
were matched to the test groups by maternal age. Application 
of the *t* test failed to show any significant difference between 
the control and test babies.
In most cases, the mitotic indices ranged between 0 - 2$%> with 
a mean value varying between 1,1% and 17•9% in the different 
oral contraceptive types. The majority of mothers had a mitotic 
index of 6,0% and the babies of 11.0%. The mean times in months 
between discontinuation of the oral contraceptive and onset of 
pregnancy by the test mothers are also shown in Tables 4 and 5y 
the range of time was between 4*5 and 17.0 months. There does 
not appear to be any relationship between length of time of dis­
continuation of the oral contraceptive and the mitotic indices 
found, that is, there was no depression of the PHA response 
by the mothers who had taken oral contraceptives or by their 
offspring (Bishun and Mills 1971)*
2. Chromosome Results.
(a). Total Results.
Altogether 181 bloods from control mothers were set up in 
culture using either the micro method alone or both the micro 
and macro methods. Similarly, a total of 185 bloods from test 
mothers were received at the laboratory and consequently cultured. 
A total of 181 bloods from the control newborns and 185 from the
Table 4 : Comparison of the Mitotic Indices from the Test and Control
Blood Cultures. 
Mothers.
TYPE OF 
*PILL».
NUMBER
OF
PATIENTS.
TIME * 
(MONTHS)
TEST CONTROL P VALUE
OVULEN 21. 20 0 - 60 
11.4
0 - 25$ 
4.7%
.0 - 10$ 
3.2$
P>0.50
ANOVLAR 21. 8 0 - 6 0
17.0
0 - 28$ 
3.6$
0 - 1 2 $
4.2$
P >0.50
GYNOVLAR 21 
• _
11 0 - 3 6
6.3
0 - 28$ 
10.0$
0 - 2 5 $
9.9%
P >0 .50
NORINYL 1. 10 0 - 1 8
4.5
0 - 20$ 
6.0$
0 - 15$
4.6$
P > O . 5O
CONOVID E. 7 O - 4 8
11.7
0 - 25$ 
5.7%
0 - 4 $
1.1$
0.50
0.10
LYNDIOL. 7 0 - 34 
11.8
0 - 2 0 $
8.0$
0 - 26$ 
9.5$
P>0.50
MINOVLAR 21. 7
00
00
I0 0 - 28$
9.8$
0 - 22$ 
6.2$
P = 0.50
discontinued I
* length of time that the mothers had . oral contraceptives.
Table 5 • Comparison of the Mitotic Indices from the Test and Control
Blood Cultures.
Babies.
TYPE OF 
O.C.
NUMBER
OF
SUBJECTS
TIME * 
MONTHS
TEST CONTROL
1
i .
P VALUE
Is
i
!
OVULEN 21 20 0 - 6 0
11.4
0 - 28$ 
13.$
0 - 26% 
9-7*
i1
i
i
P>0.50
ANOVLAR 21 8 0 - 60 
17.0
0 - 28% 
7.2%
0 - 28% 
10.6%
P >0.10
GYNOVLAR 21 11 0 - 3 6
6.3
1 -  28$ 
17.3$
0 - 28% 
14.2%
P>0.10
NORINYL 1 10 0 - 18 
4.5
0 - 25$ 
11.$
0 - 25% 
6.8%
P > 0 J 0
t
CONOVID E 7 0 - 4 8
11.7
0 - 28% 
14.4%
0 - 15%
5.0%
r
p = 0.50
LYNDIOL 7 0 - 3 4
11.8
0 -28% 
10.8%
0 -28% 
17.9%
P>0.10
MINOVLAR 21
...
7 0 - 4 8
9.8
0 - 2 8
11.2%
8 - 25% 
17.0%
P>0.10
O.C. - Oral Contraceptive* -
discontinued;
* length of time that the mothers had oral contraceptives.
test group were cultured. In the test mothers* group, 114 blood cultures 
produced good analysable metaphase spreads and 153 blood cultures gave 
chromosome results from the test babies* group. There were readable 
results obtained from 126 control mothers and 157 control babies. The 
test and control babies gave a similar percentage of successful cultures 
but there was an approximate increase of 11% in the number of satisfactory 
cultures from the control compared to the test mothers. In the control 
group there were 81 male and 100 female babies compared to the test 
group where there were 96 male and 89 female babies.
Table 6 shows the total number of cells counted in each of the four 
groups, test mothers, control mothers, test babies and control babies.
The different categories of chromosome counts are; 44 chromosomes or less, 
45, 46, over 46 chromosomes, triploids, tetraploids, endoreduplicated cells 
and polyploid cells. Table 6b shows the numbers of gaps and breaks 
observed in the metaphase spreads.
Altogether 11,516 metaphase cells were analysed from all the four 
groups,% 2164 snd 2126 spreads from the control and test mothers respectively 
and 3676 and 3550 from the control and test babies respectively. The
f
number of metaphases counted in both mothers* groups are approximately 
equal, as were those in the babies* groups. It can be seen,that 
approximately 1500 more cells were analysed in the babies* groups than 
in their mothers* groups.
>
The modal number of the. cells was 46 chromosomes (Plates 3 and 4), 
and the least number of cells was polyploid (Plate 5)• The structural 
aberrations of the chromosomes were mainly gaps and breaks, and were not 
included in the total cell count. A total of 295 cells were found with 
an abnormal chromosome count or structural alterations, excluding those 
cells with 44 and 45 chromosomes. The majority of these abnormal cells 
were tetraploid (Plates 6 and 7), that is, a cell with 92 chromosomes.
Table 6a: The Numerical Chromosome Results from the Test and Control
Groups.
Number of cells counted.
CHROMOSOMAL
GROUPS
CONTROL
MOTHERS
TEST
MOTHERS
CONTROL
BABIES
TEST 
. BABIES
No. % No. % No. % No. %.
< 44 84 3.88 89 4.20 159 4.31 169 4.76
45 19 0.87 22 1.03 37 1.00 54 1.52
46 2009 92.83 1963 92.33 3417 92.70 3270 92.11
46 f 8 0.36 9 0.42 6 0.16 10 0.28
TRIPL03D 2 0.09 2 0.09 1 0.03 6 0.17
TETRAPL03D 28 1.29 32 1.50 47 1.25 34 0.95
ENDOREDUPLICA TED 14 .0.64 7 0.32 8 0.21 7 0.19
POLYPLOID 0 0.0 2 0.09 1 0.03 0 0.0
TOTAL NUMBER 
OF CELLS.
2164 2126 3676 3550
Table 6b.
The Structural Chromosome Aberrations in the 
Control and Test Groups.
Actual Numbers and Numbers/Cell.
STRUCTURAL
ABERRATIONS
CONTROL
MOTHERS
TEST
MOTHERS
CONTROL
BABIES
TEST
BABIES
GAPS
11 8 - 3
\A \ / .  /V A
14
0.0051 0.0037 0.0008 0.0039
BREAKS
11 12 8 4
0.0051 0.0056 0.0021 0.0011
TOTAL 22 20 11 18
P = 0.01 (Chi-squared test) between the number of gaps 
present in the control and test babies groups.
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Plate 3 • Karyotype of a Normal Female. 46/XX. 
Magnification x 3500.
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Plate 4 : Photograph of a Normal Male. 46/XY,
Magnification x 3500.
♦Plate 5 • Photograph of a Polyploid cell5 containing over 
100 chromosomes. Magnification x 3500.
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Plate 6 : Karyotype of a Hypotetraploid cell containing 
90 chromosomes. Magnification x 3500.
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Plate 7 : Photograph of a Tetraploid cell . Magnification x 3500.
Both the control and test mothers had 52 cells with numerical disorders 
present in their total cell counts; the control babies 63 and the test 
babies 57 cells. Altogether, a total of 71 structural abnormalities 
were seen in the chromosomes, 22 of which were found in the control 
mothers1 group, 20 in the test mothersT, 11 in the control babies1 and 
18 in the test babies1 group.
There were 6 triploid cells (Plates 8 and 9) found in the test babies1 
group compared to only 1 found in the control babies. It was found that 
& greater number of endoreduplicated cells were present in the control 
group (mothers) than any of the other three groups and there was a 
significant difference between the numbers of endoreduplicated cells 
in the control mothers and their offspring when the Chi squared test 
was applied (0.01 >P > 0.001). The control babies were found to have more 
tetraploid cells present than the corresponding test group, whereas the 
test and control mothers had approximately the same number of tetraploid 
cells. There was a large number of hypodiploid cells, that is, cells 
with less than 46 chromosomes (Plate 10). This high frequency of hypo- 
diploidy was probably due in part to broken cells being counted early in 
the project. The difference between the numbers of hypodiploid cells 
in the test mothers and their babies was significant (0.05<>P> 0.02)•
The total results were divided into 8 chromosome groups (Tables 6 and 6b) 
and the test were compared to the control results for each chromosome 
group. No significant difference between the control and test results 
from the mothers was found when the Chi squared test was applied. However, 
in three of the chromosomes groups; triploidy, aneuploidy and hypodiploidy 
there was a significant difference between the numbers counted in the 
control and test babies (P = 0.05)* (P = 0.05) and (0.05 P > 0.02).
In the control mothers1 group 0.005 gaps per cell and 0.005 breaks 
per cell were observed (Plates 11, 12 and 13); 0.004 gaps per cell and 
0.006 breaks per cell were found in the test mothers1 group. In the
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Plate 8 : Karyotype of a Hypotriploid cell containing 
60 chromosomes. Magnification x 3500.
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Plate 9 i Photograph of a Triploid cell containing 69 chromosomes.
Magnification x 3500.
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Plate 10 : Karyotype of a Hypodiploid cell containing
45 chromosomes. 45/XX - E. Magnification x 3500.
Plate 11 : Photograph of a cell showing structural aberrations of
gaps and breaks. Magnification x 3500.
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Plate 12 : Photograph of a metaphase cell showing chromatid breaks.
Magnification x 3500.
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Plate 13 1 Photograph of a cell showing a quadriradial configuration;
scored as two breaks. Magnification x 3500.
control babies’ group, O.OOOb gaps and 0.002 breaks per cell were 
observed compared with 0.004 gaps and 0.001 breaks per cell in the 
test babies’ group. There was no statistical significant difference 
when the Chi-squared test was applied to the numbers of structural 
abnormalities (breaks plus gaps) found in the control mothers when 
compared to the test mothers, but a significant result was obtained 
in the numbers of gaps between the test and control babies (P = 0.01).
In order to test whether bias had been introduced, because of 
the great difference in the number of cells analysed from the subjects, 
a further analysis was undertaken. The results from those patients 
in which less than 10 cells were available for counting were 
eliminated from the calculations. For the remaining subjects, only 
the chromosome results from the first 10 cells analysed were included.
This would ensure that the results from each subject contributed 
equally to the overall picture. The numbers of subjects and cells 
in both analyses are shown in Table 6c.
It was found that this modification to 10 cells produced a decrease 
of 36.5% and 33<3% in the number of subjects included in the groups 
of test and control mothers respectively. In the babies case, this 
decrease was not so large, 17.8% and 18.3% in the test and control 
babies respectively. This limitation of the analysis to 10 cells 
meant that only one third of the total number of cells counted were 
-included in the modified calculations, thus, the number of cells with 
chromosome abnormalities was very small in each group.
It can be seen from Table 6d that in the majority of chromosome 
groups there is no difference between the control and test results.
There were more triploid cells in the test babies’ group compared to 
the control babies’ group, but the number of cells is too small to test 
statistically. However, this finding substantiates the initial 
difference found between the two groups when all the cells were included 
in the analysis. The control babies were found to have more tetraploid 
cells, but the difference was not so great as previously observed, Table 6a
xaoie oc.
Details of Subjects and Cells selected and analysed.
CONTROL
MOTHERS
TEST
MOTHERS
CONTROL
BABIES
TEST
BABIES
Total number of 
subjects in the survey. 181 185 181 185
Total number of 
subjects from whom cel] 
counts were obtainable.
126 114 157 153
Total number of sub­
jects from whom at 
least 10 cells were 
counted.
80 76 129 125
Total number of cells 
counted. 2164 2126 3676 3550
Number of cells
(10 from each subject) 800 760 1290 1250
The percentage of endoreduplicated and hypodiploid cells xn the 
control and test mothers respectively was greater than in their babies; 
this confirms the earlier finding. Similarly, the argument regarding 
the numbers of gaps, as mentioned in the preceding section has not 
-been invalidated, i.e. a greater number found in the test babies’ group 
compared to the control babies’ group (Table 6e). One difference 
found in this analysis was a small increase in the number of breaks in 
the chromosomes of the test mothers compared to the control mothers, 
0.0092 per cell compared to 0.0062 per cell respectively. No difference 
was found between the two groups when all the cells were included in 
the analysis (Table 6b).
Distribution of Cell Types in Subjects from whom 10 cells were
available for analysis.
CHROMOSOME GROUPS
CONTROL
MOTHERS
TEST
MOTHERS
CONTROL
BABIES
TEST
BABIES
No. % No . % No.. % No. %
<44 23 2.9 25 3-3 43 3.3 48 3.8
45 6 0.7 6 0.8 10 0.8 14 1.1
46 747 93.4 705 92.7 1211 93.9 U 64 93.9
46 + 5 0.6 3 0.4 4 0.3 3 0.2
TRIPLOID 1 0.1 2 0.3 0 0.0 3 0.2
TETRAPLOID 12 1.5 11 1.5 16 1.2 14 1.1
ENDOREDUPLICATED . 6 0.7 6 0.8 5 0.4 4 0.3
POLYPLOID 0 0.0 2 0.3 1 0.1 0 . 0.0
TOTAL NUMBER OF 
CELLS 800 760 1290 1250
TOTAL NUMBER OF 
SUBJECTS 80 76 129 125
Table 6e.‘ (Comparison with Table 6b).
Total number of Structural Aberrations found; also expressed as
Number per Cell.
GAPS
3
0.0037
4
0.0053
1
0.0008
4
0.0032
BREAKS
5
0.0062
7
0.0092
1
0.0008
2-
0.0016
Although statistical tests were not performed on the*latter results, 
due to the small number of chromosome abnormalities found, the results 
nevertheless confirm the evidence presented earlier, using the total 
cell count which showed that no bias was introduced using different 
numbers of cells from each subject.
(b). Range of Chromosome Abnormalities in Test and Control Groups.
Four histograms were drawn (Figs 1 - 4) of the percentage of cells
with chromosome abnormalities. Two histograms were constructed for each 
of the mothers and babies groups, one including and one excluding 
-chromosome counts of less than 46. In Figure 1, there is a greater 
percentage of mothers with 8 - 12% of cells with chromosome abnormalities 
in the test group than those found in the control group. When the 
hypodiploid cells were excluded, the picture was altered, in that the 
peak percentage of cells with chromosome abnormalities occur at the 
5% level in the test mothers and at the 10% level in the control 
mothers.
In the histograms of the test babies, there was a greater percentage 
of cells with chromosome abnormalities between the 10 - 25% level,
compared with the control group where the majority of babies had 3 - 10%
of their cells abnormal. When the hypodiploid cells were excluded, there 
was again a shift to the left in the range of the percentage of cells 
with abnormal chromosomes in the case of the test babies.
(c). Chromosome results of the various Oral Contraceptive Types.
The detailed counts of all the individual control mothers and babies
can be seen in the Appendices 1 and 2. The test groups are divided into 
the different oral contraceptive types and can be seen in Appendices 3 and 
4 . A summary of these results are shown in Tables 7*8,9 and 10. Only the 
main 12 types of oral contraceptives which were taken by the mothers in
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this project are listed, namely Ovulen, Gynovlar, Lj^ ndiol, Anovlar, Volidan, 
Conovid, Minovlar, Nuvacon, OrthoNovum, Sequens, Norinyl and Normenon.
Table 11 shows a resume of the percentage of cells with chromosome 
abnormalities of the test mothers who had taken these respective 
contraceptives and also of their babies. No abnormal cells were found 
in the babies whose mothers had taken Anovlar, Nuvacon or Normenon; in the 
test mothers* group, no chromosome abnormalities were found in those 
subjects who had taken Nuvacon or Volidan.
In the newborn babies, the mothers of whom had taken OrthoNovum or 
Conovid, there was a high percentage of cells with chromosome abnormalities. 
These were both higher than the mean percentage of abnormal cells found in 
the total test and control groups (babies). Table 12 lists the percentages 
of mothers who used each type of oral contraceptive and have one or more
chromosome abnormality. In the Gynovlar, OrthoNovum and Sequens groups, half
the number of women were found to have chromosome abnormalities. Tetraploid
cells were found in over 4% of the cells analysed in those babies whose
mothers had taken Volidan, but this was only a small sample (3 babies).
A block Chi squared table was constructed, consisting of the numbers 
of mothers who had chromosome abnormalities and the numbers with the 
modal chromosome constitution (all cells with 46 chromosomes) in each 
oral contraceptive group. It was found that there was a significant 
result in the test babies* group (0.05>P >0.02) but not in the test 
mothers*. Also, the number of abnormal cells was compared with the number 
of normal cells in each oral contraceptive type and there was a significant 
difference between the different types (babies only) (P — 0.02). Also, 
the Chi squared test was used to compare the chromosome results of.each 
type of oral contraceptive with the total control and test results, but 
no significant difference was found.
(d)• Analysis of Hyperdiploid Cells.
All. cells in which 47 or more chromosomes were counted, were further
Table 11 : The percentages of cells with abnormal chromosomes in
the Test Group in each type of Oral Contraceptive. 
Excluding hypodiploid cells
TYPE OF O.C. MOTHERS (%) BABIES (%)
OVULEN 4.47 1.44
GYNOVLAR 4.71 2.03
LYNDIOL 3.44 2.09
ANOVLAR 1.38 0.0
CONOVID 2.56 4.58
MINOVLAR 1.45 O .67
NUVACON 0.0 ‘ 0.0
VOLIDAN 0.0 4.12
ORTHO-NOVUM 4.44 4.63
SEQUENS 2.00 1.92
NORINYL 1.14 2.02.
NORMENON 4.00 0.0
TOTAL TEST 
(mean)
3.34 1.81
TOTAL CONTROL 
(mean)
3.40 ■1.97
Table 12 : The percentages of Mothers and Babies with Chromosome
Abnormalities in each type of Oral Contraceptive. 
Excluding hypodiploid cells
TYPE OF O.C. MOTHERS (%) BABIES {%)
OVULEN 27.2 22.6
GYNOVLAR 50.0 31.2
LYNDIOL ' 42.8 27.3
ANOVLAR 33.3 0.0
CONOVID 25.0 71.4
MINOVLAR 25.0 12.5
NUVACON 0.0 0.0
VOLIDAN 0.0 100.0
ORTHO-NOVUM 50.0 57.1
SEQUENS 50.0 66.6
NORINYL 25.0 25.0
NORMENON 100.0 0.0
TOTAL TEST 
(mean)
33.3 32.0
TOTAL CONTROL 
(mean)
26.6 27.5
analysed to ascertain to which groups, if any, (according to the Denver 
system of classification) the extra chromosomes belonged (Tables 13j 14*
15 and 16), see Plates 14 and 15* The morphology of some of the chromosomes 
was so distorted that it was not possible to fit them into any recognisable 
groups. Also, due to the overlapping of some of the chromosomes in the 
metaphase spread, it was not always possible to find the correct group for 
the extra chromosomes. Some of the counts in this group had 5 or 6 extra 
chromosomes (Plate 16).
(e). Chromosome Abnormalities and Maternal Age.
Scatter diagrams (Figs. 5 - 12) were constructed, two for each of the 
four groups of subjects. The odd numbered figures (Figs. 73 9 and 11)
included the chromosome counts of less than 46 chromosomes and the even 
numbered figures (Figs. 6, 8, 10 and 12) excluded these hypodiploid cells. 
The percentage of cells with chromosome abnormalities was plotted against 
maternal age to ascertain a correlation between the two variables. In 
all of the 8 figures, no correlation was found to exist, as there was 
a random scatter of points. The correlation coefficients ranged from 
0.062 ‘to 0.172 when a rank correlation test was carried out on the 
results. Therefore maternal age can be discounted as a factor affecting 
chromosome results.
To substantiate these findings, tables were prepared (Appendix 5) 
to ascertain whether women of 35 years and over had a greater percentage 
of cells with chromosome abnormalities than the total group as a whole.
A resume of these results are shown in Table 17* In Table 18 the 
percentages of mothers (over 34 years) and babies with abnormal chromosome 
counts are shown.
(f). Miscarriages and Chromosome Abnormalities.
Tables were prepared to ascertain whether women who had previously 
miscarried also showed a high percentage of cells with chromosome 
abnormalities; these are shown in Appendix 6. The ages of the mothers
Table 13 : Classification of the hypeidiploid cells in the Test Mother
Group. (Chromosome counts of 47 - 58-)
TYPE OF ORAL LABORATORY CHROMOSOME CLASSIFICATION
CONTRACEPTIVE NUMBER NUMBER
ANOVLAR, 
NORINYL AND 
OVULEN.
170 47 One small chromosome, 
either from group F or G.
NOT KNOWN 492 51 One small acrocentric 
and the other four from 
groups E, F and C.
OVULEN • 636 48
:
Two abnormal chromosomes, 
impossible to classify.
;
OVULEN 388 47 Either an X chromosome or 
belonging to C group.
OVULEN 388 47
!
One small acrocentric,
G group. |
'
GYNOVLAR 218 47
|
One small chromosome 
belonging to F group.
i
GYNOVLAR 434 48
i
One indistinguishable 
chromosome and one group ;
C chromosome. j
1
GYNOVLAR 434 47
*
A very small condensed j 
chromosome, possibly 
from either F or G group. 1
j
GYNOVLAR 786 47 An extra C group chromo- j 
some. |
Table 14 : Classification of the hyperdiploid cells in the Control
Mothers1 Group.
.LABORATORY 
NUMBER
CHROMOSOME
NUMBER
CLASSIFICATION
292 48 Both chromosomes abnormal, 
not possible to classify them,
346 48 Two small condensed chromo­
somes, probably F group.
422 47 One small acrocentric 
chromosome.
432 47 One small acrocentric 
chromosome, group G or a Y.
432 47 One small indistinguishable 
chromosome.
490 47 A large acrocentric D group 
chromosome.
•
490 47 A large acrocentric D group 
chromosome.
790 47 A small indistinguishable 
chromosome.
Table 15 : Classification ofhyperdiploid cells in the Test Babiest
Croup.
TYPE OF ORAL LABORATORY CHROMOSOME CLASSIFICATION
CONTRACEPTIVE NUMBER NUMBER
MINOVLAR 351 50
Four extra chromosomes 
belonging to groups C, 
E and G.
NORINYL 445 48 One group B and one group 
E chromosome.
NORINYL 445 51
Five extra chromosomes 
belonging to groups C 
and E.
NORINYL 445 48 One C group chromosome 
and one indistinguishable 
chromosome.
OVULEN 263 47 Either a Y or a G group 
chromosome.
LYNDIOL & 
NORINYL
903 47 Not possible to classify 
the extra chromosome.
CONOVID E 236 52 Six extra chromosomes, 
XXY.
ORTHO-NOVUM 439 47 One abnormal chromosome. 
Impossible to classify.
ORTHO-NOVUM 439 47 One small chromosome, eithe 
belonging to F or G group•
Table 16 : Classification of hyperdiploid cells in the Control
Babies* Group.
LABORATORY
NUMBER
CHROMOSOME
NUMBER
CLASSIFICATION
55 53 Seven extra chromosomes 
belonging to groups C, F and 
G.
417 47 One small chromosome, 
possibly group F.
421 47 One extra X chromosome, XXY.
421 47 One extra X chromosome, XXY.
421 47 One extra X chromosome, XXY.
877 50 Four extra chromosomes 
belonging to groups C and E.
KARYOTYPE OF H U M A N  M A L E 47 X X Y  B421.
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Figure 5«
A Scatter Diagram to ascertain whether there is any correlation
between Maternal Age and Chromosome Abnormalities.
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Figure 6.
A Scatter Diagram to ascertain whether there is any correlation
between Maternal Age and Chromosome Abnormalities.
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Figure 1.
A Scatter Diagram to ascertain whether there is any correlation
between Maternal Age and Chromosome Abnormalities..
Test Mothers.
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Figure 8.
A Scatter Diagram to ascertain whether there is any correlation
between Maternal Age and Chromosome Abnormalities.
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Figure 9»
A Scatter Diagram to ascertain whether there is any correlation
between Maternal Age and Chromosome Abnormalities.
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Figure 10.
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between Maternal Age and Chromosome Abnormalities.
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Figure 11.
A Scatter Diagram to ascertain whether there is any correlation
between Maternal Age and Chromosome Abnormalities.
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Figure 12.
A Scatter Diagram to ascertain whether there is any correlation
between Maternal Age and Chromosome Abnormalities.
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Table 17 : Percentages of cells with chromosome abnormalities in
Mothers (over 34 years) and Babies compared to the 
Control and Test Groups.
35 AND OVER • TOTAL
YEARS OF AGE. GROUP
CONTROL MOTHERS 2.26% 3.4($
TEST MOTHERS 3.06$ 3.34%
CONTROL BABIES 2.27$ ■1.97*
TEST BABIES 2.03% 1.81$
Table 18 : Percentages of Mothers (over 34 years) and Babies with
chromosome abnormalities compared to the total Test 
and Control Groups.
35 and OVER 
YEARS OF AGE
TOTAL
GROUP
CONTROL MOTHERS 33.33% , 26.61%
TEST MOTHERS 25.00% 33.33%
CONTROL BABIES 18.75% 27.39%
%
TEST BABIES 11.11% 31.17%
were not included , because in many cases it was not known at which age . 
the mother had miscarried. There were 42 women in the test group who 
had had one or more miscarriage, and analysable cells were available from 
29 women, with a total of 525 cells counted from their blood cultures 
(Table 19)* Twenty-two women in the control group had suffered mis­
carriages and a total of 376 cells were analysed from 17 of these 
mothers•
In Table 19 it can be seen that there was an incidence of 1.14% 
tetraploid cells in the test mothers (with miscarriages) compared with 
1.50% of these cells in the total test mothers (Table 6). A total of 
0.19% of the cells were endoreduplicated in the former group compared 
with 0.3% in the total group (Table 6). One triploid cell was seen (0.19%) 
in the miscarriage group and 2 (0.09%) in the total group, also, 2 (0.38%) 
polyploid cells were observed in the miscarriage group. Two breaks (0.38%) 
were seen in the chromosomes from the test mothers who had miscarried.
In the control mothers1 group (with miscarriages), 1.06% of the 
cells were tetraploid compared with 1.29% tetraploid cells in the total 
group: 0.-53% of the cells were endoreduplicated compared with 0.64% 
in the total results; one break (0.26%) was scored in the former group 
compared with 0.51% in the total results.(Table 6b). By comparing'the 
frequency of cells with chromosome abnormalities in the test and control 
mothers who had miscarried, it can be seen that the percentage of abnormal 
chromosome counts are similar except that in the control group there 
are no gaps, triploid cells or polyploid cells (Table 19)*
The chromosome results of the babies whose mothers had had previous 
miscarriages can also be seen in Appendix 6. A- total of 890 cells were 
analysed from the test babies and 498 from the control babies. The 
percentage of chromosome abnormalities in these groups were compared with 
those found in both the total groups. All of the frequencies were similar 
to those found in the total groups.
Table 19 : Percentages of cells in each category of aberrations i
.Mothers who have previously miscarried and in their Babi
TYPE OF CHROMO­
SOME ABNORMALITY
TEST
MOTHERS
(»
CONTROL
MOTHERS
.(»
TEST
BABIES
(%)
CONTROL
BABIES
(%)
TRIPLOIDY 1.14 1.06 0.67 1.2 |
TETRAPLOIDY 0.19 0.0 0.22 0.0 |
POLYPLOIDY 0.38 0.0 0.0 0.0
ENDOREDUPLICATED 0.19 0.53 0.11 0.0
1
GAPS 0.38 0.0 0.44 0.0 1
BREAKS 0.38 0.26 0.11 0.0
NUMBER OF
PATIENTS FROM
WHOM CHROMOSOMES 
WERE COUNTED.
29 17 37 ‘ »
. NUMBER OF CELLS 
COUNTED. 525 376 890 498
The individual percentages were then added together in each of the 
four groups, the means calculated and compared to the mean percentages 
of chromosome abnormalities found in the total groups. It can be seen 
(Table 20) that there is no increase in the numbers of chromosome 
abnormalities in mothers who have previously miscarried and their 
newborns, when compared with the total mean percentages of abnormal cells. 
Table 21 shows the percentages of mothers who have miscarried and their 
babies who have abnormal chromosomes present in their cells, compared 
with the percentages of mothers and babies with chromosome abnormalities 
in the total groups. These percentages were very similar in both the contro 
and test groups.
(g). Length of time the Test Mothers had taken Oral Contraceptives and 
the time between discontinuation and pregnancy.
The chromosome abnormalities found in all of the test mothers were 
listed beside each type of oral contraceptive with the length of time 
the mothers had taken their respective contraceptives, together with 
the length of times between ceasing oral contraception and pregnancy 
(Appendix 7) •
Scatter diagrams were drawn (Figs. 13 and 14) of the percentage 
chromosome abnormalities of the mothers and babies over the length of 
time the mothers had been using oral contraception. There was found 
to be no increase in the percentage of chromosome abnormalities with 
increased time of taking these contraceptives. The correlation coefficients 
were calculated to be 0.0572 and 0.0130 for the mothers and babies 
respectively.
The varying lengths of time the mothers had taken oral contraceptives- 
and the time between ceasing these and conception, were totalled under 
each contraceptive type and the ranges and means of these times found 
(Tables 22 and 23). In 7 groups, mothers who had chromosome abnormalities 
were on their respective contraceptives for a longer period than those 
in the total group. It was also found that the interval between oral
Table 20 : Percentages of cells with chromosome abnormalities in
Mothers who have previously miscarried and their offspring 
compared to the total Test and Control Groups.
- MOTHERS WITH 
PREVIOUS 
MISCARRIAGES.
TOTAL GROUPS.
CONTROL MOTHERS 3A9% 3.-40^
TEST MOTHERS 2.70% 3* 34%
CONTROL BABIES 1.8056 . 1.97$
•
TEST BABIES 1.8 si 1.81J6
Table 21 : Percentages of Mothers who have previously miscarried
and Babies with chromosome abnormalities compared with 
the total Test and Control Groups.
MOTHERS WITH 
PREVIOUS 
MISCARRIAGES.
TOTAL GROUPS.
CONTROL MOTHERS 35.2956 26.61%
TEST MOTHERS 31.0356 33.33%
CONTROL BABIES 26.32/6 • 27.39%
t
TEST.BABIES 29.73# 31.17%
Figure 13.
A Scatter Diagram of the length of time the Test Mothers had taken
Oral Contraceptives v Chromosome Abnormalities.
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Figure 14.
A Scatter diagram of the length of time the Test Mothers had taken
Oral Contraceptives v Chromosome Abnormalities.
Babies.
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(with and without chromosome abnormalities) had taken
Oral Contraceptives, and the time between discontinuation
— ----- ■ ■ -..
TYPE OF O.C.
MEAN LENC
TIME OVER 1 
O.C. WAS TJ
JTH OF
m C H  THE 
CKEN. ..
MEAN LENGTH OF
TIME BETWEEN DISCONTIN­
UATION AND PREGNANCY.
OVULEN
+
CBNORMALITIE
(months)
5 TOTAL 
(months)
+
lBNORMALITIEE
(months)
TOTAL
(months)
28.8 22.8 I4.O 11.3
GYNOVLAR 23.1 22.4 17.5 9.8
NORINYL 14.5 10.1 12.2 5.7-
LYNDIOL 17-6 17.2 14*6 10.0
ANOVLAR 15.0 20.4 14.5 14.8
MINOVLAR 6.0 9.0 - 9.1
CONOVID 22.5 14.9 24.0 9.9
ORTHO-NOVUM 31.5 29.8 5.0 : 3*2
VOLIDAN - 14*6 - 4.3
SEQUENS 30.0 26.0 - 8.5
NORMENON 2.0 2.0 - 0.0
NUVACON - 6.3 - 6.3
COMBINATION OF 
.JTWO O.C.
14.5 16.3 8.2 7.2
COMBINATION OF ' 
.MORE THAN TWO O.C
7.0
1 17.9
2.0 2.9
UNKNOWN NUMBER 
OF O.C.
8.2 21.3 31.5 18.6
TOTAL MEANS 17.5 18.7 16.9 9.5
Mothers•
and the time between discontinuation and the onset of
pregnancy.
TYPE OF O.C. MEAN LENGTH OF TIME OVER WHICH THE MOTHERS 
HAD TAKEN THE O.C. 
(months)
MEAN LENGTH OF TIME 
BETWEEN DISCONTINUATION 
OF THE O.C. AND PREG­
NANCY. (months)
OVULEN
+
IBNORMALITIES TOTAL
+
^BNORMALITIES TOTAL
29.4 22.8 4.0 11.3
GYNOVLAR 30.8 22.4 12.0 9.9
NORINYL 4.0 10.1 10.6 5.8
LYNDIOL 14.6 17.2 14.3 10.0
ANOVLAR 20.4 - 14.8
MINOVLAR 28.0 9.0 4.0 9.1
CONOVID 14.8 14.9 6.8 9.9
ORTHO-NOVUM . 28.2 29.8 4.7 3.2
VOLIDAN 14.6 14.7 4.3 4.3
SEQUENS 33.0 26.0 0.7 8.5
NORMENON - 2.0 - 0.0
NUVACON - .6.3 - 6.3
COMBINATION OF 
2 PILLS 21.1 16.4 9.0 7.2
COMBINATION OF 
THAN 2 PULS.
24.6 17.9 - 4.2 2.9
UNKNOWN NUMBER 
OF TYPES 22.0 21.3 N.K 18.6
TOTAL MEANS 23.1 18.7 7.2 9.5
Babies
contraceptives and conception was increased in the majority of cases 
where the subjects had chromosome abnormalities. The. mothers of the 
offspring who had chromosome abnormalities, had been taking oral 
contraceptives for a longer period than the mean length of time that all 
the mothers had been taking their respective contraceptivesf
(h). Other factors which might be responsible for Chromosome Abnormalities
• found in the Test and Control Groups.
All the mothers and babies who were found to have chromosome 
abnormalities in one or more of their cells were listed in tables which 
can be seen in Appendix 8. Any relevant information from the patients1 
history which might be a contributory factor towards chromosome 
abnormalities was written beside the laboratory number. The factors 
included the following; hazardous occupation of both mother and father; 
X-ray of mother during her pregnancy; any illness of the mother either 
before or during pregnancy; any abnormalities which have been found 
in close relatives of mother or father. Appendix 8 also lists the babies 
who have chromosome abnormalities.
Agents which are known to, or might produce chromosome aberrations 
such as hazardous occupations, X-rays and drugs are listed in Tables 
24* 25 and 26 respectively. The total numbers and percentages of 
mothers and babies with normal and abnormal chromosome counts who have been 
in contact with these agents are listed together with those mothers 
who have not come into contact with these hazards.
In the hazardous occupation category, there was a higher percentage 
of test mothers with chromosome abnormalities, compared with the non 
hazardous group (31.5% compared with 15*1%)• In the case of the 
fathers* occupations, there was a considerable difference (24.0% 
compared to 14.1%). In Table 25* 48.6% of the test mothers received 
X-rays during pregnancy amd 21.0% of these showed chromosome abnormalities. 
In the other three groups a similar trend was observed.
Table 24 : Test and Control Babies with chromosome aberrations
whose parents were exposed to hazardous occupations. 
Frequency of aberrations in these Mothers.
GROUPS
NUMBER OF 
ADULTS + 
HAZARDOUS 
OCCUPATIONS
NUMBER OF 
ADULTS + 
HAZARDOUS 
OCCUPATIONS 
+ CHR. ABN.
NUMBER OF 
ADULTS W/0 
HAZARDOUS 
OCCUPATIONS
NUMBER OF | 
ADULTS W/O ! 
HAZARDOUS j 
OCCUPATIONS | 
■+ CHR. ABN.;
M F M F M F M F !
TEST
MOTHERS 19 50
(10) (27)
6 12 
(31) (24)
166 135 
(90) (73)
25 19 j 
(15) (14)|
CONTROL
MOTHERS 21 57 
(12) (31)
2 11 
( 9) (19)
160 124 
(88) (68)
30 21 
(19) (17)
TEST
BABIES. 19 50 
(10) (27)
6 12 
(31) (24)
166 135 
(90) (73)
42 *36 
(25) (27)
CONTROL
Babies.
21 57 
(12) (31)
6 15 
(29) (26)
160 124 
(88) (68)
37 28 
(23) (22)
* percentages in parenthesis.
Table 25 : Number of Test and Control Babies and Mothers (who were
exposed to radiation) showing chromosome aberrations.
GROUPS
NUMBER OF 
MOTHERS + 
X-RAYS
NUMBER OF 
MOTHERS + 
X-RAYS + 
ABNORMAL 
CHROMOSOMES
NUMBER OF 
MOTHERS W/0 
X-RAYS
NUMBER OF 
MOTHERS W/O 
X-RAYS + . 
ABNORMAL 
CHROMOSOMES
TEST 
' MOTHERS• 90
(48.6)
19
(21.0)
95
(51.4)
12
(12.6)
CONTROL
MOTHERS 98
(54.1)
10
(10.2)
83
(45.8)
22
(26.5)
TEST
BABIES 90
(48.6)
22
(24.4)
95
(51.4)
26
(27.4)
CONTROL
BABIES
•
98
(54.1)
19
(19.4)
83
(45.8)
22
(26.5)
* percentages in parenthesis.
Table 26 : Number of Test and Control Babies and Mothers (who were
exposed to drugs during pregnancy) showing chromosome 
abnormalities.
GROUPS
NUMBER OF 
MOTHERS + 
DRUGS
NUMBER OF 
MOTHERS + 
DRUGS + 
ABNORMAL 
CHROMOSOMES
NUMBER OF 
MOTHERS 
W/O DRUGS
NUMBER OF 
MOTHERS W/0 
DRUGS + 
ABNORMAL 
CHROMOSOMES
TEST
MOTHERS
64
(35.3)
11
(17.2)
121
(64.7)
20
(16.5)
CONTROL
MOTHERS 63
(34.2)
12
(19.0)
118
(65.8)
20
(16.9)
TEST
BABIES 64
(35.3)
8
(12.5)
121
(64.7)
41
(33.8)
CONTROL
BABIES 63
(34.2)
14
(22.2)
118
(65.8)
29
(24.6)
*■ percentages in parenthesis.
The frequencies of mothers with chromosome abnormalities in the 
total group was the same as in mothers who had taken some form of 
drug during pregnancy. Details of numbers and percentages of subjects 
are shown in Table 26.
(i). Chromosome Abnormalities and Constituents of the Oral Contraceptives.
. There are 8 main constituents found in all of the contraceptives 
used in this study; two oestrogens and six progestagens. Tables 27 and 28 
were compiled with the various constituents of the oral contraceptives, 
the total number of cells counted and the percentage of abnormal cells • 
in both the mothers and babies. Only those mothers who had taken one 
type of contraceptive were included in the tables•
In the mothers1 group, it was found that ethynodiol diacetate showed 
the highest percentage of abnormal cells (4*39%) and chlormadinone. 
acetate with 4*0% of abnormal cells, although in the latter group only 
25 cells were analysed. It can be seen from Table 27 that the above 
two constituents produced a higher percentage of abnormal cells 
than found in the total test and control group. In the test babies1 
group, the largest percentage of abnormal cells was found after their 
mothers had taken norethynodrel acetate with mestranol (4*6%). This 
percentage is also high when compared with the percentage of abnormal 
cells found in both the total test and control groups (1 ,8% and 2.0% 
respectively) • As there was only one oral contraceptive with Norethynodrel 
as a constituent it was not possible to prove that this steroid 
was responsible for this high percentage of chromsome abnormalities.
To ascertain whether these results tallied with the number of 
mothers who possessed abnormal cells rather than the percentage of 
abnormal cells, another table was constructed with the various 
constituents of the oral contraceptives, the number of mothers who 
had taken these chemicals and the percentage of mothers with chromsome 
aberrations. It was found again that chlormadinone acetate produced
Table 27 : Frequencies of abnormal cells found in Mothers and Babies
in each Oral Contraceptive Constituent Group. 
Mothers.
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Acetate
J \ 2.7$
(47D
1.8$
(219)
Ethinyl
Oestradiol
1.256
(656)\ 0.0$(60)
Mestranol 2.0% (796) \ 3.55?(116) 4.3$(314) 2.6% (78) - * ' 2.0$(50)
Lynestranol
2.1$
(239)\
Ethynodiol
Diacetate
1.5$
(629) \
Norethynodrel 4.6$
(174) \
Megestrol
Acetate
2.2$
(181) \
Chlormadinone
Acetate
*I ' 1.9*
(52) \
Babies.
Total test mothers 3*3% (2126) Total control mothers 3*4% (2164)
Total test babies 1.8$ (3550) Total control babies 2.0 (3686)
Number of cells analysed in parenthesis.
Table 28 : Percentages of Mothers and Babies with chromosome
abnormalities in each Oral Contraceptive Constituent Group.
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Vcetate \ 36.0$(22) 33.0$(12)
Ethinyl
Oestradiol
20.0$
(30)\ 0.0$(3)
Mestranol 36.8$
(19) \ 42.8%(7) 27.3^(22) 25.0% (8) 50.0%(2)
Lynestranol 27.2% 
(ID\
Ethynodiol
Diacetate
22.5#
(31) \
Norethynodrel 71.4$
(7) \
Megestrol
Acetate
50.0$
(6) \
Chlormadinone
Acetate
33.3$
(3) \
Babies.
Total test mothers 33*3% (114) Total control mothers 26.6$ (124)
Total test babies 31•2$ (154) Total control babies 27.4% (157)
Number of subjects in parenthesis.
100$ of mothers with chromosome abnormalities, but' from Table 28 it can 
be seen that only one mother was in this group. Forty-three per cent 
of mothers who had taken Lynestranol with Mestranol showed chromosome 
abnormalities, which was an increase compared with the total test and 
control groups (33«3$ and 26.6$ respectively). In the group Ethynodiol 
diacetate a high percentage of abnormal cells were observed (Table 27) 
but only 27$ of mothers had these chromosome abnormalities, similar to 
that found in the total test and control mothers 1 groups• In the test 
babies1 group, the highest percentage of babies with abnormal cells 
were observed after their mothers had taken Norethynodrel acetate 
(71.4$) and Megestrol acetate (50.0$). Both these percentages are higher 
than those found in the total groups.(31•2$ and 27.4%)*
(j). Paired Mothers and Babies with Chromosome Abnormalities.
It was found that 11 control mothers who had abnormal chromosome
counts or breaks and gaps, had offspring with one or the other
abnormality present in their cells. In the test group 13 pairs of
mothers and their babies were found to have cells with chromosome 
%
abnormalities. This can be seen in Tables 29 and 30.
In the control group (Table 29) it can be seen that in 8 pairs, 
at least one type of chromosome abnormality is the same in the mother 
and her baby. For example, it was found in one pair that the mother 
and baby both had endoreduplicated cells amongst their metaphase spreads. 
In Table 30 the test mother and baby pairs with abnormal chromosome 
counts were divided into the different oral contraceptive types. It 
was found that 10 mothers had only taken a single preparation and one was 
unknown. Fifty per cent of these mothers had taken hormonal contra­
ception for longer than 24 months and no more than 2 mothers had 
taken the same type of preparation. Of these pairs, 7 had similar 
chromosome abnormalities, usually in the form of tetraploidy. There 
was found to be no significant difference between the observed and 
expected values in both control and test groups. .. . .
Table 29 : Types of chromosome abnormalities in Mother /Baby Pairs.
Control.
LABORATORY
NUMBER
NUMBER OF 
CELLS TYPE OF ABNORMALITIES
32 20 1 tetraploid and 1 endoreduplicatec
31 20 1 tetraploid.
38 27 #4 tetraploids, 1 endoreduplicated. 
'2 gaps.
37 20 1 endoreduplicated.
48 25 2 gaps.
47 21 1 tetraploid.
346 25 jl cell with 47 chromosomes, j 
1 tetraploid.
345 25 1 tetraploid.
382 15 1 endoreduplicated.
381 25 1 endoreduplicated.
422 24 /I cell with 47 chromosomes, 
1 tetraploid.
421 30 3 cells with 47 chromosomes,
432 26 2 cells with 47 chromosomes.
431 25 2 tetraploids.
448 . 23 2 tetraploids, 1 endoreduplicated.
447 23 #8 tetraploids, 1 polyploid, 
1 break.
490 50 #2 cells with 47 chromosomes, 
2 tetraploids and 1 break.
491 20 1 tetraploid.
574 50 2 tetraploids and 2 breaks.
575 50 1 tetraploid and 1 break.
642 38 2 breaks.
643 39 1 tetraploid, 1 endoreduplicated.
Table 30 : Types of chromosome abnormalities in Mother / Baby Pairs.
Test.
TYPE OF O.C. LABORATORYNUMBER
NUMBER OF 
CELLS
— .....  i
TYPE OF CHROMOSOME j 
ABNORMALITIES !
OVULEN 826 50
' ...... ..... .
1 gap.
827 41 1 gap.
GYNOVLAR 434 26 2 cells with 47 chromo­
somes and 1 endoredup­
licated cell.
433 25 2 gaps••>
468
4 6 9
50 #3 tetraploids and .
1 break. ,
1 • tetraploid.
NORINYL 446 25 1 break.
445 55 /3 cells with 47 chr. 
'1 break.
LYNDIOL 172 13 ■ 1 polyploid.
171 25 1 gap.
436 25 1 tetraploid.
435. 25 3 tetraploid.
CONOVID 162 16 1 gap.
161 25 1 tetraploid.
ORTHO-NOVUM 424 25 1 tetraploid.
• 423 . . 25 /3 tetraploid and 
' 2 endoreduplicated cells,
440 15 1 tetraploid.
439 25 2 cells with 47 chr.
SEQUENS 132 25 1 tetraploid.
131 25 1 tetraploid.
GYNOVLAR/ 684 38 1 endoreduplicated cell.
ORTHONOVUM 685 32 1 tetraploid.
OVULEN/ 1022 • 26 1 tetraploid.
ORTHONOVUM 1023 28 . 2 tetraploids.
UNKNOWN 622 50 1 tetraploid.
621 11 1 break.
------------------------------------------------------- * -------------------------------------------------------
3. Patients1 History.
These details were investigated in order to ascertain (i) whether 
the patients1 history was significant in producing chromosome abnormalities;
(ii) whether there were cases where a possible significant factor might 
show an obvious relationship to chromosome abnormalities and (iii) whether . 
there were any differences between the histories of the test and control 
subjects.
(a).Present History.
Three hundred and sixty six patients were interviewed at Cuckfield 
Hospital, this number was composed of the 181 control and 185 test subjects. 
Two women who suffered miscarriages were not included in the total. The 
ages of the women in the control group ranged from 15 to 46 years with 
a mean age of 25.6 years. The ages of the mothers in the test group 
were very similar, a mean of 26.1 years with an age range of 17 to 42 years 
was found..(Table 31)• The marital status of these women was found to be 
as follows: 174 (96.1$) married and 7 (3*9%) single in the control group;
183 (98.9$) married and 2 (l.l$)single in the .test group. The consumption 
of alcohol and smoking was found to be considerably lowered in these women
1
when they became pregnant, and in some cases was completely absent.
The number of women who had, or at one time were engaged in a hazardous 
occupation was totalled. The number of women in the control group was 
found to be 21 (11.6$) and in the test group 19 (10.3$). The number of men 
engaged in a hazardous occupation was increased threefold compared to the 
women, 57 (31*5%) in the control group and 50 (27.0$) of men in the test 
group. -
These results were subdivided into separate classes of hazards which 
can be seen in Table 32. It was found that some people came into contact 
with more than one class of contaminants, therefore in most cases the 
number of people in each group is larger than the number of people involved.
Table 31 • Table of Patients1 History.
HISTORY OF 
THE MOTHERSe
CONTROL
MOTHERS.
TEST
MOTHERS.
MEAN AGE 25*6 years 26.1 years
AGE RANGE 15 - 46 years 1 7- 4 2 years
MARITAL STATUS
. MARRIED 174
(96.1)
183
(98.9)
SINGLE
•
7
( 3.9)
2
( 1.1)
HAZARDOUS
OCCUPATION
MOTHER 21
(11.6)
19
(10.3)
FATHER 57
(3U5)
50
(27.0)
j
Table 32 : Types of Hazardous Occupations in Control and Test Groups.
HAZARDOUS
OCCUPATION
CONTROL
MOTHERS
CONTROL
FATHERS
TEST
MOTHERS
TEST
FATHERS
RADIATION 4
(19.0)
2
( 3.5)
4
(21.0)
3
( 6.0)
INDUSTRIAL
CHEMICALS
3
(14.3)
19
(33.3)
5
(26.3)
14
(28.0)
DUST 6
(28.6)
‘ 25 
(43.8)
2
(10.5)
23
(46.0)
AGRICULTURE
CHEMICALS
; 2 
( 9.5)
8
(14.0)
6
(31.6)
8
(16.0)
CYTOTOXIC
DRUGS
0
( 0.0)
2
( 3.5)
1
( 5.3)
2
( 4.0)
OTHERS'* 6
(28.6)
6
(10.5)
3
(15.8)
9
(18.0)
■* These hazards include hairsprays5 motor fumes and electric 
shocks. • .
Percentages are shown in parentheses.
It can be seen that 19*0% of the total control mothers who had a hazardous 
occupation, came into contact with radiation compared to 21.0% of the 
test mothers. Only 3*5% of the men subjects (control group) worked with 
radiation and 6.0% of the men in the test group. There were 3 (14*3%) 
and 5 (26.3%) of women in the control and test groups respectively who 
worked in contact with industrial chemicals compared with 19 (33*3%) and 
14 (28.0%) in the control and test groups of fathers.
The numbers and percentages of mothers and fathers who came into 
contact with dust, agricultural chemicals and cytotoxic drugs can be seen 
“in Table 32. The class of hazards called TothersT included hairsprays, 
petrol fumes and gases.
(b). Menstrual History
The total results of the menstrual history of all the subjects can
be seen in Table 33* In the control group the range of ages of menarche
„were found to be between 10 and 16.0 years of age with a mean age of 12.7
years. A very similar situation can be seen in the test group, where there
is the same age range and an identical mean.
*
From the 181 women interviewed in the control group, 169 (93*4%) had 
a regular menstrual cycle with only 6.6% having irregular cycles. In the 
test group, 163 (8*8.1%) women had regular menstrual cycles and a pro­
portion of the 22 (1,1.9%) who were classed as having irregular cycles 
had experienced regular cycles before they had discontinued oral 
contraceptives. The lengths of the cycles varied considerably from 
individual to individual as can be seen from the table. The control 
mothers had cycles ranging from 21 to 90 days with a mean time of 28.8 days 
the test mothers had a range of 14 to 90 days with a slightly higher mean 
of 30.8 days.
Table 33 also shows the numbers of mothers who have suffered from 
amenorrhea at some stage of their menstrual life. In the control group,
144 (79*8%) women have never had amenorrhea and a corresponding total
Table 33 : Menstrual History of Test and Control Mothers.
MENSTRUAL HISTORY CONTROL MOTHERS TEST MOTHERS
MEAN AGE OF MENARCHE 12,7 years 12.7 years
AGE RANGE OF MENARCHE 10 - 16 years 1 0- 1 6 years
CYCLE
Regular 169
(93.4)
163
(88.1?)
Irregular 12
(6.6)
22
(134)
Not known 0
(0.0)
0
(0.0)
MEAN LENGTH OF CYCLE 28.8 days 30.8 days
RANGE OF CYCLE LENGTH 2 1 - 9 0  days 14 - 90 days
AMENORRHEA
Infrequently 15
(8.1)
19
(10.2)
Yes 14
(7.7)
25
(13.5)
No 144 
. (79.8)
132
(71.4)
Not known 8
(4.4)
9
(4.9)
-''-HORMONAL CONTRACEPTION
Yes 0
(0.0)
113
(61.1)
No 181
(100.0)
60
(32.4)
Not known 0
(0.0)
12
(6.5)
* Hormonal contraception in the 6 months prior to pregnancy. 
Percentages are shown in parentheses.
of 132 (71.4%) women had not experienced this complaint in the test 
group. Fifteen women in the control group had suffered from this 
problem occasionally with minor illnesses or anxiety states as the 
primary cause. Nineteen women in the test group including one mother 
who had amenorrhea before taking oral contraceptives and two after 
discontinuing this form of contraception, were found to have had 
amenorrhea infrequently. Fourteen (7*7%) women in the control group 
suffered from amenorrhea quite frequently compared with 25 (13•5%) 
women in the .test group. Of these latter 25 mothers, 10 had amenorrhea 
during their course of hormonal contraception and 2 after ceasing.
All the women in the test group had taken oral contraceptives at some 
time during their reproductive life and 113 (61.1%) had continued 
oral contraception in the 6 months prior to pregnancy. In 12 (6.5%) 
cases it was not known how long before conception, the patient had 
ceased taking oral contraceptives.
(c). Obstetric. History. .
The obstetric history of all the patients in the survey can be 
seen in Table 34- This table is divided into 7 categories and each 
one will be dealt with separately. The number of women with previous 
live births ranging from 0 to over 3 were noted. Forty-four per cent 
x)f women had not given birth prior to their present baby in the control 
group compared with 40.5% of mothers in the test group. It was found 
that 35*9% and 11.0% of mothers had given birth to 1 or 2 children 
respectively prior to this study in the control group and 33*5% and 
15.1% of test mothers had given birth to 1 and 2 babies earlier.
Only 1 (0.5%) woman in the control had a still birth prior to 
this study, compared with 6 (3*2%) in the test group. Most of the 
still births in the latter group occurred before these women had 
taken oral contraceptives.
Table 34 : Obstetric. History of Test and Control Mothers.
OBSTETRIC;, HISTORY CONTROL MOTHERS TEST MOTHERS
LIVE BIRTHS
0 81 (44.7) 75 40.5)
1 65 (35.9) 62 33.5)
2 20 (11.0) 28 15.1)
3 11 ( 6.0) 15 8.1)
'4 + 7 ( 3.9) 5 2.7)
STILL BIRTHS
YES I ( 0.5) 6 3.2)
NO 180 (98.5) 179 96.8)
MULTIPLE BIRTHS 
YES 1 ( 0.5) 3 1.6)
NO 180 (98.5) 182 98.4)
SPONTANEOUS 
MISCARRIAGES *
0 159 (87.8) 143 77.3)
1 20 (11.0) 28 15.1)
2 2 ( 1.1) 10 5.4)
3 + - 0 ( o.o) 4 2.2)
INDUCED ABORTIONS 
YES 2 ( 1.1) 3 1.6)
NO 179 (98.9) 182 98.4)
FOETAL ABNORMALITIES
YES 5 ( 2.8) 10 5.4)
NO 176 (97.2) 175 94.6)
FAMILIAL ABNORMALITIES
YES 10 ( 5.5) 16 8.6)
NO 171 (94.5) 169 9.1.3)
Percentages are shown in parentheses.
It is possible that some reported miscarriages are in fact the 
result of induced abortions.
The number of spontaneous miscarriages in both the control and test
groups of mothers can be seen in Table 34. The total number of miscarriages
in the control group was found to be 24 compared with 56 in the test group.
It can be seen though, that half of the latter miscarriages occurred before
‘Appendix 6‘‘
hormonal contraception had been practisedX(30 occurred after the mothers had 
been taking oral contraceptives). In 3 cases it was not known whether the 
miscarriages occurred before or after oral contraception. It can also be 
seen from Table 32 that 20 (11.0%) women had one miscarriage in the control 
group. Two (1.1%) women had 2 miscarriages and none of the women had 
more than this number in the control group, compared with 10 (5.4%) women havii 
miscarried twice and 4 (2.2%) women having more than 2 miscarriages in the 
test group. Induced abortions, those not occurring naturally, were 
experienced by 2 (1.1%) women in the control group and 3 (1.6%) women 
in the test group.
Foetal abnormalities were grouped with previous offspring abnormalities 
and the numbers of these can be seen in Table 34* These abnormalities 
included congenital defects which ranged from being mentally handicapped 
to webbed feet. These numbered 5 (2.8%) in the control group compared with 
10 (5*4%) in the test group. In many cases it was not known whether the 
previous offspring were born with these defects before or after their 
mothers had taken oral contraceptives.
(d). Present Pregnancy History.
The total results of the mothers1 present pregnancy history is 
tabulated in Table 35. The number of weeks of gestation ranged from 33 to 
40 with a mean of 39*6 weeks in the control group and a range of 32 to 42 
weeks with a mean of 39*4 weeks in the test mothers* group.
It was observed that over 50% of the mothers had received X-rays 
during their pregnancy in the control mothers* group and approximately the 
same percentage (48%) in the test group. Also, all illnesses that required 
medication by drugs or surgery,were noted. Influenza and minor ailments
Table 35 : History of present pregnancy in Control and Test Mothers.
CONTROL MOTHERS TEST MOTHERS
WEEKS OF GESTATION
Mean 39.5 39.4
Range 33 - 40 32-42
X-RAYS
Yes 98 (54.1) 90 (48.6)
No 83 (45.8) 95 (51.3)
ILLNESSES BEFORE 
PREGNANCY 
Yes 36 (19.9) 66 (35.7)
No
Not known
140
5
(77.3)
( 2.7)
112
7
(60.5) 
( 3.8)
DRUGS BEFORE PREGNANCY Not known Not known
HORMONES
l
Progestagen 3 ( 1.6) 4 ( 2.2)
SERIOUS ILLNESSES 
DURING PREGNANCY 
Yes
No
Not- known
57
118
6
(31.3) 
(65.2) 
( 3.3)
58
117
10
(31.3)
(63.2) 
( 5.4)
Percentages are shown in parentheses.
Table 35 : History of present pregnancy of Test and Control Mothers,
(continued)e
MILD ILLNESSES 
DURING PREGNANCY
Nausea and Sickness 
Heartburn
Dizziness and Fainting
Colds
Others
Not known
CONTROL MOTHERS TEST MOTHERS
44 (24.3) 
30 (16.6) 
4 ( 2.2) 
24 (13.2) 
4 ( 2.2) 
6 ( 3.3)
44 (23.8) 
30 (16.2) 
4 ( 2.2) 
17 ( 9.2) 
5 ( 2.7) 
10 ( 5.4)
DRUG THERAPY
Chemotherapeutic drugs 
and Antibiotics
Antiemetics 
Barbiturates 
Iron 
Vitamins 
No drugs 
Not known
22 (12.1)
34 (18.8) 
11 ( 6.1) 
129 (71.3) 
62 (34.2) 
12 ( 6.6) 
4 ( 2.2)
30 (16.2)
33 (17.8) 
10 ( 5.4) 
148 (80.0) 
77 (41.6) 
6 ( 3.2) 
2 ( 1.1)
HORMONES
Thyroxine 1 ( 0.5) 1 ( 0.5)
Progestagen 5 ( 2.6) 4 ( 2.5)
Percentages are shown in parentheses.
were not included in the total count. There were 36 (19*9%) women in the 
control group and 66 (3 5 *7%) women in the test group who had an illness 
either at a much earlier date or just prior to their present pregnancy.
It was difficult to ascertain the drugs given to these women during their 
various illnesses before pregnancy. It was found that 3 (1,6%) and 4 (2,2%)
.women in the control and test groups respectively had taken progestagen, 
usually in the form of Duphaston or Primulut D. Progestagen was taken to 
arrest bleeding in threatened miscarriages.
All illnesses during pregnancy were recorded and totalled. In this 
case influenza was included because it could have a detrimental effect 
on the foetus, especially during the first trimester. In the control group
57 (31 *5%)> and 58 (31«3%) women were ill in the test group; these numbers
~\
being high because of the number of women who had influenza during their 
pregnancy. Mild illnesses and ailments during pregnancy were recorded and 
are shown on Table 35* They were divided into the following groups: 
nausea and sickness; heartburn, dizziness and fainting,and colds.
Drug treatment during pregnancy, was divided into two main groups, 
hormonal‘ therapy and non hormonal therapy. The hormonal treatment consisted 
of either progestagens or thyroxine and it was found that 5 women in the 
control group and 4 women in the test group were given progestagens and 
1 mother from each group was given thyroxine. The non hormonal group 
of drugs ranged from chemotherapeutic agents and tranquillizers to iron 
and vitamin tablets• Nearly all the mothers received the latter, 71*3% 
and 80% of women in the control and test groups respectively; whilst the 
minority, 6.6% and 3*3% in both groups received no treatment.
(e). Contraceptive History.
The total results of the history of the patients taking oral, 
contraceptives can be seen in Table 36. Eighty-seven per cent of mothers 
were found to have taken a combination preparation of the contraceptive^ 
while only 2 ,7% of women had taken the sequential type of preparation.
Table 36 : Oral Contraceptive history of the Test Group.
ORAL CONTRACEPTIVE HISTORY TEST MOTHERS
One type of Oral Contra­
ceptive e 124 (67.0)
Two types of Oral Contra­
ceptive 29 (15.9)
Three and more types of 
Oral Contraceptives. 14 ( 7.6)
Not known •18 ( 9.7)
Combination preparations 162 (87.6)
Sequential preparations 5 ( 2.7)
V
Not known
- 1 ? (-9.7)
Mean length of time the 
Oral contraceptive was taken. 18.7 months
Range of time the Oral 
Contraceptive was taken. 0.25 - 84.0 months
Mean length of time between 
ceasing O.C. and conception. 9•6 months
Mothers who had taken O.C. 
continuouslv 85.4%
Percentages are shown in parentheses.
It can be seen from the table that 124 (67.0%) women had taken one variety 
of oral contraceptive; 29 (15*9^) had taken two types (the majority of these 
women had taken them consecutively) and 14 (7*6%) had taken at least three 
different named types of oral contraceptives. In 9.7% of the cases it was 
not known how many different types of oral contraceptives had been taken.
The overall mean length of time that one type of oral contraceptive 
had been taken was 18.7 months with a range of 0.25 to 84 months. The 
combination of two or more types was not included in the ranges and mean 
lengths of time. The mean length of time between discontinuing contra­
ceptives and conception was found to be 9*6 months. Eighty-five per cent 
of the women had been taking oral contraceptives continuously.
The results shown in Table 36 can be viewed in greater detail in 
Table 37• In. 18 cases it was not known which oral contraceptive the 
patient had taken, either because the patient was missed at the interview 
or else the patient herself could not remember the brand name. In some 
cases, Norinyl for example, there are 2 different types available on the 
market, Norinyl I and Norinyl II. However, the women taking either of these 
preparations have been grouped together in order to facilitate analysis.
(f). Constituents of the Oral Contraceptives.
The oral contraceptive is composed of two main constituents, a 
progestagen and an oestrogen. There are 8 commonly used hormones of which 
these contraceptives are composed (Table 38). Only 3 oral contraceptives 
in this project are sequential preparations; Sequens, Serial 28 and 
Normenon. They are composed of two different tablets, one containing . 
oestrogen alone and the other consisting of both oestrogen and progestagen.
In some cases the oral contraceptives have the same constituents, ' 
but different quantities, as in the cases of Minovlar, Gynovlah and Anovlar. 
All these contain 0.05mgm of ethinyl oestradiol , but the progestagen 
component, norethisterone acetate varies, 1.0, 3*0* and 4*0 mgm respectively. 
Table 1 in the introduction gives the details of all the oral contraceptives 
used in this study.
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DISCUSSION
A . Blood Culture Techniques.
1 Lymphocyte Transformation and Mitotic Indices.
In the present study it was found that cord bloods from newborn 
infants gave a higher response to phytohaemagglutinin (PHA) stimulation 
than did the adult venous bloods. Also, there were more successful 
cultures from the newborn babies’ bloods compared to the adults.
The situation regarding the stimulatory effect of PHA on human 
bloods is rather confusing due to many conflicting published reports. 
Prindull (1971) working with blood lymphocytes from newborns, has 
quantitatively correlated PHA induced lymphocyte transformation and 
the number of cultured cells (culture cell ratio) with the initial 
number of blood lymphocytes in the primary culture. He used a micro­
method of culturing these lymphocytes and found that the culture cell 
ratio and transformation ratios were significantly larger in newborn 
premature infants than in older premature infants and adults. Both 
these ratios in full term babies were higher than in the adults.
These observations are in agreement with the published works of 
Bishun (1967); Winter and coworkers (1965) and Kay and colleagues (1970)* 
Bishun (1967) compared the mitotic growth rates of human whole blood 
(micromethod) in a variety of media. He took blood samples from two 
groups 3 (a) newborn babies and (b) adults,and found that the mitotic 
indices, with the three micromethods tried, were between 25% - 5 0% 
higher in the blood cultures from newborn babies compared to adults.
Winter and coworkers (1965) found increased RNA and DNA turnover 
rates of lymphocytes from newborn babies after in vitro stimulation 
by PHA. Kay and workers (1970) reported a variable, sometimes 
high, PHA responsiveness of thymic lymphocytes from human foetuses. 
Several other workers; Jones (1969) and Pentycross (1969)5 found 
that there was no significant difference between the response of
lymphocytes from adults to PHA and those from newborns or younger 
persons. Jones (1969) used a macromethod of setting up the blood 
cultures and found that cord blood lymphocytes responded to PHA in all cases 
and that there was no apparent correlation with gestational age 
(range 33 - 42 weeks). He also showed that these results were lower 
than the adult controls but that there was considerable overlap between 
the two groups.
In 1969  ^ Pentycross further studied lymphocyte transformation in 
blood cultures, after having previously found (1968) that the number 
of transformed cells was often less than expected in normal persons 
under the age of 26 years. He investigated lymphocyte transformation 
in a larger group of people, including newborn babies, children 
and additional adults. In the cord blood cultures, the degree of 
transformation of the lymphocytes was over a similar range to that 
which he found in people over 26 years of age. Leiken and workers 
(1968) also demonstrated that the cord blood lymphocyte response 
was within the adult range. Ayoub and Kasakura (1971) compared the 
reactivity of foetal lymphocytes stimulated by PHA to that of adult 
cells. Also, they studied the effect of foetal plasma on the reactivity 
of foetal and adult cells by using a leucocyte rich supernatant 
(macromethod), and found that reactivity was significantly higher in 
adult cells suspended in adult plasma when compared with foetal cells 
suspended in either foetal or adult plasma. Adult cells suspended 
in foetal plasma showed a significant suppression of their reactivity 
compared with adult cells suspended in adult plasma, thereby indicating 
.that there was an inhibitory entity present in the foetal plasma.
Several theories have been suggested by the above workers who 
have found these conflicting results. That cord bloods respond to 
PHA stimulation with a higher degree of transformation than the adult 
venous blood, lends support to the belief that cellular immunity is 
evident in early postnatal life (Elves 1966). It has been suggested
that a mixed cell population in the foetus, caused by transference 
of circulating maternal cells via the placenta could cause a high 
degree of spontaneous transformation of blast cells (Pulvertaft and 
Pulvertaft, 1966). This seems unlikely according to Jones (1969), 
since transplacental migration of lymphocytes in significant numbers 
is a rare event (Turner and coworkers 1966), However, it has been 
demonstrated that in the mouse the admixture of maternal and foetal 
cells is possible and could lead to an enhanced PHA response (Tuffrey 
and colleagues 1969a & b). Prindull (1971) suggested that this enhanced 
„ response of cord blood leucocytes to PHA is due to infants having 
larger PHA sensitive lymphocyte populations in the peripheral blood than 
adults. •
Explanations for the decreased stimulation of cord blood lympho­
cytes by PHA have been put forward by Ayoub and Kasakura (1971) in 
support of work by Leventhal and workers (1970) and Cooperband and 
colleagues (1968). One possibility is that lymphocytic toxic antibodies 
originating from the mother might be responsible for this inhibitory 
activity or that fetuin in foetal plasma may be responsible for this 
effect. .Other studies have shown that fetuin competitively binds 
PHA (Mendelsohn and workers, 1970), but it has not been ascertained 
whether fetuin is an inhibitory factor in foetal plasma. Both these 
theories are not substantiated by the work of Ayoub and Kasakura (19^1) 
as firstly, they found that inhibition of the PHA response by 
antibodies is unlikely, since their study included samples of cord 
blood from primaparous women whom do not usually have lymphocytoxic 
antibodies, and yet, there was a similar degree of inhibition produced. 
Secondly, the PHA response of foetal cells in foetal plasma was not 
significantly different from that of foetal cells in adult plasma, and, 
if fetuin is an inhibitory factor in the foetal plasma, there should 
be a marked decrease in the transformation of foetal cells in foetal
plasma compared to foetal cells in adult plasma. These workers 
suggested that the reason why foetal lymphocytes show a more vigorous 
response to their first exposure to an antigenic stimulus (PHA) is 
because they have not been exposed to exogenous agents and have been 
protected by the maternal environment. Also, their finding that cord blood 
showed no impairment of response to PHA stimulation suggests that infants 
are born with an intact* immunological system.
The present results would confirm this theory and the published 
reports of Prindull (1971)5 Winter and coworkers (1965)5 Bishun (1967) 
and Kay and workers (1970)5 since a higher degree of transformation 
was found in the cord bloods from newborns than in the venous bloods 
from adults. These results do not agree with several reports mentioned 
in the preceding text. Several explanations are possible in explaining 
these discrepancies; firstly, mitotic index was used in the present 
study and since this represents only selected cells, this form of 
assessment could induce bias in the results . However, it must be 
borne in mind that this is the most reliable means of estimating cell 
transformation since only transformed cells undergo division. Other 
methods used to assess transformation by workers included (a) tritiated 
thymidine or uridine uptake, (b) cytological examination of blast cells,
(c) cell culture and transformation ratios; all of these have their 
advantages and disadvantages.
Secondly, since mitotic indices are not very high in blood cultures 
the numbers of cells available for assessment is limited and, as a 
result, a smaller sample of cells are counted. However, despite these 
discrepancies, the present results lend support to the view that the 
lymphocyte transformation rate in newborns is comparitively higher 
than in adults.
2 . Comparison of Micro and Macro Blood Culture Techniques.
In the present study it was found that the micro cultures produced 
a higher percentage of transformed cells than the macro cultures.
The former method was more advantageous in several ways. Firstly, 
only 0.5ml of whole blood was required from the subject instead of 
10.0ml which was necessary for the macro culture and which was often 
difficult to obtain from the cord. Secondly, the micromethod was 
much less time consuming in the actual setting up process than the 
macromethod.
Approximately half the total blood cultures set up, were done 
so by both the micro and macro methods. .Eventually it was established 
that the micromethod produced a higher mitotic index than the macro­
method and as a result the latter method of culturing was abandoned.
Zang and Black (1968) reported that when comparing micro and macro 
methods a significantly lower number of mitoses was involved in the 
former case compared to the latter. Several factors can explain 
these contrary findings; the culture media used, the percentage of 
calf serum and the quantity of blood in both the micro and macro 
cultures contribute enormously to the differences in results obtained 
by many workers (Bishun 1967).
Noguchi (1969) found, when experimenting with micro cultures, that 
between 0.1 - 0.15ml of whole blood gave the best results, producing 
at least 20 analysable cells; Too small or too large a sample of whole 
blood in 35% or 40% foetal calf serum did not produce any analysable 
cells. Intermediate amounts of these constituents produced an 
intermediate number of readable metaphase spreads. Bishun and coworkers 
(1965) compared two macromethods with three micromethods by assessing 
the growth rate of each, by means of the mitotic indices and found 
a higher mitotic index using a macromethod when the blood was cooled 
immediately after withdrawal from the subject. They further mentioned
that with only small amounts of blood available a micromethod using 
T. C. 199 and AB serum gave as good a result as that produced by the 
macromethod in which the blood was not cooled prior to culture.
The success of the micro culture is very promising in adults since 
it follows that successful chromosome examination can be carried out 
on small samples of blood. Following the principles of previously 
published work by Bishun (1965 & 1967)5 experimentation with the 
techniques has lead to reliable methods producing satisfactory 
results.
Hence, in this project, both the macro and micro methods used 
gave adequate mitotic indices and metaphase spreads in the control^ 
cultures comparable with those found in other studies. Therefore, 
it is concluded that it is justifiable to combine the results from 
macro and micro cultures in this study.
3>. Oral Contraceptives and the PHA Response.
Contrary to the results published by other workers, there was 
not found to be a depressed lymphocyte response to PHA by women 
who have taken oral contraceptives. This could be explained on the 
grounds that the time between discontinuation of the oral contraceptives 
and the collection of the bloods for culture was in most cases over 
12 months. If the oral contraceptive had any adverse effect on 
blastoid transformation it is possible that this response was lost 
when oral contraceptives were discontinued.
Other workers, Fitzgerald and workers (1973) and Hagan and Froland 
(1972)5 found depressed lymphocyte responses to PHA in long term users 
of oral contraceptives. Fitzgerald and workers-(1973). looked at 
the blood cultures from 17 patients who were taking, oral contraceptives 
continuously for an average length of time of 5*9 years, over a range 
of.. 4.5 to 10.0 years. The age range of these women were 25 to 47 
years, that is, slightly older than that found in the present survey
and also the oral contraceptives had been taken for a longer period in 
the former study. The mitotic index of the control group was found to 
be lower than that found in the present study as were those of the 
test groups. These workers found that there was a significant 
difference between their control and test results. Previous workers 
Hagan and Froland (1972) took blood samples from 18 women, half of 
whom were using oral contraceptives and the other 9 women acting as 
their controls. Transformation was determined by the incorporation 
of tritiated thymidine into the lymphocytes in the last three hours 
of culture. A statistically significant difference was found in 
favour of a depressed leucocyte reaction in women who were using oral 
contraceptives and the authors suggested that this might be due to 
non specific oestrogen or progesterone action.
In another study, Shapiro and coworkers (1972) calculated the 
mitotic indices from blood leucocytes from several women after one 
and two months of taking the oral contraceptive ’Norinyl1. Before 
these women had taken oral contraceptives their mean mitotic index was 
2.8%, after one month 3*4%* and after two months 3*2%. Shapiro and 
coworkers further obtained blood from 4 women who had been using oral 
contraceptives for 3 or more years. The average mitotic index was 
found to be 3»4% with a range of 2.9% - 4*9%« When the latter results 
were compared to their respective controls (2.5%), an increase in 
the mitotic index was found in the test subjects both for short and 
long term users of oral contraceptives. When these mitotic indices 
were compared to those calculated in the present study, especially 
from those women taking Norinyl (10 subjects), where the mean mitotic 
index was 6.0% and the average length of time that the women had taken 
Norinyl was 4*5 months, an appreciable increase was observed.
In addition, there was also an increase in the mitotic indices from 
the Norinyl test subjects compared to the controls in the present study.
By considering the mitotic indices of the blood cultures from 
babies of control mothers and those whose mothers had used oral 
contraceptives, there was also an increase in the mean mitotic index 
of the babies born to mothers whom had taken Norinyl (11.3% compared 
with 6.8%). The fact that Shapiro and coworkers (1972) did not find 
that the mitotic index was affected by oral contraceptives indicated 
that cell replication is not impaired in peripheral lymphocytes 
stimulated by PHA. The results in the present study also substantiate 
the above findings.
It has also been reported that there was a significant reduction in' 
the maternal lymphocyte response to PHA in most pregnant women. The 
difference between the lymphocyte responses to PHA of the pregnant women 
and non pregnant controls is significant (Purtilo and colleagues 1972). 
This occurs at all stages of pregnancy and is very significant between 
the 26th and 31st week of gestation. The above workers suggested that 
this situation could result from the cumulative action of blocking 
antibodies, hormones and certain plasma proteins. It has also been 
shown that immediately after delivery of the baby, the mothers* lymphocyte 
response to PHA was still depressed, which could be the reason why the 
mothers * blood cultures did not grow as well as was expected in this 
project.
However, there have been conflicting reports on this subject.
Leiken (1972) found that serum taken from mothers at the time of giving
birth had a suppressive effect in vitro when added to make a final
concentration of 20%, to cells from pregnant women and non pregnant
\
controls. Purtilo and workers (1972) did not find this effect with 10% 
serum. Leiken*s results suggest that a depressed lymphocyte response 
in pregnancy is due to a plasma effect and not to an intrinsic cellular 
change. Harrison (1972) working with rats has also found no evidence of 
an intrinsic defect in the lymphocyte immunocompetance in pregnancy.
Obviously, some controversy still exists over the effect of steroids 
on blastoid transformation in vitro. As far as lymphocyte transformation 
during the time of oral contraception is concerned, the results from 
this study are not completely comparable to those reported in the 
preceding text, on account of the fact that the test subjects had 
ceased taking oral contraceptives for at least 12 months. However, 
in accordance with the results of previous reports it would appear that 
the former results show that in time there is a recovery from the 
depressed blastoid transformation induced by the oral contraceptive.
It can be seen from the above sections, that there are still 
conflicting reports in the literature. Firstly controversy exists 
regarding lymphocyte transformation between adults and newborns; 
secondly there are differences of opinion regarding the utilisation 
of the micro and macro methods; and thirdly, controversy exists 
regarding PHA stimulation of lymphocytes from test subjects (women 
who have taken oral contraceptives).
The present results conform with many previous reports in as far 
as the aforesaid parameters are concerned. Therefore the methods and 
techniques employed in this study are reliable in assessing lymphocyte 
transformation.
B. Chromosome Abnormalities.
1• Comparison of Controls with other Surveys.
.(a). Numerical Chromosome Abnormalities.
In human somatic cells, the major type of abnormality is 
aneuploidy. The most common form of aneuploidy is hypodiploidy, that 
is, cells with less than the modal number of chromosomes (Bloom and 
colleagues 1966,5 Court Brown 1967). The other form of aneuploidy is 
cells with more than 46 chromosomes, usually 2n + 1 (jarvik and 
coworkers 1971)* The proportion of hyperdiploid cells is generally 
less than hypodiploid cells in a sample, and this suggests that 
aneuploidy is often an artefact due to culturing and harvesting methods 
(Bloom 1966). The type of mechanism which will give rise to non modal 
counts is cell rupture, resulting in the loss of one or more chromosomes; 
if these chromosomes become included in a neighbouring cell, a hypermodal 
count is obtained. Usually however, a true hypermodal cell can be 
distinguished from one which has gained a chromosome from a neighbouring 
cell since such a ’foreign1 chromosome can be recognised because of 
its different degree of contraction. Chromosome preparations tend to 
differ between cells, as the cells will be in different stages of 
their division cycles when colchicine is added to the culture medium, 
hence the resultant chromosome morphologies will differ.
Hypomodal cells are likely to be caused by anaphase lagging or 
nondisjunction, which may be simply defined as the failure of two 
chromosomes or sister chromatids at cell division to pass to opposite 
poles of the spindle. This may result in both chromosomes being 
included in one daughter cell, thus giving rise to a hypodiploid and 
a hyperdiploid cell respectively. In the analysis of these cells 
however, it is difficult to distinguish between those that are the 
products of error in division and those that result from the technique, 
exeeptin cases where it is truly obvious.
Several explanations have been put forward in order to point out 
the true significance of hypomodal cells. They are firstly, that the ab­
normal divisions may have occured in ancestral cells, so that cells 
which divide in culture to produce abnormal daughter ones were them­
selves abnormal when taken from the body. Secondly, that some of the 
abnormal daughter cells are viable and maintain themselves in equilibrium 
with the normal cells and thirdly, that the cells were normal when 
taken from the body and that the abnormal division is related to the 
conditions of culture (Jacobs 1972). The latter worker suggested that 
3.5% of hypomodal cells at birth would provide an approximate 
estimate of the proportion of aneuploid cells arising from artefacts 
with her techniques.
The percentage of hypomodal cells in the control mothers from this 
study was found to be 4»7%* including those cells with less than 44 
chromosomes. A large proportion of the latter counts could be taken as 
broken cells. Only 0.87% of the cells had 45 chromosomes present.
In the control babies’ group, 5«3% of hypomodal cells were counted, 
but similarly only a small percentage (1.0%) were cells with 45 
chromosomes.
r
Other workers have found varying percentages of hypomodal cells 
in metaphases from lymphocyte cultures, with a few recording a high per­
centage of these cells; 10 - 20% by Zang and Zankl (1970), and 12.5% by 
Goh and Sumner (1968). Other reports have shown a lower percentage;
4.0% in an age group similar to that of the present study by Court 
Brown (1966); Muller (1971) found 1.7% cells with 45 chromosomes in 
over 4*500 cells; Bender and Gooch (1963) found 4»0% cells with a 
hypomodal cell count in 981 cells examined. Between 92 - 93% of the 
cells from the control mothers and babies in the present study had 
the normal human chromosome number. This agrees well with other
similar studies where a range of between 85 - 96% true diploids were 
counted (Muller 1971 * Bender and Gooch 1963 ; Goh and Sumner 1968 ;
Court Brown and Smith 1969)*
Hyperdiploid cells (2n + 1) were much less frequent than hypo­
diploid cells. In.the control mothers’ group 0.36% of the cells had 
over 46 chromosomes, excluding those cells which were triploid, tetra- 
ploid or polyploid. The control babies had 0.16% of their cells 
with a hypodiploid count. Only 3 in 4754 (0.06%) were found to be 
hyperdiploid in babies of a similar study by Muller (I97I), but in 
women aged between 25 and 34 there were 0.3% of cells with 47 chromosomes 
present (Court Brown and workers 1966).
Triploidy (cells with 69 chromosomes) occurs rather frequently 
in products of conception. In spontaneous abortions 4«0% have a 
triploid chromosome constitution in every cell. In these cases, the 
cause of triploidy is invariably due to an error in fertilization 
and is lethal (Carr 1970)* In some cases however, an increase in 
triploidy could be due to a common factor, that is, the failure of the 
cytoplasm to cleave in time with the division of the chromosomes in
meiosis. In man, only 10 cases of triploidy are known to date
(Schindler and MIkamo 1970). In this study only two individual cells 
(0.09%) from 2164 cells examined were found to be triploid in the 
control mothers’ group, and only 1 cell (0.03%) was triploid in the 
control babies’ group. It has not been possible to find other 
reports of the incidence of triploid cells in human metaphases to 
compare with the above results.
Tetraploid cells are presumed to arise as the result of the 
failure of the normal nuclear membrane to break down during early 
mitosis (failure of karyokinesis). Generally the spindle fails to 
form in such cells and anaphase movement has not incurred. There is
then a partial mitosis in which the chromosome number is doubled.
In this study, tetraploidy was the most common chromosomal disorder, 
apart from the hypomodal cells. Twenty eight (1.29%) and 47 (1.25%)
.tetrapldd cells were found in the control mothers and babies respectively. 
Muller (1971) found 0.8% of a total of 4754 cells counted to be tetra- 
ploid from lymphocytes of male and female babies. Jackson and Lindahl- 
Kiessling (1963) found 0.5% of polyploid cells with the majority being 
tetraploid in human leucocyte cultures in their control populations.
In this study polyploid cells were defined as cells with over 
100 chromosomes (4nf), the origin being similar to that of tetraploid 
cells. In this study only one polyploid cell was found in the control 
group, occuring in a metaphase spread from a leucocyte culture of a 
baby (0.03%). Since only this one cell was found, it is difficult to 
compare percentages of polyploidy with other studies of normal control 
populations. In a bone marrow study from 20 male adult patients who were 
in hospital, 0.53% of the 879 cells analysed were polyploids, but this 
high percentage could be due to drugs or other illnesses while in the 
hospital (O’Riordan 1970)*
The endoreduplicated cell has a diploid appearance, except that 
with each chromosome there is an endomitotic duplication with the 
duplicates lying in close proximity (Bloom 1972). In the present 
study, the partial endoreduplicated (that is, cells with only a few 
of the chromosomes duplicated) and the endoreduplicated cells were 
grouped together. In the control mothers, 0.64% of the cells showed 
this disorder while only 0.21% of the cells from the control babies 
were partially or fully endoreduplicated.
There are many reports of endoreduplicated cells from human 
material. Most of these studies have used the Moorhead method 
(with modifications) for setting up the blood cultures. Bishun and 
Morton (1965) found that 7 cells from a total of 3023 (0.23%) were 
endoreduplicated. These workers suggested that cooling the blood in
order to obtain the leucocyte rich supernatant, may be one of the 
factors involved in causing endoreduplication. Powsner (1966) also, 
using the Moorhead method, found a range of endoreduplicated cells, 
between 0.0% - 0.7% (2in 274 cells). Friedman and coworkers (1964) 
found 0.2% of endoreduplicated cells in their control subjects and 
Ohnuki and associates (I96I) found 0.01% of these cell types. These 
workers^reported only the true endoreduplicated cells, and there was 
no mention of partially endoreduplicated ones. If those latter cells 
were excluded from the count in the present study, then the percentage 
of wholly endoreduplicated cells was similar to that found by these 
other workers.
On the whole, the numerical chromosome abnormalities and the 
percentages of modal cells are within the same range as those found 
by other workers. Therefore the present control sample serves as 
a satisfactory comparison for the test subjects.
(b). Structural Chromosome Aberrations.
Structural chromosome aberrations include, chromatid and iso­
chromatid breaks, gaps, acentric fragments and complex re-arrangements, 
for example quadriradial figures. These latter aberrations result 
from multiple breaks. A chromatid break was defined as a visual dis­
continuation of the chromatid and was scored as one break, the same 
•as fragments. A quadriradial and other-re-arrangements were scored 
as two breaks. An attenuated region, and a visual discontinuity of 
the material without displacement of the distal portion of the 
chromatid were classified as gaps. These were scored seperately 
from breaks. Studies with the electron microscope have shown that 
this criterion for the designation of gaps and breaks may not be the 
true discrimination. This is due to the fact that some breaks 
observed under the electron microscope have shown obvious microfibrils 
(Brinkley 1970), while gaps have been observed as fclean1 breaks.
The mechanism of chromosome damage is unknown. It is quite possible 
that different agents may act by way of different mechanisms (Hirschhorn 
and Cohen (1968). Among the postulated mechanisms are the following:
(a) free radical formation due to ionizing radiation; (b) incorporation 
of nucleotide analogues into DNA; (c) crosslinking of the DNA molecules 
by agents such as mitomycin C; (d) faulty ATP and protein synthesis 
needed for repair and (e) the release of lysomal DNAse and cathepsins 
by agents incorporated into lysosomes, Ahnstrom and Natarajan (I968) 
believe that chromosome damage is caused by an enzyme which coincides 
with the duplication of the chromosome material and that this enzyme 
actively removes nucleotide material from the already formed chromosomal 
DNA. They concluded that the DNA polymerase, the enzyme which is 
normally responsible for polymerising DNA is also responsible for 
chromosome damage.
In the control mothers1 group in the present study, 1.02% of the 
cells had chromosomes with either gaps or breaks present. Exactly 
half, (0.51%) of these aberrations were gaps, ranging from 1 to 5 
per subject, and the breaks ranged from 1 to 2 per subject. In the 
control babies’ group, over twice the number of breaks were found compared 
to the number of gaps • The percentage of gaps was lower than that 
found in the mothers’ group (0.08%), with no subject having more than 
one gap. The percentage of breaks (0.21%) was also lower in the babies 
compared to the mothers’ chromosomes.
There have been numerous reports concerning the numbers and per­
centages of breaks and gaps found in the chromosomes of iBwborn and adults 
of a normal control population. The percentage of gaps fpund in the 
chromosomes derived from adult lymphocyte cells from other workers 
ranged from 0 - 14*7% (Brogger,1971 5 Bloom and Tijio, 1964 ; Court 
Brown and workers, 1966 ; Lubs and Samuelson, 1967 ; Patil and associates 
1972 ) Adams and Evans, 1970 and Goodman and others, 1969). The results
of these workers can be seen in appendix 9« The majority of the 
results ranged from 1 - 5% of aberrations. Two surveys, undertaken 
by Goodman and coworkers (1969) and Patil and associates (I972), 
compared the percentage of chromatid gaps in adult cells to those 
found in newborns. Both these groups of workers found that there 
was a much higher percentage of gaps in the mother cells (almost 
twice) when compared to those cells from the babies. This was also 
found in the present study.
The range of breaks was found to be between 0 - 7 % in other 
published studies of adult subjects (Brogger,1971 i Court Brown and 
workers,1966 3 Bochkov,1972 3 Patil and associates,1972 3 Bloom, 1967 3 
Goh and Sumner,1968 3 Lubs and Samuelson, 1967 3 Aula and coworkers,1965 
Goodman and associates, 1969 and Landau and others,1966). The 
majority of these workers found between 0.5% - 3«0% of breaks in 
the chromosomes from their subjects. Three studies were reported 
whereby the percentages of breaks occuring in adults were compared to 
those found in newborn populations (Bochkov 1972 3 Patil and associates, 
1972 and Goodman and others, 1969)• In all these studies the per­
centages of breaks found in the adult subjects was greater than those 
scored in the newborns. A similar observation has been made in the 
present study. The frequency of breaks present in the babies of 
Lhe^above three studies ranged from 1 - 2%, which is a higher 
frequency to that found in the control babies in the present study.
Several workers, (Jacobs,1972 3 Muller,1971 I Bender and Gooch,1963 
Littlefield and Goh,1973) grouped all structural aberrations in one 
class and found a frequency of 0.18% of aberrations in 24,468 babies 
which is in agreement with the percentage of aberrations in the 
control babies in the present study (0.29%). Muller (1971) looked 
for chromosome aberrations in premature babies and found that 4*75% 
of the cells had gaps or breaks. This seems very much higher than 
that found in other nonpremature babies. Bender and Gooch (1963)
and Littlefield and Goh (1973) examined 931 and 17*759 cells 
respectively, from adult subjects and found 2.0% of structural 
chromosome aberrations in the former group and 6.5% of these anomalies 
in the latter group.
It can be seen from those reports, that there is a great deal of 
variation between the results of the numbers of chromosome aberrations 
occuring in adult and newborn populations from different workers.
Many factors may contribute to this variation in the frequencies of 
gaps and breaks found in the different laboratories; (a) the definition 
and the scoring of these lesions have varied due to the uncertainty 
over regions of achromatic material and also, the workers themselves 
have neither, given a full description of the scoring method they 
have employed, nor defined breaks and gaps; (b) many achromatic areas 
are minimal, and so provide the means for under-scoring or over-scoring 
these aberrations; therefore studies where large frequencies of gaps 
or breaks have been found should be viewed with caution; (c) also, 
some of the differences in the results are due to seemingly minor 
variations in the techniques of harvesting and preparing the cells 
for analysis, for example, some of the investigators use colchicine 
and others vinblastine, to arrest cell division at metaphase 
(Cohen and coworkers 1971)l (d) the concentration of these preparations 
-and the duration of exposure of cells are both critical in determining 
the contraction of the chromosomes and therefore may present false 
achromatic lesions. A further complication is that over a period 
of time, leucocyte cultures from the same individual have given 
different break frequencies (Littlefield and Goh 1973)- Therefore, 
it is of great importance to have a large enough sample of subjects 
in order to distinguish between the percentage of breaks from the 
individuals and those actually induced by the specific agent under 
investigation.
2. Comparison of Controls with Test Subjects.
When the incidence of chromosome abnormalities from the control 
subjects in the present study are compared to those of other reports, 
there is no essential difference between those reported in this study 
and those in previous studies, (see preceding text under the various 
types of abnormalities). It can be assumed therefore, that the 
results in the control populations are comparable, and the percentages 
of abnormalities obtained in the control are a direct reflection of 
those present in the general population. It is then feasible to 
compare the results from the control subjects with those from the 
test subjects in the present study.
(a). Comparison of Numerical Abnormalities from the Test and Control 
Groups.
Dealing firstly with the total chromosome results from the four 
groups, control mothers and babies, and test mothers and babies, 
no significant difference was found between the percentage of cells 
with 45 chromosomes in the test and control groups. However there 
was a higher percentage of cells with less than 44 chromosomes in 
the test subjects.
Goh (1967) looked for chromosome abnormalities produced by oral 
contraceptives in the leucocytes from 5 women who had taken oral 
contraceptives for varying lengths of time. He found that from over 
1000 cells examined, 3*1% had less than 45 chromosomes. This agrees 
well with the results from the present study, where 4*2% of the cells 
had less than 45 chromosomes present. Goh also found 5*6% of cells 
with 45 chromosomes which is an increase compared to the findings 
in this study (1.03%). Goh further observed a lower percentage- of 
hypodiploid cells in his control mothers1 group (1.4% of cells with 
less than 45 and 4*1% with 45 chromosomes), although only 341 cells
were examined from 3 people. Because of the small sample, these 
results need to be confirmed, although, in the present study an 
almost similar number of hypodiploid cells were found (3*8% compared 
to 4*1%). In the same study by Goh, the chromosomes of 7 women 
who had taken the oral contraceptive for 3 months were also examined.
He found 3*2% of cells with less than 45 chromosomes and 5*9% of cells 
with 45 chromosomes. This is also in a similar range to those observed 
in his former group, and to the present study. Also, leucocytes from 
3 normal men were cultured with the plasma obtained from women who 
were taking oral contraceptives (Goh 1967) and he found only 0.4% of 
cells had less than 45 chromosomes. In view of this finding, he 
suggested that the hormones are diluted when added to blood cultures 
of non oral contraceptive persons or, perhaps, the percentage of mutant 
cells decreased when this type of culture procedure was used.
The chromosome counts of the test mothers and babies in the 
present study were divided into the different types of oral 
contraceptives and a range of 0 - 7*7%> hypomodal cells was found 
in the mothers1 group whilst a range of 3*7$ - 7*2% was found in the 
babies1 cultures. In the group of 45 chromosome counts, there was 
a range of 0 - 4% and 0 - 8% in the mothers and babies respectively. 
These results are in agreement with those of Goh (1967)*
There was no statistical significant difference between the 
percentage of true diploid cells in the test and control cultures; 
they ranged from 92 - 93%* In all of the experiments performed by 
Goh (I967) the percentage of diploids was between 89 - 95% for those 
women who were taking oral contraceptives. In-all the different 
oral contraceptive types in this study, the range of normal diploid 
cells was 88 - 100% in the mothers and between 86 - 94% in the babies 
in both test and control groups.
In the present survey, the percentage of cells with more than 
46 chromosomes (excluding triploid and tetraploid cells) was similar 
• in the control and test mothers1 groups (0.42% and 0.36%). In the 
test babies however, a higher frequency of such cells was found when 
compared to the control babies (0.28% and 0.16%). The majority of 
these hyperdiploid cells had two or three extra abnormal chromosomes '
I
?
of which some could not be allocated into any of the groups J
\
according to the Denver system . j
Goh (1967) also found a higher percentage of cells with 47 j
chromosomes present in women who had been using oral contraceptives j
compared to the test mothers in this project. He further found that 
the control cultures did not show any hyperdiploid cells. In the 
cultures from the mens1 leucocytes plus plasma from his test women, ‘
Goh found only 0.8% of the cells had 47 chromosomes. There was no 
indication from the report of the latter worker whether these extra !
chromosomes were sex chromosomes or autosomes. In the test mothers1 !
' I
group in the present study, the percentage of cells with 47 chromosomes 
ranged from 0 - 1.4% in the different oral contraceptive groups; the 
range of these type of abnormalities in the babies1 group was 0 - 0.9%* 1
There was found to be an identical frequency of triploid cells in j
the test and control cultures of the mothers in the present study (0.09%)• !I
.Jn the test babies though, there were over five times as many triploid 
cells in the test group compared to the control group. No culture 
was found to have more than one triploid cell present. It was not 
possible to trace any previous report which gave the frequency of 
triploid cells in women who have been taking oral contraceptives and 
their progeny. Goh (1967) calculated the incidence of cells with 
over 47 chromosomes, which probably included triploidy, and found 
0.9% of these cells in 5 women who were taking oral contraceptives 
compared to 0.3% in his control subjects.
There was a slight increase of tetraploid cells found in the 
test mothers compared to the number in the control mothers (1.50% 
and 1.29% respectively); but the opposite effect was observed from the 
babies1 group. The percentage of tetraploid cells in the different 
oral contraceptive groups ranged from 0% - 4*4% in the mothers and 
from 0% - 1.9% in the babies1 group. No data has been found from 
the literature on the frequency of tetraploid cells in women’who were 
taking oral contraceptives.
It was found that there was twice as many endoreduplicated cells 
in the control mothers than in the test mothers in this study,
(0.64% and 0.32%), this difference was not significant. In the test' 
and control babies1 groups, the percentage of endoreduplicated cells 
was very similar. The former finding may or may not have any 
biological significance, since technical factors could be responsible 
for this discrepancy in the results. Only 2 polyploid cells were 
found in the test mothers1 group and 1 in the control babies1 group 
in the whole of this survey, and therefore, it is difficult to 
make* any comparison with other studies or to state how significant 
the result is, by comparing control and test groups. ,
In pooling the results and making the comparisons, one must be 
aware of the shortcomings, that is, the different constituents 
and actions of the oral contraceptives. However, it has been done 
in the present study because only a small number of subjects on each 
oral contraceptive was examined and therefore a small number of cells.
When the results from the test and control subjects were 
compared, no significant differences in the frequencies of abnormalities 
were found. This observation was not repeated as far as the babies 
were concerned, since a higher frequency of triploid cells was 
discovered. However, on closer scrutinisation of the results, it 
is apparent that this is not a frequent occurrence in all the
oral contraceptive groups investigated as no more than one triploid 
cell was counted from each type of oral contraceptive. Therefore it 
can be generally concluded that, bearing in mind the shortcomings of 
pooling the results, no appreciable differences in the numbers of 
chromosome abnormalities can be observed in the mothers or babies.
(b). Structural Chromosome Aberrations.
The largest difference between test and control results in so far 
as structural chromosome abnormalities were concerned was in the 
babies1 groups. Nearly five times as many gaps were found in the 
chromosomes of the babies whose mothers had been taking oral 
contraceptives (0.39% compared to 0.08%). This was found to be 
very significant, but the differences between the percentages of 
gaps counted in the test and control mothers was not significant.
In many studies involving chromosome investigations, gaps have not 
been assessed presumably because of their doubtful significance 
but, on account of their possible importance, they were included in 
the present study.
In similar studies by other workers, gaps have not been assessed 
in women who have taken oral contraceptives. As a result, no 
details are available to compare with the findings here, but, in all 
of the control and test groups, with the exception of the test babies, 
.a lower frequency of gaps than breaks was discovered.
The percentage of chromosome breaks scored in the test babies 
was 0.11% compared to 0.21% in the control babies. The range of 
frequencies of the breaks found in the different oral contraceptives 
groups was 0% - 0.6%, with the highest frequency being found in the! 
Conovid group. There is a great deal of variation in the incidence 
of breaks occuring in the chromosomes from women who had taken or 
are continuing to take oral contraceptives in other studies.
McQuarrie and colleagues (1970) studied three groups of people in 
order to determine the incidence and type of chromosome aberrations. 
They looked at groups of healthy females taking oral contraceptives and 
their progeny, a similar objective to this study. Their first group 
consisted of 50 newborn babies whose mothers had taken sequential 
preparations equivalent to the oral contraceptive ’Sequens*. The 
mothers had been exposed to the contraceptive agent for an average time 
of 20 months with a range of 6-4-1 months. The mean length of time 
was very similar to that of the present study (19 months), but the 
present range was greater, between 0.25 - 84 months. The mean length 
of time Sequens was taken by the mothers in this study was 26 months
and the mean maternal age and the age range of the mothers in
McQuarrie*s study was also very similar to the present study. There­
fore, as the ages of the mothers and the lengths of time they had 
been using oral contraceptives was comparable in both studies, it is 
appropriate that the percentage of breaks in the two groups should 
be compared.
In the 50 blood cultures of babies studied for chromosomal 
breaks, 9 babies had breaks ranging from 5% - 20% per subject
(McQuarrie and colleagues 1970)3 whereas in the present study only
4 babies from the test group had chromosome breaks and in each case 
only 1 break per subject was observed. Another study involving 
chromosomal examination of babies whose mothers had taken oral 
contraceptives was undertaken by Rice-Wray and coworkers (1970).
They reported on 61 babies born to mothers who had been taking 
oral contraceptives for a period ranging between 2 and 80 months 
with a mean time of 19*8 months; this is approximately the same time 
as mothers in the present study had been taking oral contraceptives.
The types of contraceptives the mothers had taken were Sequens, 
OrthoNovum, Ovulen, Lyndiol and Anovlar. The ages of the mothers
ranged from 19 - 38 years with a mean age of 27.3 years. At least 23 
well spread metaphases were counted from each blood culture. Rice-Wray 
and coworkers found no structural or numerical abnormalities in any 
of the cells examined from the babies.
These two studies (McQuarrie and colleagues and Rice-Wray and 
coworkers), show strikingly different results with nearly an equal 
number of babies involved; 50 in the former and 61 in the latter study, 
j Rice-Wray and workers did not find any difference between the test 
and control subjects, however, McQuarrie and colleagues found a high 
- percentage of chromosome breaks, but did not perform any cytogenetic
analysis on cells taken from control babies, so it is difficult to ■
appreciate the relevance of their work as one can only compare their 
results to those of other workers supplying similar information.
The frequency of breaks in the cells of the test mothers was
j
0.56% compared to 0,51% in the control group in the present study. . *
There was a range of 0% - 1.9% of breaks in the different oral j
contraceptive groups with the highest proportion of breaks occuring «
in the* mothers who had taken Ovulen for contraceptive purposes.
McQuarrie and colleagues (1970) further studied the effect; of 
sequential mestranol with mestranol plus chlormadinone acetate I
(Sequens) cyclically in 20 female subjects. Only 50 metaphase spreads *
-were examined and 18 (36%) of the cells contained chromosome breaks,
with a range of 2% - 4% per cell. In a 48 hour culture method, 16 (32%) 
of the cells had chromosome breaks with a range of 6% - 24%. Both 
these percentages were much higher than those found in the present -
study (test). In the control group of McQuarrie^ study, 7 from the 50 
subjects (14%) had chromosome breaks with a range of 4% - &%•
Although no statistical evidence is available from their study between
the two sets of results, it is obvious that there must be a significant j
difference. This was not found to be the case in the present study, neither |
were there any breaks found in the mothers who had taken Sequens nor 
in- their progeny.
A third group, comprising of 3 patients who had taken norethindrone 
(a progestagen only contraceptive) 0.35mg daily for 6 months, had 
their cells examined for chromosome aberrations (McQuarrie and colleagues 
1970)* The blood cultures were again harvested at 48 and 72 hours.
In the former case only 1 subject had chromosome breaks, but this was 
10$ in 50 cells counted. After 72 hours, 2 patients had breaks, 
the first, 10$ in 50 cells and the second, 8$ in 25 ceils. These 
percentages are again very high compared to those found in the 
present study.
McQuarrie and colleagues also studied satellite association of the 
chromosomes in the metaphase spreads from their test patients after 
they had analysed their results. They suggested that increased 
frequencies of satellite association were usually connected with 
increased frequencoes of chromosome breaks. This observation has 
not been confirmed in a similar study by Bishun and coworkers (1972). 
McQuarrie and colleagues found a very high frequency of D/G satellite 
associations in their test patients, three times higher than in 
four families reported to have mongoloid children. Zellweger and 
others(1966) postulated that an increased frequency of D and G 
chromosome associations tends to render the progeny of the individuals 
more susceptible to D/G and G/G translocations. In a study by Bishun 
and coworkers (1972) on satellite association, it was found that 
there was an increase in the frequency of D/D associations in those 
women who were taking oral contraceptives, unlike McQuarrie and 
colleagues who found an increase in D/G associations. Since the 
significance of these phenomena are not fully understood, it is 
necessary for the mechanism to be more thoroughly investigated.
Goh (1967) studied the breaking potential of oral contraceptives 
on leucocytes from 5 patients. They had been taking OrthoNovum, Oracon 
or Enovid for 3 months. In 1004 metaphase spreads examined, 9.9% of the 
cells had chromosome breaks and 2.3% of the cells had chromatid breaks, 
compared to their control cultures of 0.8% of chromosome and 3.5% of 
chromatid breaks. The observed differences were statistically 
significant. Goh also studied the percentage of chromosome breaks 
occuring in cultures of normal leucocytes with plasma from women who 
were taking oral contraceptives, and found a large difference between 
the two groups. There were 10.2% of chromosome and 1.3% of chromatid 
breaks during the usage of oral contraceptives compared to only 1.5% and 
2.0% of chromosome and chromatid breaks respectively, after the 
oral contraceptives had been discontinued.
In one case, where a patient had discontinued oral contraceptives 
before cytogenetic studies of the blood culture, a much lower incidence 
of breaks was discovered 3»0%, compared to an average of 9*9% in those 
patients who were still taking oral contraceptives (Goh 1967).
This author further found that the percentage of breaks returned to 
an almost normal range in another case, 6 and 12 weeks after 
discontinuation of the oral contraceptives. Due to these observations, 
Goh suggested that these individuals were capable of removing those 
feutant cells1. In the present study it was found that only half 
of the test mothers who had chromosome abnormalities had taken oral 
contraceptives within the 6 months before conception.
One group of workers, Shapiro and associates (1972) used internal 
controls, so that each patient was studied before and after oral 
contraception. They felt that this was necessary because chromosome 
abnormalities may be caused by multiple factors and may antedate the 
use of oral contraceptives. Seven women were given Norinyl for 2 
months and chromosome studies were carried out before this oral
contraceptive was taken, after 1 month and after 2 months of Tusage1. 
Sixteen cells per blood sample were analysed and 5.0% of the total 
cells counted were found to contain chromosome breaks after 1 month.
After 2 months, 2.3% of the cells, less than half the number of the 
previous month, had structural aberrations. The control group had 4*7% of 
cells with breaks and they were unable to show any significant 
differences between the control and test results. In the present 
study 8 patients had been taking Norinyl for an average of 10 months 
and only 1 break and 1 gap was observed in 174 cells.
Shapiro and coworkers (1972) also studied the cytogenetic effect 
of oral contraceptives after an average use of Norinyl for 4 years 
(range 3 - 5 years), and found a decrease in the number of breaks 
compared to the untreated controls, 2.2% compared to 4«0%. No 
significant difference was found between these two sets of results.
This study utilising internal controls, therefore failed to demonstrate 
any cytogenetic effect in short and long term users of oral contra­
ceptives, a finding similar to that found in the present study using 
structural aberrations as the basic parameter.
Therefore, it can be concluded that there was no difference - 
between the frequencies of gaps and breaks between the test and control 
mothers. This however, is not the situation regarding the test babies, 
since there are five times as many gaps in the chromosomes from 
these subjects compared to the control group. It is not possible 
to state dogmatically that these gaps were caused by the mothers 
taking oral contraceptives since (i) only relatively small numbers of 
these aberrations were observed (ii) their true mechanism of formation 
is controversial and (iii) technical errors in identification, could 
have contributed to the observed frequencies. Obviously a still 
larger sample of cells needs to be examined before this problem can 
be solved.
Scrutinisation of Table 6b, would show that a higher frequency of 
breaks occured in the control babies1 cells compared to the test. However., 
as described before, both these frequencies are lower than those observed 
by other workers. An important observation from this table however, 
is the higher number of breaks in the test and control mothers 
compared to their babies. It is therefore apparent that the adult 
cells, because they are more exposed to external environmental agents, 
show a higher percentage of chromosome breaks. The newborns1 cells 
are not so subjected to these agents, since they are protected in utero. 
Therefore, since there are no differences in the frequencies of breaks 
between the test and control mothers it can be concluded that the 
taking of oral contraceptives does not induce chromosome breakage.
(c). Individual Oral Contraceptive Groups,
In Table 12 the percentages of mothers showing chromosome 
abnormalities from each oral contraceptive group are shown. It is
£
not possible to draw any definite conclusions from these results since ;
1
in several cases only a few subjects were investigated. Only the 
Ovuleh and Gynovlar groups contained more than 10 subjects from whom 
chromosome preparations were obtained, and the number of women 
showing aberrations was quite high (2 7 ,2% and 5 0 ,0% respectively).
Also, these two groups, from which the highest number of cells were 
counted from the mothers, did not have a significantly higher frequency 
of aberrations when compared to the total control group. The same 
situation applies for the babies of these groups.
In some of the other oral contraceptive types, there are 
differences in the percentages of cells with chromosome abnormalities 
between the control and test mothers and babies. However, due to the 
fact that only a small number of subjects was involved and a 
comparitively small number of cells examined, any conclusions drawn from 
these results would be only speculative. If these contraceptive agents
possessed any definite chromosome breaking potential/ irrespective of 
the small number of subjects examined, then one would have expected more 
positive results than those shown in Tables 11 and 12 .
3. The Constituents of Oral Contraceptives.
In the present study, a relationship may exist between the different 
constituents of the oral contraceptives and an increase in chromosome 
abnormalities. This was borne out in the women who had taken any 
oral contraceptive containing the progestagens ethynodiol acetate 
or chlormadinone acetate (Ovulen, Sequens and Normenon) where there 
were 4*3% and of cells with chromosome abnormalities in 314 and
25 cells respectively. In the latter case however, where only 25 
cells were counted, biased results may arise, so obviously a much 
larger sample is required to confirm or disprove these results.
The highest percentage of mothers who had chromosome abnormalities
were found in the group who had taken oral contraceptives containing
either lynestranol (Lyndiol) or ethinyl oestradiol (a constituent 
%
of 6 oral contraceptives), discounting chlormadinone acetate where 
only 1 person was involved. The babies who produced the highest number 
of chromosome abnormalities were found in the norethynodrel group, where 
more than twice the mean percentage of babies with chromosome 
abnormalities were found. Seven babies were in this group and 5 of 
them had cells with chromosomal defects.
There have been several studies to ascertain the effect of various 
constituents of the oral contraceptives on in vitro and in vivo systems. 
Five progestagens, viz: progesterone, megestrol acetate, dimethisterone, 
norethindrone acetate and chlormadinone acetate, and three oestrogens, 
oestradiol, ethinyl oestradiol, and mestranol were evaluated in 72 hour 
cultures of human leucocytes for their chromosomal effects. Each 
substance was studied in 2 concentrations and compared to controls and
no significant difference in the number of chromosome abnormalities 
were found in any substance studied,(Stenchever and colleagues 1969). 
These findings were corroborated by Singh and Carr (1970) who also 
added various hormones, mestranol, ethinyl oestradiol (oestrogens), 
norethindrone diacetate and medroxyprogesterone acetate (progestagens) 
to human leucocyte cultures. They found neither mitotic inhibition 
nor an increase in polyploid cells, thereby implying that these agents 
had no direct effect on dividing cells. From these two in vitro 
studies there appears to be no effect on the chromosomes by the 
progestagens or oestrogens tested.
Several in vitro tests have been performed to ascertain the 
cytogenetic effect of various oral contraceptives in culture.
Karbarity and Khodary (1967) found that Anovlar (4.0mg norethisterone 
acetate plus 0.05mg ethinyl oestradiol) when added to plant root cells 
showed anaphases of a multipolar type. After treatment with different 
concentrations of these constituents the cells appeared multinucleated 
and each of the nuclei had less chromosomes than the normal diploid 
number. The spindle formation was not affected by the addition of 
Anovlar to these cells.
These workers (1967b) also studied the effect of Conovid E (O.lmg 
mestranol and 2.5mgnorethynodrel)on Allium root tips. In stronger 
-concentrations of Conovid E, there was a pronounced stathmokinetic 
effect producing polyploidy, ^tar1 metaphases and anaphase bridges. 
Lyndiol did not have any effect on the metaphases although irregulations 
of the anaphase stage of mitosis was observed. They further mentioned 
that the conditions of the present experiments need not be representative 
of those found in the human body where there is a different biochemical 
sytem. Any conclusions from these experiments must be viewed with 
caution, although it does appear that a potential hazard exists with 
some of the oral contraceptives.
One study, undertaken by Timson (1969) dealt with the in vitro 
and in vivo cytogenetic effects of Lyndiol 2.5. Lyndiol was added 
•to blood cultures from normal healthy individuals and no specific 
structural or numerical chromosomal aberrations were found. Secondly, 
blood cultures from 19 women who had taken Lyndiol for an average 
length of 3*6 years were examined for chromosome abnormalities. All 
the chromosomes were found to be normal. In this present study, there 
were 7 women who had taken Lyndiol and altogether 116 cells were analysed. 
Approximately 4.0% of the cells had structural aberrations, figures 
which are not significantly different from the results obtained from 
the other oral contraceptive groups.
Studies using in vivo systems have produced different results, when 
the carcinogenicity aspect was considered. In a review by Zanartu and 
coworkers (1973)} workers found breast nodules in the beagle bitch when 
treated with progesterone, and they considered the effect to be 
significant enough to discontinue the manufacture of chlormadinone 
acetate (constituent of the progesterone only contraceptive) until 
its potential risk was clarified (Hill and colleagues 1970)* An increase 
in the number of tumours has also been observed when chlormadinone 
acetate was fed to mice (Drug Safety Committee Report, 1972). Due to the 
fact that in this present study only one subject had taken chlormadinone 
-acetate as a single preparation, it is difficult to draw any conclusions 
as to its chromosome breaking potential.
Ethynodiol acetate, which is a constituent of the contraceptive 
Ovulen, was found to produce a large number of benign and malignant tumours 
in the livers of mice, the pituitaries of female rats and mice and 
in the mammary glands of mice (Drug Safety Committee Report, 1972). 
Norethynodrel is a constituent of Conovid E and it was found to 
induce an increase of benign liver and pituitary tumours in male rats 
and mice by the above Committee. The babies born to mothers who had 
taken Conovid E for varying lengths of time, in this study, were found
to have an increase in the number of cells with chromosome abnormalities 
compared to the control group.
Reports of the effects of the oral contraceptive constituents are
scanty and an enormous amount of further work needs to be done. In the 
reports cited in the preceding text, none of the constituents tested
in vitro caused any chromosome or other cellular abnormalities.
This is substantiated by the in vivo studies on women who have taken
oral contraceptives with the aforementioned constituents and who did
not show any significant increase in the number of chromosome aberrations.
However, the in vivo studies have shown that some of the constituents
can cause cancer in mammalian species, therefore the question of the oral
contraceptive producing chromosome damage should be regarded as still
being open. Furthermore, any changes caused by the oral contraceptive
might not be apparent by the present cytogenetic methods, since smaller
suptler changes for example, translocations and inversions might
escape unnoticed. These latter aberrations can be seen with the aid of
new techniques such as banding. Since the in vivo results regarding
the constituents of oral contraceptives suggest that minute changes
can lead to cancer formation; then a longer term investigation into
the chromosome breaking effects and cancer formation ought to be instituted.
4. The Inheritance of Abnormal Chromosomes.
Generally, after referring to Table 34 it would appear that the 
mothers who had taken oral contraceptives, had a higher incidence of 
babies with congenital malformations. Unfortunately, it is not possible 
to ascertain whether these babies were born before or after their mothers 
had been using these contraceptives. When these abnormalities were 
grouped with anomalies from close relations, no obvious difference in 
numbers between the test and control groups were found. Also, there was no 
increase in the percentage of chromosome abnormalities in these mothers who
had these sibs compared to the total sample.
• There has been a considerable amount of work concerning the trans­
mission of translocations from mother or father to offspring. Lejeune 
and colleagues(1970) concluded from their work, that the risk of an 
unbalanced karyotype resulting in a live birth is of the order of 
10 - 20% among the progeny of heterozygous mothers and considerably less 
for heterozygous fathers. Although Downs syndrome usually occurs as 
a sporadic event in a family, several affected members have been 
described (Wright and coworkers 1963). It is impossible at the present 
~time to seperate chance events from events for which there is some 
predisposition, particularly when dealing with a condition as common 
as Downs syndrome. If all the evidence is considered, there seems to be 
some genetic control over disjunction (Hamerton 1971).
In the present study, 11 pairs (mother and baby) were found in 
the control group with chromosome abnormalities; 13 pairs were found in 
the test group. There was no significant difference between the numbers 
of pairs in the two groups or between the expected and observed values 
within each group. In 8 of the 11 control pairs, the babies had at least 
one type of chromosome abnormality similar to their mothers. Seven pairs 
in the test group had common chromosome abnormalities in mother and 
offspring.
Bloom {1972) and Awa (1971) looked at the transmission to offspring, 
of somatic cell aberrations in women who were resident in Hiroshima after,, 
the atomic bomb explosure. They found complex aberrations but so far have 
not found any in the FI generation. In the latter case the agent in 
question is a well established chromosome mutagen and to prove that a 
recognized mutagenic substance can increase nondisjunction or meiotic 
chromosome damage in man is a very hard task. Therefore, investigating 
the effect of a chemical which has not been proved to be mutagenic is 
even more difficult and would mean the examination of thousands of cells 
from each baby. Two factors which complicate the situation are the high
frequencies of persons with major chromosome anomalies in the general 
population (0.5%) and the percentage of structural heterozygotes in 
the population (2% - 4%)> (Cohen and Bloom 1971)*
5. The Relevance of Chromosome Abnormalities.
Various kinds of chromosome abnormalities are common in most types 
of neoplastic disease,* chronic myeloid leukaemia,(Nowell and Hungerford, 
I960 ; De Grouchy and colleagues, 1966 ) lymphomas,(Epstein and Barr, 
I964) and carcinomas (Makino and coworkers, 1964). The possibility 
that neoplasm might be associated with chromosome abnormalities was 
first suggested by Boveri (1902) and there is still controversy .concerning 
this problem today. There are three ways of considering the relationship 
of a chromosome abnormality to malignant change; firstly, the chromosome 
change is caused by the malignant transformation; secondly, the malignant 
transformation resulted in the chromosome abnormality and thirdly, the 
same common factor which caused the malignant change also caused . 
the chromosome abnormality.
There are several theories at the present time in support of one of 
the above three points. There is the chromosomal theory of carcinogenesis 
and the stem line theory of carcinogenesis put forward by Makino (1957)*
The latter theory is tumour progression in which the basic or stem line 
is clonal in origin and contains a particular but constant chromosome 
abnormality. As a result of abnormal divisions, cells containing other 
chromosome complements aris.e from this stem line.*Atkin and Baker (1966) 
have provided convincing evidence that the chromosomes of cells from 
human tumours support the view that malignant tumours frequently arise from 
a single cell in which chromosome changes occur. The presence of the 
same marker chromosomes in many tumour metaphases, together with other 
similarities in the karyotypes, suggest strongly that these metaphases 
arose from a single cell bearing a marker chromosome. Wakonig-Vaartaja
and Hughes (1967), Sandberg and colleagues (I967) and Porter and others 
(1969) have confirmed that primary and secondary tumours arise from 
the same stem line and that further, the marker chromosomes demonstrate . 
clonal evolution in cancer progression.
According to the chromosomal theory of carcinogenesis, chromosomal 
aberrations are the common pathway through which carcinogenic factors 
induce cancer (Bishun 1973)* Further, it has been established beyond 
doubt that certain viruses, chemicals and other therapeutic drugs 
cause chromosomal damage. It then stands to reason that the chromosomal 
damage that these exogenous agents cause, could be a causal factor in 
the evolution of neoplastic disease.
Down!s syndrome is known to be a congenital disease which pre­
disposes to the development of leukaemia. It has been found that the 
incidence of leukaemia in these people is eighteen times higher than
fi
that for the general population(Koller 1966; Holland and colleagues,1962). j 
The frequent association of leukaemia or other cancers, with congenital [■
abnormalities has also been emphasized, for example, ovarian cancer |
in patients with Turner1s syndrome, leukaemia with Bloom1s syndrome,
Fanconis anaemia and ataxia telangiactasia.
The role of viruses in producing chromosome aberrations has been 
extensively studied; the damage is similar to that seen in some 
malignant and irradiated cells. Since it has now been established J
that these types of chromosomal aberrations are present in precancerous 
and cancerous conditions, then everything points to the fact that 
chromosome re-arrangements are the common pathways through which carcino- ;■
genesis induces malignancy. ;
The findings that certain psychoactive drugs eventually lead to 
leukaemia has exemplified the need for careful screening of drugs for if
possible chromosome breaking potentialities. More information and f
£
investigation should be sought regarding the incidence of neoplastic |
diseases associated with various compounds either taken as short term 
relief for common ailments or for considerable lengths of time^ e.g. 
the oral contraceptive which is taken for suppression of ovulation.
!
i
C• Environmental Factors•
1. Maternal Age.
It has been well documented that increase in maternal age is a 
causal factor in some types of human chromosome abnormalities, for 
example, DownTs syndrome (Penrose and Smith, 1966 and Collman and Stoller, 
1962). In a survey published by the latter workers, it was found that 
the incidence of DownTs syndrome in babies is fairly low in mothers of 
. less than 30 years, but rises sharply in women of over 40 years. Due 
to the fact that high maternal age increases the frequency of Down!s 
syndrome and other autosomal trisomy syndromes, it is of great importance 
that one should look at the effect of maternal age on the mothers1 
chromosomes and of their newborn infants.
In this present study, the chromosome results of all the mothers 
who were 35 years and over were grouped together and compared with 
the chromosome abnormalities present in the total group. Thirty five 
years was chosen as a standard age comparable to that used in other 
studies. There was no increase in the number of chromosome abnormalities 
found in the mothers or their offspring on the test and control patients 
of mothers of over 34 years of age. Scatter diagrams were also drawn 
and the points plotted were found to be completely at random. These 
results conflict with those presented by Lubs and Ruddle (1970) who 
found that 26% of the mothers who were over 34 years of age produced 
infants with chromosome abnormalities compared to 7$ in "the total 
sample. Also 1.5% of the babies born to mothers of over 34 years of 
age were chromosomally abnormal compared to 0.5% in the total sample.
The mean age of the total group of mothers in their study was 25.7 
years, an age group which is similar to that of the present study. 
Paternal age has not been found to be a causal factor in producing 
chromosome abnormalities.
2. Hazardous Occupations.
The possible effects of a variety of low dose exposures that are 
encountered by relatively small,populations of people as a consequence 
of their work, were studied. This was due to reports from a number 
of laboratories which have noted significant increases in the 
frequency of chromosome type aberrations in individuals receiving 
intermittant low dose exposures from external sources.
In the present study many mothers and fathers in each group worked 
in contact with different exogenous agents, and therefore, it is 
necessary to ascertain whether the chromosome defects (if any) that 
are found in these patients are caused by the radiation, drugs or 
illnesses. As the numbers of workers in the various occupations were 
too low to be able to carry out suitable statistical tests, the total 
number of workers in all the different occupations were grouped together 
and compared with the numbers who had chromosome abnormalities in the 
total group. Only in the test mothers1 : group was there any noticable 
difference between the two frequencies. This could be a relevant 
factor to be considered but because of the small sample available, 
it would not be possible to ascertain with confidence which hazard, 
if any, could have caused this deleterious effect.
Normons group (1964) studied the chromosomes from 36 hospital 
radiation workers who had received culminative doses of 10 - 98 rads, 
over 7 - 1 6  years. In this study there was a highly significant 
difference between the number of chromosome abnormalities observed in 
these people compared to the control group. They suggested that a 
significant increase in the general background radiation will lead to 
a significant increase in the frequency of aberrations in the 
general population.
Another hazardous occupation noted in the present study was work 
involving the use of industrial chemicals. Only 3 women in the
control and 5 in the test group worked with these chemicals and there 
was a much larger group of fathers found in this particular group.
It has been known for some time that a great many chemicals are 
potential mutagens or have chromosome breaking properties, e.g. ; 
alkylating agents, (Sanders 1969); acridine dyes, (Fishbein 1972); 
ethanol, (Bregman 1971); benzene, (Tough and Court Brown 1965*
Forni and Moreo 1969)* Therefore it is of great importance to ascertain 
whether workers involved in the usage of these chemicals are affected 
by them, thereby disguishing the cytogenetic effect (if any) caused 
by the oral contraceptive.
In the control group 2 mothers and 8 fathers used agricultural 
chemicals, and 6 mothers and 8 fathers were working with these 
chemicals in the test group. A.number of pesticides and insecticides 
are known to be mutagenic or possess chromosome breaking potential. 
Captan, a widely used fungicide in agriculture has recently been 
shown to break chromosomes of human embryonic lung cultures (Legator 
1972), DDT, one of the most effective pesticides has been shown to be 
mutagenic in human cell cultures in vitro (Fishbein 1972). More 
recently it has been shown to cause chromosome damage to cultured 
mammalian cells (Palmer and workers 1972).
Since man is exposed to mutagenic agents in the environment, 
any assessment made of chromosome damage induced by chemicals and drugs 
in the general population, should be done with the knowledge that there 
exists a tolerable background of genetic damage. The chemical or drug 
under study may then have a cumulative effect on the chromosomes in which 
case an increased frequency of damage will be-found. This has not 
been observed in the present study.
3. Spontaneous Miscarriages.
The number of spontaneous abortions which a mother has experienced
is very important, due to the fact that several famsilies have been 
described in the literature in whom recurrent abortion has been 
associated with chromosomal abnormalities in a parent (Yunis and 
coworkersj 1964; Jacobsen and colleagues, 1966; Lucas and others, 1969 
and Hsu and workers, 1970)• Also many surveys have been carried out 
involving women with recurrent abortions in which 13 major chromosome 
anomalies have been.discovered among 306 couples (Rowley and others, 
1963; Bishun and Morton, 1968 ; Stenchever and Jarvik, 1971)* Due 
to the above data, the percentages of mothers who have had previous 
miscarriages were calculated in the present study, firstly to ascertain 
whether there were a greater number of miscarriages in the test group 
compared to the control; secondly ,to ascertain whether the percentage 
of these chromosome abnormalities occured more frequently in mothers 
who have had previous miscarriages than in the total sample.
At first it was discovered that there were twice as many 
spontaneous miscarriages in the test group than in the control group, 
but after separating these abortions into before and after the 
oral contraceptive had been taken, the number occuring in the test 
and control were approximately the same. This could be explained on 
the grounds that women who had suffered from one or two miscarriages, 
decided they they would not bear any children and therefore started to 
take oral contraceptives. This supports the observations by Poland 
(1970) who observed that in 394 abortions there was no evidence that 
the prior use of oral contraceptives increased the incidence of 
abortions. Secondly, the fact that mothers who had had miscarriages 
prior to this study, also had a greater proportion of chromosome 
abnormalities was disproved. Approximately the same percentage of 
mothers had chromosome aberrations as found in the total sample.
This data .also confirms the findings of Carr (1967) who stated that 
chromosome defects appeared to be no more common among women having
several abortions than among women having a single abortion.*
There have been numerous studies on embryonic tissue derived 
from spontaneous abortions, and workers have demonstrated that between 
20 - 25% of these abortuses are chromosomally abnormal (Boue and Boue, 
1969; Carr 1965). Of greater consequence is whether the spontaneous 
abortions which occur in women who have taken oral contraceptives 
affect the chromosomes of their live births. The babies born to 
mothers with a history of previous spontaneous miscarriages in this 
study, did not show an appreciable change in the number of chromosome 
abnormalities when compared to the total group, between the test and 
control babies.
Carr (1970) has performed many cytogenetic studies on abortus 
material. He found that there was a striking difference in the. 
incidence of triploidy , between the women who had conceived within 
6 months of discontinuing oral contraceptives and the control group.
In the present study however, there appeared to be no difference in 
the percentage of chromosome abnormalities in those babies born to 
mothers who had conceived within 6 months of discontinuing oral 
contraceptives and those from the total group. An interesting point, 
is the number of triploid cells found in the test babies compared to 
the control babies. Carr (1970) explained the evidence of triploidy 
by suggesting that there is a temporary hormonal imbalance in some 
women after they discontinue oral contraceptives. This could affect 
the timing of fertilisation, thereby producing unequal division of 
the cell. Also, it is not clear when the pituitary hormone level, 
returns to normal in women who have been taking oral contraceptives. . 
There may be direct after effects also on the ovary and this could 
cause failure of the cytoplasm to cleave in time with the division of 
the chromosomes at meiosis II. Several other factors could interfere 
with this mechanism and there are circumstances in which hormones
have been shown to affect cell division.
Another study by Poland (1970) was set up to examine the 
chromosomes from abortuses from women who had been taking a single 
oral contraceptive. She found 14 with systemic anomalies and 20 with 
growth disorganisation. The control showed the reverse effect and 
she concluded that it was the effect of the ageing ova which produced 
a blighted ' ovum in these women who had been taking oral contraceptives
4* Amenorrhea.
This was found to occur in 15«9$ of the control subjects and in 
21.4$ of the test mothers at some time during their reproductive 
life. It is a well recognised fact that amenorrhea usually occurs 
following termination of both sequential and combination types of 
oral contraceptives (Rice-Wray 1967)* In a study by Arrata and Alvares 
(1972)5 it was found that the post contraceptive incidence of 
amenorrhoea ,was between 1$ and 10$ in women. The results in the present 
study support these, an incidence of 2.5$ of women. It was not known 
in* this study whether the women ovulated in the first post treatment 
cycle. Rice-Wray (1967) found that the return of ovulatory function 
appeared to be equally prompt whether contraception had been taken 
for 1 - 4 years or from 5 - 6  years in 67$ of the women.
In spite of the considerable data available on the effect of 
oral contraceptives on pituitary hormone production during actual 
administration of medication, relatively few data are available 
on the rate of recovery after the contraceptives have been discontinued 
The return of regular cycles gives no assurance that FSH and LH are 
at their normal levels during this time. Flowers and colleagues (1966) 
reported some irregularities in FSH and LH excretion during the first 
cycle after therapy with ethynodiol acetate and mestranol. The time 
interval before complete, recovery is not as yet known.
.Studies have been carried out by various workers on the return of 
fertility to animals and humans after they have been given or used oral 
contraceptives. It was discovered that control rats conceived 8 to 10 
offspring, compared to the test animals where only 4 to 6 per litter 
were produced (Beaconsfield and Ginsberg 1968). A similar effect was 
discovered in rats and rabbits by Saunders and Elton (1967)* This work 
was criticised by Bishop and Hill (1968), because rats were used in 
preference to human subjects by the above workers. These latter workers 
studied 63 women who had discontinued oral contraceptives in order to 
have a baby. They found that 18 conceived immediately, 31 in 1 - 6 months 
and 10 in 7 - 12 months; 2 failed to conceive. In the present study,
61$ of the mothers had conceived within 6 months of discontinuing oral 
contraceptives; an observation which is similar to that made by Bishop 
and Hill (1968).
5* X-Rays.
Another predisposing factor which is known to contribute to 
chromosome aberrations is X-rays. In the test and control groups, 
approximately half of the mothers had been X-rayed during their present 
pregnancy. The percentage of mothers who had received X-rays during 
their pregnancy and also had chromosome abnormalities were compared to 
the total in order to ascertain whether there were an increase in the 
numbers of cells with chromosome abnormalities in those patients who had 
received X-rays. This was not found to be the case in the control mothers 
though in the test mothers there was a slight increase.
Tough and colleagues (i960), were the first to report chromosome 
aberrations in the blood cells of individuals exposed to X-rays; this was 
followed by two other reports substantiating the results obtained 
(Stewart and Sanderson, I960; Conen and coworkers, 1961 & 1963). A study 
by Bloom and Tijio (1964) disagreed with the above results when they did 
not find any dicentric aberrations when 3000 cells from people exposed
to X-rays were examined.
. . An interesting observation by Tough and colleagues (i960) was the 
effect of a single exposure X-ray to a patient. They found a decrease in 
the percentage of modal chromosome cells from 93 to 72, an increase in 
abnormal chromosomes from 1 - 21$, but by the fifth day the percentage of 
modal cells had' returned to normal and there was also a sharp decline of 
cells with structural abnormalities.
In this study the mothers had received their X-rays many weeks before 
the blood samples were taken. These X-rays given to the test and control 
-mothers played no role in causing chromosome abnormalities in the cells 
of their newborns.
6. Illnesses.
Due to the fact that viruses have been shown to induce chromosome 
aberrations, e.g. chicken pox, (Aula 1963); measles, (Nichols and coworkers, 
1962, 65* 66. ; Tanzer and colleagues, I963) and herpes simplex (Stich 
and associates, 1964)5 the chromosomes of mothers who had had any serious 
illnesses either before or during pregnancy were investigated.
The same number of test and control mothers, in this study, had 
suffered from a serious illness (including flu) during their pregnancy. 
There was no noticable difference between the percentage of mothers who 
had chromosome abnormalities were ill either before or during pregnancy 
and the percentage of others who were ill from the total group. This was 
also true in the case of the babies.
7« Drugs.
An enormous range of drugs are taken by the general population today, 
and a large proportion of these drugs are taken by pregnant women, e.g. 
sedatives and tranquillizers. Therefore, it is of utmost importance 
that the effect of these drugs on human chromosomes should be investigated.
At the present time there is a great deal of controversy over the effect 
of various commonly used drugs on chromosomes. Aspirin has been shown to 
produce a significantly high percentage of breaks in human leucocyte 
cultures (jarvilc and Kato 1968), but this work has not been substantiated. 
Diazepam, a tranquillizer, has been studied by Nielsen (1969) and shown to 
produce chromosome breaks, but only during the time that the drug is taken. 
These results disagree with Cohen and others (1969) and Stainger (1970) 
who found no such effect. Other commonly used drugs such as antibiotics, 
e.g. chloramphenicol have produced chromosome breaks and fragmentations 
(Mitus and Coleman ,1970)o
It is also of equal importance to ascertain the effect of drugs 
taken by the mother of the newbornbabies, especially since the thalidomide 
incident. A number of drugs have been found to be teratogenic, for 
example, salicyclates (Larsson and colleagues 1963), insulin (Smithberg 
and coworkers 1956) and other antibiotics such as actinomycin (Tuchmann- 
Duplessis and Mercier- Parot 4958 )• All this work has been performed on 
rats and mice, and therefore if these results are to be extrapolated to 
man, it must be done with the utmost caution.
D• The Future for Oral Contraceptives,
There have been many developments to improve the existing oral 
contraceptive, or to find safe alternatives. Amongst the discoveries 
have been ’morning after pills’, prostaglandins, oral male contraceptives, 
single dose long term injections, sustained release :low dose progesterone 
and the ’mini’ pill (Tyler 1972). Many of the side effects of the present 
day contraceptives (oral) have been attributed to the oestrogen content. 
Hence, there have been increasing numbers of tests on synthetic progestagens 
alone, to inhibit fertility. Norgestrel, a homologue of norethisterone is 
one of the hormones on trial. This has been given to 125 patients 
for a total of 706 cycles and no pregnancies occured at the l.Omg dose; 
also, there was no evidence of cardiovascular disturbances or malignancy 
found. The results suggested that norgestrel may prevent conception 
by means other than the suppression of ovulation. Sperm incapacitation 
or migration may be involved (Roland and coworkers 1973)•
Another progestagen only contraceptive which has been tried on 5 women, 
was norethindrone. This gave reasonable results as an effective contra­
ceptive (Moghissi and colleagues 1973)• The problem with the progesterone 
only contraceptives is that a high degree of menstrual irregularity 
occurs (Liggins 1971), and the onset of amenorrhea after discontinuation. 
Results with a combined low oestrogen contraceptive in 1085 women showed 
that a dosage of less than 5 yhg is compatible with satisfactory cycle 
control and efficiency (Bye and Elstein 1973)•
Some work has been carried out using a five weekly intramuscular 
injection of medroxyprogesterone acetate with oestradiol. This would be 
useful for people who cannot be relied upon to take birth control Spills’. 
However there are a few side effects, namely irregular bleeding patterns 
and amenorrhea following discontinuation, which might not make this 
regimen so desirable (Scommegna and colleagues 1970)*
Preliminary reports of a sustained low dose progestagen only 
contraceptive suggests that this form is safe and promising (Liggins 1971). 
Various progestagens have been incorporated into capsules which are 
slowly released up to 1000 days when implanted in the cervix (Mishell 
and Lumkin 1970).
Bingel and Benoit (1973) suggest that agents with abortifacient 
properties, for example, prostaglandins, may be very useful in the 
future, as such agents would only have to be taken once a month.
Tyler (1972) goes even further and thinks that with the wider use of 
laparoscopy, more females will be sterilised and the need for the 
present contraceptives will decline.
Concluding Remarks.
The main criticism of the work dealing with previous cytogenetic 
studies on women who have been or are continuing to use oral contraceptives, 
is that the samples chosen have not been large enough. McQuarrie and 
colleagues (I97O) examined the chromosomes of only 50 babies whose 
mothers were taking oral contraceptives and from 20 women who were, 
using these contraceptives. In order to ascertain if there was an 
adverse cytogenetic effect produced by the oral contraceptives, 20 
control subjects were chosen who had never taken oral contraceptives.
Goh (1967) published work with even fewer subjects in his sample, 5 
women as test subjects, and compared their chromosome results with only 
3 subjects. His control group consisted of blood cultures from men, 
a situation which is not nearly as valid a comparison as if he had used 
women. Rice-Wray and coworkers (1970) in a similar survey, studied the 
cytogenetic effect of the oral contraceptive on 61 babies whose mothers 
had been using this agent for varying lengths of time. In their study, 
there were no control subjects and, as has been discussed earlier, it 
is very difficult to compare one set of results to those of another study 
because of the variations in results found by different workers and also 
because of the different techniques employed. The present study is the 
first to be carried out to such an extensive scale, utilising at least 
180 subjects from each of the test and control mothers’ and babies’ 
groups whilst other studies have either examined the chromosomes from 
the mothers or from their babies.
It has been shown by several workers that drugs, radiation, viruses 
and other environmental agents can have an adverse effect on cells 
thereby producing abnormalities of the chromosomes. However, once these 
hazards or agents are discontinued, the abnormalities tend to disappear 
after a period of several weeks. As already mentioned in the foregoing
discussion, chromosome abnormalities of radiation workers were found to 
decrease several weeks after the X-rays (Tough and colleagues i960), 
and after a patient had been given diazepam, the effects of this drug 
decreased with time (Nielsen 1969). Cytosine arabinoside, used for 
treating severe herpes viral infection was found to cause chromosome 
abnormalities .in bone marrow cells. Two weeks after therapy these 
changes disappeared (Bell and others 1966). Triaziquone, an alkylating 
agent, used in the treatment of cancer was shown to produce chromosome 
breaks, but this damage gradually decreased with the increase of time 
after discontinuation (Schmid and associates 1971)« Another example 
is benzene, which was found to cause breaks in the chromosomes of rat 
bone marrow cells within 12 hours, but there was recovery after 36 hours 
(Philip and Jensen 1970).
A lot of the above studies have not been substantiated by other 
workers, but the theory that mutant cells do disappear from the system 
once the harmful chromosome breaking agent is removed is still valid.
Goh (1967) found that breaks in the chromosomes of women who were 
taking oral contraceptives to be quite high, but after only 6 weeks of 
discontinuing these types of contraceptives, the number of breaks found was 
considerably less. A similar mechanism operating in the present study could 
explain why there fras no increase in the number of breaks or other 
chromosome abnormalities in the test group than in the control group as 
the test mothers had discontinued oral contraceptives for at least 
9 months.
F. Conclusions.
When the total cytogenetic results were compared from the 185 
test and 181 control mothers, no significant difference in the frequency 
or type of chromosome aberrations was observed. However, minor 
differences in the numbers of chromosome abnormalities were found between 
the two groups, but these were not regarded to be of any special biological 
significance because of their low frequency. Their true significance 
can only be appreciated after long term studies of the individuals 
concerned and their progeny.
The only abnormalities observed in the offspring of the mothers who 
had been taking oral contraceptives-were increases in the number of tripleid 
cells, gaps and breaks. The preceding discussion has dealt with the 
possible significance of these findings but, it should be borne in mind 
that before any correlation between taking oral contraceptives and 
chromosome abnormalities in the offspring can be made, a much more 
intensive and long term study must be instituted.
The test and control mothers were sepaxated into different age 
groups, and those who had previously miscarried. It was observed that 
the incidence of chromosome abnormalities was not affected by these 
factors.
Also the length of time the oral contraceptives was taken and 
the time between discontinuation and conception was taken into 
consideration in order to ascertain whether these factors contributed 
to the incidence of chromosome abnormalities in the mothers and their 
offspring. It was observed that these factors did not result in an 
increase in the number of aberrations in these subjects.
The preceding discussion pointed out that certain constituents of 
the oral contraceptives may predispose to an increased frequency of 
chromosome abnormalities. However, individual, work regarding these
constituents singly. . , ? should be undertaken in order to substantiate 
these observations.
4* Naturally it would be expected that the incidence of chromosome
abnormalities would be exaggerated where the mothers, in addition 
to taking oral contraceptives, had been exposed to external environmental 
hazards. No such increase was observed which suggests that the 
chromosome breaking potential, if any, of the oral contraceptive 
is not exaggerated by an external influence.
5* In the test and control subjects a similar number of pairs (mothers
and babies) showed chromosome abnormalities. Between 50$ - 70$ of these 
pairs showed similar chromosome abnormalities. In the latter cases it 
is possible that this is under a degree of genetic control but, whether 
or not these abnormalities were produced by the oral contraceptive, 
is still a matter of conjecture, on account of the small numbers 
observed.
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4 29 6 6
16 27 1 1
22 25 1 1
26 28 3 3
30 27 1 16 17
32 26 1 17 1 1 20
34 21 14 14
38 28 1 22 3 1 2 27
46 26 0
48 26 1 1 23 2 25
56 23 0
58 29 14 14
74 28 0
76 23 1 8 9
0
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84 23 11 11
86 25 3 3
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98 25 2 2
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200 23 4 4
206 31 1 1
208 25 1 1 16 18
214 21 1 1 13 15
220 25 0
229 26 * 0
235 23 1 1
239 26 0
241 27 o'
243 21 1 5 6
246 29 7 7
248 22 0
258 25 4 4
260 23 1 4 5
266 26 2 21 23
268 25 1 22 23
276 39 25 25
280 27 3 3
282 27- 2 2
292 28 1 23 1 ' 25
294 27 9 9
310 25 0
320 28 0
322 20 ' 1 22 2 25
324 37 0
328 29 3 22 25
330 22 1 22 1 24
332 27 25 25
346 25 1 22 1 1 25
348 18 1 24 25
358 36 2 - 2
364 32 2 22 1 25
366 16 9 9
370 30 1 10 11
382 22 1 13 1 15
392 24 - ■ 0
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396 25 0
404 24 1 24 25
408 46 1 1
414 21 16 16
416 19 1 24 25
418 . 34
* 0
422 37 1 1 20 1 1 24
426 15 8 8
428 21 1 27 2 5 1 30 ’
432 27 1 23 2 26
444 22 1 21 1 23
448 27 20 2 1 23
452 28 0
454 17 ' 0
458 22 1 19 4 1 25
466 25 0
470 16 0
482 23 3 47 50
490 24 2 45 2 1 1 50
496 18 13 13
512 19 0
518 25 12 12
530 25 1 11 12
532 36 0
568 18 0
574 21 2 46 2 2 50
576 29 1 19 20
586 25 0
590 27 0
604 24 1 1
606 27 1 15 16
608 31 0
612 35 0
624 29 2 35 2 1 1 40
630 30 7 • 7
634 20 0
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638 18 8 8
642 22 1 37 2 38
644 20 0
664 29 1 15 16
668 28 ■ 0
672 27 No Dlood oultur  ^• -
692 19 17 1 1 18
700 27 0
716 24 0
736 23 1 25 26
738 27 0
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760 23 No Dlood' cultur • i -
762 23 No Dlood Dultur 2k• j -
790 22 2 46 1 ! 1* 49
794 32 2 35
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798 31 1 19 i 20
816 26 | 0
828 25 1 17 18
830 22 0
832 36 1 1
834 26 2
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838 19 1 1 48 50
840 21 0
844 21 1 26 27
846 32 1 1
848 20 2 28 30
850 34 1 22 23
856 21 2 47 1 1 50
870 29 0
874 29 0
876 24 8 8
878 23 0
880 20 0
888 36 3 1 46 50
892 22 2 37 1 1 40
896 21 1 11 _12
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924 28 0
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930 20 0
940 32 0
948 21 0
950 26 12 2 14
956 30 26 26
958 26 2 1 36 1 40
960 27 3 47 . i ' 50
974 23 5 3 8
984 22 16 • 1 16
988 40 21 i1i 21
992 22 !1 0
996 29 7 7
1000 30 1 31 32
1018 22 4 ■ 4
1020 28 0
1030 29 1 16 17
1032 23 7 ' 7
1066 21 0
1070 24 8 8
1074 23 1 12 13
1078 35 2 17 1 20
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1086 28 12 12
1088 33 4 1 5
1114 24 0
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1126 20 8 1 9
1128 27 3 - 3
1132 24 13 13.
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3 XX 1 18 19
15 XX 1 20 20
21 XX 19 19
25 XX 1 1 22 24
29 . XY 1 1 20 22
31 XX •19 1 20
33 XY 1 1 22 24
37 XY 19 1 20
45 XX 1 1 21 23
47 XX 1 19 1 21
55 XX 1 H 1 6 22
57 XX 1 1 22 1 25
73 XX 1 1 23 25
75 XX 2 1 20 | 23 !
77 XY 8 1 8
83 XX . 25 i 25
89 XY No Ilood (culture -
93 XY 2 2
97 XX 4 4
103 XY 0
111 XX 1 22 1 2* 23
115 XX 2 1 18 21
117 XX 21 21
121 XX 1 1 22 1 25
135 XX 0
139 XX 1 23 1 25
141 XX 1 12' 13
145 XX 4 21 25
149 XX 1 1 23 1 25
153 XX 25 25
155 XX 1 23 - ■ 24
159 XY 25 25
181 XX 3 - 3
193 XX 13 13
195 XX 8 1 1 10
199 XX 4
•
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205 XX 1 17
i
1
. 1
18
207 XX | 0
213 XX 25 i1 25
219 XX 1 24
i
1 25
228 XX 2
.
■ 2
234 XX . 4 .1 5
238 XX 11 11
240 XX 2 1 18 21
242 XX 1 1
247 XX 0
249 XY 1 24 25
259 XX * 0
265 XY 2 ' 23 25
267 XX 1 1 21 2 25
2 75 XY 2 1 22 25 V
279 XY 1 24 25
281 XX 1 24 25
291 XY 2 21 23
293 XX 14 14
309 XX 2 22 1 25
319 XY 2 19 1 22
321 XX 1 24
f 25
323 XY 2 22 1 25
327 XY 12 12
329 XX 1 24 25
331 XY 2 23 25
345 XX 1 23 1 25
347 XX 1 24 25
357 XY 2 1 22 25
363 XY 1 1 23 25
365 XX 25 25
369 XY 1 23 24
381 XX 1 1 47 1
~ 52
391 XX 1 24 ■ 25
395 XX 3 1 47 1 52
403 XY 6 6
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409 XX 1 24 25
413 XX 2 2
415 XX 1 1 23 25
417 XX 9 1 1 11
421 XY 2 25 3 - 30
425 XY 1 1 22 1 25
427 XY 1 24 25
431 XY 1 22 1 24
443 XX 1 24 25
447 XY 14 8 ■ 1 1 23
449 XX 1 24 25
453 XY 1 1
455 XY 2 24 25
459. XY 2 24 1 26
467 XX 3 1 46 50
471 XY 1 24 2 27
483 XX 13 13
491 XX 1 18 1 20
497 XY 0
513 XY 3 3
519 XY 0
531 XX 0
533 XX 13 13
569 XY 11 11
575 XY 4 45 1 1 50
579 XY 11 11
591 XY 2 1 21 24
597 XX 0
605 XY 0
607 XX 2 27 29
609 XY 1 18 1 20
613 XX 1 22 1 24
62 5 XX 2 41 43
631 XX 2 3 5
635 XX 2 1 26 29
639 XX 0
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643 XX 2 35 1 1 39
645 XY 3 47 50
647 XY 1 48 1 1 50
655 XX 2 2
665 XY 2 2
669 XX 1 20 21
673 XX 3 1 37 41
693 XY 0
701 XY 15 15
717 XY 2 1 45 2 50
737 XY 1 24 V 25
739 XX 12 12
741 XY 1 17 18
761 ‘ XY 6 6
763 XX 2 2
791 XX 0
795 XX 13 13
799 XX 3 47 50
817 XY * 48 1 50
829 XY 18 18
831 XX 3 47 50
833 XX 0
835 XY 1 30 31
839 XY 2 1 46 1 49
841 XY 3 47 50
845 XY 3 1 46 50
847 XY 2 36 1 39
849 XX 1 24 25
851 XX 2 46 1 1 50
857 XY . 1 16 17
871 XY 2 1 30 1 34
875 XX 0
877 XX 2 46 1 1 ' 50
879 XX 1 22 23
881 XX 2 48 50
889 XX 3 2 44 1 50
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893 XX 
897 XY 
899 XX 
905 XX 
919 XX 
925 XX
929 XY 
931 XX 
941 XX 
953 XX 
957 XY 
959 XX 
961 XX 
975 XY
985 xx 
989 XY 
993 XY 
997 XX 
1001 XY 
1019 XX 
1021 XY 
1031 XY 
1033 XY 
1067 XY 
1071 XY 
1075 XY 
1079 XX 
1083 XY 
1087 XX 
1089 XY 
1115 XY 
1117 XX 
1119 XX 
1127 XX 
1129 XY 
1131 XX 
-1143-1— xx
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10 21 2 2
24 21 4 4
40 35 9 9
70 *32 0
80 23 10 10
148 31 7 1 8
168 35 3 3.
176 31 1 23 1 3 ■ 25
190 20 10 10
226 29 0
264 29 1 1 23 ' 25
314 . 29 • 0
•326 23 0
334 26 0
356 25 0
388 28 1 22 2 1 25
476 37 0
504 29 • 0
516 28 1 1 22 1 1 2 26
526 21 1 1
528 27 2 2
540 23 0
626 29 0
636 31 1 29 1 31
686 26 3* 3
708 26 1 1
754 25 1 1
826 26 2 48 1 50
862 26 1 12 13
920 23 2 48 50
954 27 0
982 24 9 9
036 26 6 6
10 2 295 3 1 2 1 0 1 6 314
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14 25 0
138 19 5 5
216 23 1 1 20 22
218 26 1 22 1 1 25
244 31 0
250 23 0
254 21 0
290 23 1 1 19 21
368 27 1 1 23 25
410 30 2 21 2 25
434 28 1 21 2 ' 1 25
468 ■ 23 3 44 3 1 50
488 2.4 0
600 30 0
632 23 2 1 24 27
726 29 11 1 12
786 23 1 27 1 29
964 24 10 10
1072 27 0
13 4 247 4 0 7 1 0 0 1 276
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108 27 4 4
172 25 1 1 10 1 13
278 36 2 23 25
338 20 1 23 1 1 25
360 24 1 20 21
406 24 0
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1124 31 3 3
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8 25 0
12 18 1 16 17
88 29 0
252 30 1 1 15 ' 17
272 18 0
288 29 0
312 25 1 24 25
336 21 1 19 20
420 20 1 1 23 25
446 39 2 23 1 25
582 18 0
616 31 1 19 1 20
1062 23 0
IO84 24 0
•
9 2 163 0 0 0 0 0 1 1 174
MIN3VLAR.
2 39 1 8 9
120 24 1 1 20 1 22
224 35 r 0
230 19 0
352 34 1 24 25
362 30 13 13
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2 2 65 1 69
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72 28 5 5
92 20 9 9
110 22 6 6
162 22 1 15 1 16
236 24 0
350 33 2 22 1 25
380 25 1 1
842 23 5 5
926 24 1 10 11
1028 27 No blood cultur5.
4 0 73 0 0 0 1 0 1 0 78
ORTHO - NOVUM.
424 27 2 22 1 25
440 26 1 13 1 15
544 22 0
610 26 * 0
694 22 4 4
710 23 1 1
1090 22 0
3 0 40 0 0 2 0 0 0 0 45
ANO 7LAR.
96 31 4. 4
124 36 2 2
186 26 0
192 24 0
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60 25 1 1 23 25
132 29 2 1 21 1 25
438 1 28
3 2 44 0 0 1 0 0 0 0 50
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44 30 0
430 23 15 15
858 27 0
0 0 15 0 0 0 0 0 0 0 15
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28 22
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130 31 2 2
374 26 0
398 24 1 1 18 1 21
460 42 9 1 1 11
492 27 16 1 1 1 18
602 28 0
620 31 No blood culture. —
622 28 2 2 45 1 50
650 25 11 11
690 24 2 29 1 31
724 25 0
836 30 1 18 19
864 36 11 11
900 31 14 1 1 16
978 24 52 52
1024 31 15 1 1 16
1038 24 0
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7 3 240 1 0 5 2 1 2 1 259
-
vLAB.
NO.
SEX <44 45 46 46 H-
TRIP-
LOID
TETRA
PLOID
ENDO
POLY
PLOID
GAPS BREAKS
TOTAL
CELL
COUNT
OVUIEN.
9 XY 1 1 18 20
23 XY 1 13 14
39 XY 2 1 22 25
61 XX 2 21 1 24
69 XX 2 • 23 25
79 XX 1 20 3 24
147 XX 3 1 21 25
167 XY 2 23 25
175 XX 2 23 25
189 XX 5 1 6
227 XX 3 3
263 XX 1 1 22 1 25
313 XX 1 1
325- XY 2 23 25
333 XX 3 22 25
355 XX 1 1 23 25
387 XX 1 24 25
477 XY 1 4 5
505 XY 1 23 24
517 XY 2 1 46 1 50
527 XX 1 13 14
529 XY 1 24 25
541 XX 9 9
627 XY 1 7 8
637 XX 0
687 XY 2 6 8
709 XX 0
755 XY 0
827 XY 1 1 39 1 41
863 XX 1 12 13
921 XX 4 4
955 XX 1 1 35 1 37
983 XX 2 29 31
1037 XX 18 18
34 12 576 1 0 5 1 0 2 0 629
unromosome Results.
LAB.
NO.
SEX <44 45 46 46+
r--
TRIP—
LOID
1 ■■i
TETRA
PLOID ENDO.
POLY­
PLOID[gaps BREAKS
iotal
CELL
30UNT
GYNOVLAR.
13 XY 2 22 24
137 XY 1 23 24
215 XX 2 ' 26 28
217 XY 1 24 25 !
245 XX 1 19 20
251 XY 2 1 22 1 25
255 XY 1 1 18 20
289 XY 1 1 23 25
367 XY 1 24 25
409 XX 1 1
433 XX 2 23 2 25
469 XY 1 14 1 16
489 XX 2 23 25
601 XY 3 44 1 48
633 XY 0
727 XY 0
78 7 XX 0
965 XX 2 42 2 46
1073 XY 1 1
22 3 349 0 1 3 0 0 3 0 378
LY1JDIOL.
107 XY 1 24 25
171 XY 1 23 1 24
277 XY 2 23 25
337 XX 9 9
359 XY 0
405 XY 11 11
435 XY 1 21 3 25
525 XY 8 8
563 XY 1 15 1 - It
697 XX 1 1 20 22
981 XY 2 1 47 50
1125 XY 1 1 21
\
23
10 3 222 0 0 4 0 0 1 0 239
Test naDies.
LAB POLY-TRIP- TETRA BREAKS1? ^  
U E L L  !
COUNT I
SEX ENDO GAPS
NO PLOIDLOID ploii
NORINYL
XX
XY
22XX
253
271
287
311
335
419
445
559
583
891
LO63
L085
XY
XX 20
XX
XY
XY
XX
XX
XY
XX
XY
XY
XX
348325
MINOVLAR
XY
119
223
231
351
361
683
1081
XY
XX 22
XY
XX
XY
XX
XY
149
VOIJIDAN,
20XY
315
977
XY
LAB.
NO. SEX <44 45
46 46f-
TRIP-
LOID
TETRA
PLOID ENDO.
POLY­
PLOID
GAPS BREAKS
TOTAL
CELL
COUNT
COllOVED.
77 XX 1 24 1 25
91 XX 0
109 XX 4 ■ 1 18 1 1 25
161 XY 2 22 1 • 25
236 XY 1 1 2 2
349 XY 1 24 25
379 XY 1 23 1 25
843 XY 0
927 XX 0
1029 XY 1 46 47
8 3 158 1 1 3 0 0 2 1 174
OR'[■HO - I'IOVUM.
423 XX 20 3 2 25
439 XX 2 21 2 25
545 XY 1 26 27
611 XY 2 21 23
695 XY 3 47 50
711 XX 2 47 1 50
1091 XX 2 46 1 48
12 0 228 2 1 3 2 0 0 1 248
AN(!)VLAR.
95 XY 12 12
123 XY 12 12
185 XX 1 1 18 20
191 XX 10 10
273 XY 2 1 22 25
571 XY 3 1 46 50
923 XY 0
995 XY 0
6 3 120 0 0 0 0 0 0 0 129
i
A C O U  J D d U X t J S  .
\
LAB.
NO.
SEX <44 45 46 46^ TRIP-
LOID
TETRA
PLOID
ENDO. POLY
p l o h
GAPS BREAKS
TOTAL
CELlj
count;
SECJUENS.
59
131
439
XX 
XY 
. XY
1
2 1
2
23
22
1
2
25
25
3 1 * 47 0 0 1 0 . 0 0 0 52
NlJVACON.
, 43
'429
859
XY
XX
XX
2
3
1
1
22
9
46
25
9
50
5 2 77 84
NORMENON.
285 XY 1 2 22
COMB]:natiof •
25
OVl
17
803
LEN/CO
XY
XY
NOVID
14 14
0
OVl
81
157
LEN/LI
XX
XY
NDIOL.
1 23 1 2
0
25
OVl
101
LEN/NC
XX
RINYL.
1 2 21 1
-
25
OVl
463
671
887
len/gi
XX
XY
XY
NOVLAR
1
1
2
•
1
21
27
47
1
3 - 25
30
49
4 1 95 0 1 3 0 0 0 0 104
OVl
1023
LEN/OF
XY
THO-NC
2
VUM
24 2 28
LAB.
NO.
OVULEN /ANpVLAR, 
XY393
35
41
ANOv
67
SEX <44
ANOYLAR/GYNOVLAR
XY
XX
rLAR/NpRINYL 
XY
GYNOVLAAR
143-
317
XX
XY
gynOvlar/:
485
GYNO
685
*689
999
XY
GYNOVLAR/ljllNOVLlR
853 xx 2
GYN )VLAR AORLES^RIN 
173 XX 2
LYN)IOL/sfRIAL £8
465 xx
/NORIK a,
iYNDIO
45
o a r /o^tho-novum
XY 2 
XX 
XX
0
46 46 H-* TRIP-
LOID
COMB!-NATION (co itinuek).
9
14
23
23
23
46
29
56
85
47
21
25
0
0
TETRA
PLOID
ENDO. POLY­
PLOID
0
GAPS
0
BREAKST82£fc 
ICOUNT
0
0
M  A large number of cells were counted from this patient for the 
purpose of a separate investigation (Bishun and coworkers 1971a).
LAB.
NO. SEX <44 45 46 46-f
TRIP-
LOID
TETRA
PLOID ENDO.
POLY­
PLOID GAPS BREAKS
TOTAL
CELL
COUNT
LYNpiOL/NjUVACO^ 
1261 XY
LYKDIOL/CpNOVID 
855 XX
LYNDIOL/NbRINYL
903 XX
LYNDIOL/SEQUENS
789 xx
VOIIDAN/NJJVACOF 
991 XY
VOIIDAN /ojft THO-FSOV UM
1069 xx 
mi^ ovlar/Jnorinyil
27 XX
169 XX
203 XY
269 XX
521 XX
581 XX
735 XX
793 XX
797 XX
873 XY
909 XX
943 XX
973 XY
1121 XX
23 25
45
45
50
50
0
VARIOIS (MORE THAN 2 TYPES OF
13
6
24
22
5
6
19
20
26
12
153
ORAL CONTRACEPTIVES
13 
6
25 
25
5
6 
21
0 
0 
0 
22 
0 
28 
12
0 0 163
POLY­LAB TRIP­ LE TR A BREAKS
COUNT
SEX ENDO GAPS
PLOIDLOIDNO PLOID
UNKNOWN NUMBER OF TYPES OF ORAL CONTRACEPTIVES.
129
373
397
461
493
603
621
623
651
691
725
837
865
901
979
1025
1039
1057
1077
XY
XX
XY
XX
XY
XY
XY
XY
XX
XX
XX
XY
XX
XX
XY
XX
XY
XX
XX
226 236
XXX X JJl'IL'Xii J  «
Chromosome results from mothers of over Control Mothers.
34 years of age.
LAB.
NO.
AGE sro. ofMISC. <*44 45 46
CHROMOSOME
ABNORMALITIES
CELL
COUNT
90 35 0 1 17 .18
104 38 0 5 5
160 40 1 0
276 39 0 25 25
408 46 0 1 1
422 37 2 1 1 20 1 cell with 47 chr.5 24
1 tetraploid cell
532 36 0 0
612 35 0 0
832 36 0 1 1
888 36 1 3 1 46 50
988 40 0 21 21
1078 35 0 2 17 1 triploid cell 20
1082 35 0 9 1 tetraploid 10
Test Mothers.
LAB.
NO, AGE
NO. OF 
MISC. <.44 45 46
CHROMOSOME
ABNORMALITIES
CELL
COUNT
2 39 1 1 8 9
40 35 1 9 9
124 36 0 2 2
168 35 0 3 3
224 35 1 0
278 36 0 2 23 25
446 39 0 2 23 1 break 25
460 42 1 9 1 tetraploid cell 11
476 37 0 0
942 37 0 1 12 13
864 36 1 1
Appendix 5 {continued).
Control Babies.
LAB.
NO.
(VGE 
OF M.
SEX 
OF B. <44 45 46 CHROMOSOME ABNORMALITIEgg™i
89 35 XY 0
103 38 XY 0
159 40 XY 25 25
275 39 XY 2 1 22 25
407 46 XX 1 24 25
421 37 XY 2 25 3 cells with 47 chr. 30
523 36 XY 13 13
613 35 XX 1 22 1 tetraploid cell 24
659 36 XY 0
889 36 XX 3 2 44 1 tetraploid cell 50-f
989 40 XY 1 1
1079 35 XX 19 19
1083 35 XY 8 8
Test Babies.
LAB.
NO.
AGE 
OF M.
SEX 
OF B. <44 45
46 CHROMOSOME ABNORMALITII.qCELL ' COUNT
1 39 XY 4 4
• 39 35 XY 2 1 22 25
123 36 XY 12 12
167 35 XY 2 23 25
223 35 XX 1 2 22 25
277 36 XY 2 23 25
445 39 XX 2 1 49 3 cells with 47chr. ' 55
1 break.
461 42 XX 21 21
477- 37 XY 1 4 5
943 37 XX 0
865 36 XX * 0
ArrHiiNJJJLA u .
Chromosome results from mothers who have Test Mothers
miscarried.
LAB.
NO.
NO. 0] 
MISC.
r B or 
A
O.C.
TYPE OF 
ORAL CONTRACEPTIVE <44 45 46
TYPE OF 
CHROMOSOME 
ABNORMALITY.
TOTAL
2 1 B Minovlar 1 8 9
18 4 1A Ovulen & Conovid 0
36 2 B Anovlar & Gynovlar 12 12
40 ‘ 1 B Ovulen 9 9
88 1 B Norinyl 0
120 1 A Minovlar 1 1 20 1 gap. 22
148 1 B Ovulen 7 1 tetraplo:.d 8
158 1 A Lyndiol & Ovulen 10 10
174 2 A Norlestrin & Gynovlar 1 24 25.
204 1 A Sequens & others 2 2
224 1 N.K. Minovlar & Gynovlar 0
262 1 B Lyndiol & Nuvacon 1 5 6
264 '2 A Ovulen 0
318 1 A Gynovlar & Norinyl 1 7 8
326 1 A Ovulen 0
334 1 B Ovulen 0
336 1 A Norinyl 1 19 1 gap. 20
352 2 A Minovlar 1 24 25
436 1 A Lyndiol 1 1 22 1 tetra. 25
460 2 B N.K. 9 1 tetra^ 11
1 poly.
464 1 A Serial 28 & Lyndiol 3 3
516 1 A Ovulen 1 1 22 1 triploid 26
1 tetra.
2 breaks
524 1 A Lyndiol 0
528 1 A Ovulen 2 2
622 1 A N.K. 2 2 45 1 tetra. 50
626 2 B Ovulen 0
650 1 B N.K. 3 3
670 2 1A Gynovlar & Ovulen 0
688 1 B Gynovlar & Ortho-Novum 0
802 1 A Ovulen & Conovid 3 46 (l endo) 50
' 836 2 B N.K. 1 18 (1 gap) 19
862 1 A Ovulen 1 12 13
864 1 N.K. N.K. ' 1 1
886 3 ‘ A Gynovlar & Ovulen 1 17 18
920 1 A Ovulen 2 48 50
990 2 A Nuvacon & Volidan 29 29
1024 1 A N.K. 15 1 tetra. 16
1028 2 B Conovid E No alood cultur —
1038 3 N.K. N.K. 0
1068 4 B Ortho-Novum & Volidan 0
1090 1 A Ortho-Novum 0
1120 1 B Gynovlar & others 10 - 10
A - after oral contraception 
B - before oral contraception
Appendix 6 (continued).
Control Mothers.
LAB.
NO.
NO. OF 
MISC.
<44 45 46 TYPE OF 
CHROMOSOME ABNORMALITIES
CELL
COUNT
26 1 3 3
78 1 1 6 7
94 1 1 13 14
154 2 6 • 8
160 0
246 1 7 7
248 1 0
258 1 4 4
292 1 2 1 cell with 47 chromosomes 4
294 1 9 9
330 1 1 21 1 tetraploid, 1 endo. cell 24
378 1 0
422
426 1
1 1 20 1 tetraploid, 1 cell with 
47 chromosomes.
24
0
432 1 1 23 2 cells with 47 chromosomes 26
448 1 20 2 tetraploids, 1 endo. cell 
1 break. .
23
790 1 2 46 1 cell with 47 chromosomes 49
888 1 3 1 46 50
940 1 0
960 1 3 47 50
988 21 21
1000 1 1 31 32
Appendix 6 (continued).
Control Babies.
LAB.
NO. <44 45 46
TYPE OF 
CHROMOSOME ABNORMALITIES
CELL
COUNT
25 1 1 22 24
77 8 8
93 2 2
153 25. 25
159 25 25
249 0
257 1 24 25
291 2 21 23
293 14 14
329 1 24 25
377 0
421 2 25 3 cells with 47 chromosomes 30
425 1 1 22 1 tetraploid cell 25
431 1 22 2 tetraploid cells 25
449 1 24 25
591 2 1 21 24
889 3 2 44 1 tetraploid cell 50
941 3 46 49
961 3 47 50
989 1 1
1001 1 45 2 tetraploid cells 48
Test Babies.
LAB.
NO.
TYPE OF 
ORAL CONTRACEPTIVE <44 45
46 TYPE OF CHROMOSOME ABNORMALITY
CELL
COUNT
1 Minovlar 4 4
17 Ovulen & Conovid 14 18
35 Anovlar & Gynovlar 9 9
39 Ovulen 2 1 22 • 25
87 Norinyl 2 22 1 tetraploid, 1 gap 25
119 Minovlar 2 2 21 25
147 Ovulen 3 1 21 24
157 Lyndiol & Ovulen 1 23 1 triploid cell. 25
173 Norlestrin & Gynovlar 2 1 21 2 gaps 24
203 Sequens & others 2 23 25
233 Minovlar 1 2 22 25
224 Minovlar 0
261 Lyndiol & Nuvacon 1 1 23 25
263 Ovulen 1 1 22 1 cell with 47 chr. 25
317 Gynovlar & Norinyl 1 23 1 tetraploid cell 25
325 Ovulen 2 23 25
333 Ovulen 3 22 25
351 Minovlar 1 9 1 cell with 47 chr. 11
435 Lyndiol 1 21 3 tetraploid cells 25
459 N.K. 0
465 Serial 28 & Lyndiol 23 23
517 Ovulen 2 1 46 1 endoreduplicated cell 50
525 Lyndiol 8 8
529 Ovulen 23 23
623 N.K. 15 15
651 N.K. 0
671 Gyrfovlar & Ovulen 1 1 27 1 triploid cell 30
689 Gynovlar & Ortho-Novum 4 56 60
803 Ovulen & Conovid 1 1
837 N.K. 1 42 43
863 Ovulen 1 12 13
865 N.K. 0
887 Gynovlar & Ovulen 2 47 49
921 Ovulen 4 4
991 Nuvacon & Volidan 0
1025 N.K. 4 4
1029 Conovid E 1 46 47
1039 N.K. 2 26 1 tetraploid cell 29
1069 Ortho-Novum & Volidan 7 1 gap 7
1091 Ortho-Novum 2 46 1 break 48
1121 Gynovlar & others 12 12
APPENDIX 7
Chromosome results and length of time the Test Mothers.
m.oth,ers had taken oral contraceptives.
LAB.
NO.
.................
TYPE OF 
O.C.
TIME 
ON O.C.
(months
TIME
*0FFT0.C
(months)
TYPE OF 
* CHROMOSOME ABNORMALITIES
CELL
COUNT
148 Ovulen 24c 18 1 tetraploid cell 8
176 Ovulen 12d 36 1 endo, 3 breaks. 25
388 Ovulen N.K. N.K. 2 cells with 47chr. 1 break 25
516 Ovulen 24d 8 1 triploid, 1 tetraploid,
2 breaks
26
636 Ovulen 24c 7 1 cell with 47 chr. 31
826 Ovulen 60c 0.5 1 gap 50
218 Gynovlar 22c 2 1 cell with 47chr, 1 tetra. 25
410 Gynovlar 18c 36 2 tetraploids 25
434 Gynovlar 63c 4 2 cells with 47 chr. 1 endo. 26
468 ■ Gynovlar 12c 6 3 tetraploids, 1 break. 5 0 .
726 Gynovlar 12c 48 1 tetraploid 12
786 Gynovlar 12d 9 1 cell with 47 chr. 29
446 Norinyl 5c 24 1 break 25
890 Norinyl 24c 0.5 1 gap 20
172 Lyndiol 2c 34 1 polyploid 13
238 Lyndiol 15c 8 1 tetraploid, 1 break. 25
436 Lyndiol 36d 1.5 1 tetraploid 25
274 Anovlar 18c 24 1 tetraploid 25
994 Anovlar 12d 5 1 tetraploid, 1 break 50
120 Minovlar 6c 10 1 gap 22
162 Conovid 12c 0 1 gap 16
350 Conovid 33c 48 1 endoreduplicated cell 25
Appendix y ^continued).
Test Mothers.
LAB, TYPE OF TIME ON TIME TYPE OF CELL
NO. O.C. O.C.
(months)
'OFF*O.C. 
(months')
CHROMOSOME ABNORMALITIES COUNT
424 Ortho-Novum 24c 6 1 tetraploid 25
440 Ortho-Novum 39c 3.5 1 tetraploid 15
802 0vulen/C onovid 14c 12 1 endo, 1 gap 50
1022 Ovulen/Ortho-Nov. 20c 4 1 tetraploid 26
394 Ovulen/Anovlar 8c 24 7 tetraploids 123
684 Gynovlar/,Otho-N. 15c 3 1 endoreduplicated cell 38
132 Sequens 30c 0 1 tetraploid 25
286 Normenon 2c 0 1 tetraploid 25
170 More than 2 types 7c 2 1 cell with 47 chr.
1 triploid, 1 tetraploid
25
398 N.K. N.K. N.K. 1 endoreduplicated cell 21
460 N.K. 2c 24 1 tetraploid, 1 polyploid 11
492 N.K.
*
N.K. N.K. 1 cell with 47 chr.
1 tetraploid, 1 break
18
622 N.K. 6c 48 1 tetraploid 50
69O N.K. 24c 12 1 gap 31
900 N.K. 6c N.K. 1 tetraploid, 1 endo. 16
1024 N.K. 3c 42 1 tetraploid 16
Appendix 7 (.continued).
Test Babies.
LAB.
NO.
TYPE OF 
O.C.
TIME ON 
Oo C.
(months)
TIME
*0FF*0.C
(months).
TYPE OF 
CHROMOSOME ABNORMALITIES
CELL
COUNT
61 Ovulen 24c 7 1 tetraploid 24
79 Ovulen 12c 9 3 tetraploids 24
189 Ovulen 14d 3 1 tetraploid 6
263 Ovulen 24d 0 1 cell -with 47 chr. 25
517 Ovulen 24d 8 1 endoreduplicated cell 50
827 Ovulen 60c 0.5 1 break 41
955 Ovulen 48d .0.5 1 gap 37
251 Gynovlar 13c 0.5 1 gap 25
433 Gynovlar 63c 4 2 gaps 25
469 Gynovlar 12c 6 1 tetraploid 16
601 Gynovlar 12c 48 1 triploid 48
965 Gynovlar 54d 1,5 2 tetraploids 46
11 Norinyl 2c 5 1 triploid 25
87 Norinyl 5c 3 1 tetraploid, 1 gap 25
445 Norinyl 5c 24 3 cells with 47 chr. 1 break 55
171 Lyndiol 2c 34 1 gap 25
435 Lyndiol 36d 1.5 3 tetraploids 25
563 Lyndiol 6c 7 1 tetraploid 16
351 Minovlar 28c 4 1 cell with 47 chr. 11
71 Conovid 30c 1 1 break 25
109 Conovid 12c 23 i triploid, 1 tetraploid 25
161 Conovid 12c 0 1 tetraploid 25
236 Conovid 12c 3 1 cell with 47 chr. 2 breaks 2
379 Conovid 8c 7 1 tetraploid 25
Appendix 7 (continued).
Test Babies.
LAB.
NO.
TYPE OF 
O.C.
TIME ON 
O.C. 
(months)
TIME 
lOFFi O.C 
(months)
TYPE OF 
CHROMOSOME ABNORMALITIES
.................................  ' ..........................
CELL
COUNT
423 Ortho-Novum 24c 6 3 tetraploids9 2 endos.
i
. 25 !
1
439 Ortho-Novum 39c 3.5 2 cells with 47 chr. 25
711 Ortho-Novum 2c 0.5 1 triploid 50 j
1091 Ortho-Novum 48c 9 1 break 48 Il
j
49 Volidan 2c 12 1 tetraploid
!
23 |
315 Volidan 36c 0.5 1 tetraploid 25 !
i
977 Volidan 6c 0.5 2 tetraploids 49 !
131 Sequens 30c 0 1 tetraploid 25 !!
439 Sequens 36d 1.5 2 cells with 47 chr. 25 |
|
903 Lyndiol/N orinyl 15c 0.5 1 cell with 47chr.
1 tetraploid, 1 endo.
i
50
789 Lyndi ol/S e quens 12c 12 1 endoreduplicated cell 50
1069 V olidan/Ortho-N. 39c 1 1 gap 7
41 Anovlar/Gynovlar 15c 0.5. 1 gap 16
317 Gynovlar/Norinyl 18c 0 . 1 tetraploid 25
.685 Gynovlar/Ortho-N. 15c 3 1 tetraploid 32
157 Ovulen/Lyndiol 4 c 42 1 triploid, 2 gaps 25
101 Ovulen/Norinyl 36 2 1 cell with 47 chr. 25
463 Ovulen/Gynovlar 5 24 3 tetraploids 25
671 Ovulen/Gynovlar 14c 1,5 1 triploid 30
1023 Ovulen/Ortho-N. 20c 4 2 tetraploids 28
269 Various 9c 2.5 1 endoreduplicated cell 25
735 Various 60d N.K. 1 endoreduplicated cell 21
973 Various 5c 7 1 tetraploid 28
603 N.K. 36d N.K. 1 break 11
1039 N.K. 18c N.K. 1 tetraploid 29
1077 N.K. 12c N.K. 1 gap 42
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Mitotic Indices and Oral Contraceptives
Sir,—During the last year we have been 
investigating various aspects of oral contra­
ceptives—for example, transformation of 
peripheral blood lymphocytes, chromosomes, 
sex chromatin, etc. We thought it might be 
of interest to make available our results 
relating to mitotic indices of peripheral blood 
leucocyte cultures of mothers who had taken 
various types of “pill,” and their progeny, 
together with the time between stopping the 
“pill” and the onset of pregnancy.
Bloods (cord from the newborns and 
and peripheral venous from mothers) were 
collected at the time of delivery from 
mothers who had been on any form of oral 
contraceptives, their newborns, and from 
suitable controls. They were then coded and 
sent to the cytogenetic laboratory for cultur­
ing and harvesting by standard procedures 
previously described.1
Calculation of mitotic indices (percentage 
of mitoses) involved examination of 500 cells 
from each subject and then recording the 
number of metaphases. The Table shows 
the ranges and means of mitotic indices in 
each subject. Application of the Student’s t 
test to these results failed to prove any signi­
ficant differences between the test and 
control mothers and babies.
We therefore conclude that, provided the 
constituents of the “pill” are still effective 
after discontinuing the varying lengths of . 
time (see Table), the taking of the “pill” does 
not have an appreciable adverse effect on the 
mitotic activity of p e r i p h e r a l  blood • cells 
stimulated with phytohaemagglutinin.—We 
are, etc.,
N. P. Bishun 
J. M ills
Research Department,
Marie Curie Memorial Foundation,
Oxted,
Surrey
i Bishun, N. P., Morton, W. R. M., and McLaverty, 
B., Lancet, 1964, 2, 315.
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Chromosomal Satellite Association in Women Using 
Oral Contraceptives and their Progeny
N. Bishun, J. M il ls ,  N . L l o y d ,  D. C. W i l l i a m s  a n d  E. G r i s t w o o d
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It is now quite well established that radiation and chemicals that include 
food additives, narcotics, anti-biotics, pesticides, air and water pollutants etc. can 
cause chromosomal damage. The relationship of the latter to neoplastic and 
abnormal growth has also been established; hence it becomes of paramount im­
portance that commonly used drugs, and others to which individuals are frequently 
exposed, be carefully and fully investigated for their chromosomal damaging effects.
The action of oral contraceptives, so far intended for the use of groups of the 
female populations, are not completely understood, hence it is important that all 
biological effects that have been researched into are forthwith reported.
In view of the importance attached to the association of satellited chromo­
somes of mothers of child bearing age (Harnden 1960, Shaw 1961, Bishun 1966,) 
we have investigated the effect, if any, of the taking of oral contraceptives on satellite 
associations in cells of mothers of child bearing age.
Materials and methods
One hundred metaphases were chosen randomly from the peripheral blood 
cultures of both test (pregnant women who had previously taken oral contraceptives) 
and control (pregnant women who had never taken any form of oral contraceptive) 
mothers. One hundred metaphases were also chosen from the cultures (set up 
as described by Bishun 1966) of the newborns of each type of mother. All the 
cultures were set up as a project initiated to study the long term effect of oral con­
traceptives on chromosomes. Peripheral bloods are collected from test and con­
trol mothers and babies in the maternity ward of a general hospital, coded and 
then sent to this laboratory for culturing and eventual analysis of the chromosomes.
Analysis of the metaphases involves scrutinisation for satellite associations 
as described by Ferguson-Smith and Handmaker (1963). The ten acrocentric 
chromosomes are located and, by means of a divider, are paired off according to 
the Denver system (1963) of classification. By this means we were able to identify 
and pair the members of groups D and G. Satellite associations (Figs. 1 and 2) 
are then located and each member of the association is identified and recorded as 
shown in the Tables.
640 N . Bishun, J. Mills, N . Lloyd, D. C. Williams and E. Gristwood Cytologia 37
Results
The test m others (age range 20-30 years) had been on the “pill” (mainly Ovular 
and Gynovlar) continuously for 1-3 years (mean time 20.4 months). None o f 
these m others had taken any type of medication tha t is known to cause chrom o­
some damage or abnorm al cell division. The control mothers were screened to 
ensure that they had not been exposed to any chromosomal damaging exogenous 
agents.
The frequencies obtained for each member of groups D and G in all the subjects 
are shown in Table 1 below.
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Figs. 1-2. 1, photograph o f an association between a No. 13 and a N o. 15 chrom osom e (Gp D).
2, association between 2G and D chromosomes.
Table 1. Association per cell and frequencies of 
individual acrocentrics
Subjects N o. cells examined
No.
associations
Mean
assoc/
cell
Chrom osom e groups
D (% ) G (% )
13 14 15 21 22
Test mothers 100 149 1.49 17.5 26.4 24.4 18.4 13.3
Control m others 100 59 0.59 21.0 17.8 16.0 27.7 17.0
Test babies 100 66 0 .66 17.9 19.4 25.4 19.4 17.9
C ontrol babies 100 63 0.63 20.4 23.7 16.4 20.4 19.1
Analysis was also made of the frequencies of D -D , G -G  and D -G  associ­
ations as they are im portant in determining the frequency with which translocations 
occur. Table 2 below shows the results obtained.
The frequency with which satellite associations occur in the cells of test mothers 
is significantly (0.01 < P > 0 .001) higher than that o f the control mothers (1.49 
compared to 0.59). The frequencies of satellite associations in the test and control 
babies however, are practically the same as are the frequencies with which individual 
members of groups D and G occur in the four types of subjects (Table 1).
The associations of D -D  chromosomes occur more frequently (45%) in the 
test than control mothers, unlike the test and control babies where the frequencies 
are approximately the same (Table 2). There are no appreciable differences in
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the frequencies with which D -G  associations occur in the four groups of subjects 
(see also Table 2), although G-G associations are less frequent in test than in con­
trol babies.
Table 2. Frequencies with which D -D , G-G, and D -G  
associations occur
Subjects D -D G -G D -G
Test mothers 45 12 35
Control mothers 12 10 43
Test babies 24 3 39
Control babies 20 12 30
Discussion
Several observations had been made regarding the ability of satellited chromo­
somes to lie in close proximity to one another at the metaphase stage of cell division 
(Harnden 1960, Shaw 1961, Bishun 1966). This phenomenon, which has been 
defined by Ferguson-Smith and Handmaker in 1963, is exemplified by the satellited 
acrocentric chromosomes lying closer together than would be expected if the 
chromosomes were randomly arranged at metaphase.
The frequencies with which the acrocentric chromosomes occur in dividing 
cells of normal subjects vary, (Froland 1964, Reitalu 1964, and Bishun 1966) the 
significance of which has recently been reviewed by Zellweger et al. (1966). The 
latter postulated that an increased frequency of D and G chromosome associations 
tends to render the progeny of the individuals more susceptible to D/G and G/G 
translocations.
McQuarrie et al. (1970) have established that the taking of the “pill” can induce 
chromosomal damage and also lead to an increased frequency of associations be­
tween the D/G chromosomes. This would undoubtedly render the progeny sub­
ject to an increased risk of chromosomal translocations, some of which would 
result in non-viable zygotes and eventual abortion.
The types of chromosomal abnormalities that have been described in abortions 
associated with the taking of the “pill” are mainly numerical and include mainly 
triploidy and tetraploidy (Carr 1970). These abnormalities indicate abnormal 
pairing of the chromosomes at the equatorial plate and separation at anaphase 
during cell division. The fact that no translocations have been described so far in 
the abortuses of women who had taken the “pill” could indicate that these trans­
locations when they occur cause early foetal loss—before chromosome analysis 
could be carried out.
Zellweger et al. had further pointed out that the range of satellite associations 
in normal subjects is from 2 to 27 %, and that the range in mothers of mongoloid 
children was 28 to 60 %. Our results in Table 2 do not support their findings, as 
D-D associations in the test mothers and D -G  associations in all subjects occur 
with a higher frequency (28 to 60 %) than that which is expected of mothers of mon­
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goloid children. There is no difference in the incidence of D -G  associations 
between our test and control subjects.
The lower frequency of G-G association in test babies and higher frequency 
of D-D associations in test mothers would indicate abnormalities in satellite as­
sociations during cell division, probably caused by the taking of the “pill” .
The higher incidence of D-D associations in the test mothers is not reflected 
in the cells of the test babies since the incidence in the latter and their controls are 
approximately the same. Obviously according to these results the increased satellite 
associations are not necessarily transmitted from parent to offsprings as has been 
postulated by Zellweger and colleagues.
McQuarrie and colleagues had further suggested that increased frequencies 
of satellite associations were usually associated with increased frequencies of 
chromosomal breaks. We have also scored chromosomal breaks in a larger 
series of cells and have failed to confirm their observation. However, the latter 
results will be the subject for a later publication.
Apart from the increased incidence of D-D associations in the test mothers, 
we have not found any other abnormal associations of the kind described by 
Zellweger et al. Since the significance of this phenomenon is not completely under­
stood, our results should now indicate that this mechanism be more fully and 
thoroughly investigated.
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Summary
Analysis of metaphases for satellite associations from women taking oral 
contraceptives and control women showed a significantly higher incidence of these 
associations in the former subjects. There was also a significantly higher frequency 
of D-D associations in those women taking the “pill” compared to their controls. 
These abnormalities were not transmitted to the progeny.
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Summary
Blood cultures were utilized to assess the mitotic response of newborn cord blood 
to phytohaemagglutinin stimulation by both micro- and macromethods. A 
significantly higher response was obtained in the newborn cord blood than in 
venous blood of a proportionate number of mothers. The significance of this 
enhanced response is discussed.
T h e  cellular immune response of the human 
newborn infant is variable. The ability of the 
newborn to synthesize adequate immunoglobulin 
and to respond to antigenic stimulation during 
early neonatal life determines its resistance to 
early infections, and is an indirect reflection of 
its immunological state (Sterzl and Silverstein, 
1967).
’ Phytohaemagglutinin (PHA) has now been 
used extensively to investigate the immunological 
competence of patients with clinical conditions 
which could have an autoimmune aetiology. 
This substance, regarded as a ubiquitous antigen, 
stimulates blast cell transformation in adult 
peripheral lymphocytes. The ability of the latter 
to respond to this antigenic stimulation reflects 
the immunological status of the lymphocytes 
(Jones, 1969).
To investigate the cellular immunological 
response to PHA stimulation we have scored 
mitotic indices as an index of response. This was 
considered to be more reliable than measurement 
of tritiated thymidine uptake by scintillation 
counting or examination on morphological 
grounds.
* Grand Island Biological Company, Long Island, 
U.S.A. Chromosome Media 1A.
M aterials a n d  M ethods
Approximately 10 ml. of blood was collected 
from the umbilical veins of 60 newborn infants 
and from the antecubital veins of 50 mothers 
who were randomly selected from an antenatal 
ward of a large general hospital. For each subject 
two micromethods* and two macromethods were 
set up using the same sample of blood. The 
former involved the addition of 0.1 ml. of whole 
blood into the chromosome medium and then 
the further addition of 0.2 ml. of PHA to one of 
the cultures. The culture without PHA served as 
a control.
For the macromethods 0.2 ml. of PHA was 
added to half of the remainder, of the whole 
blood which was then cooled at 4 °C. for one 
hour before centrifuging at 1000 rpm for ten 
minutes. No PHA was added to the other half of 
the whole blood which acted as a control. The 
supernatant plasma, which contained not less 
than 80 per cent mononuclear cells, was with­
drawn and set up in culture by the addition of an 
equal amount of Eagle’s Minimum Essential 
Medium and one part of fetal calf serum 
(Fraberg Ltd.).
All cultures were incubated for approximately 
70 hours when 20 /xg. of colchicine (Colcemia 
CIBA) was added and incubation was continued
163
164 BISHUN, MILLS AND WILLIAMS
for a further three hours. The cells were then 
treated with an 0.85 per cent sodium citrate 
solution, fixed in a mixture (3 : 1) of ethanol and 
acetic aid, dropped on to clean frosted slides and 
stained in a 2 per cent lacto-acetic orcein stain.
The mitotic indices, which are the percentages 
of mitotic figures in the total number of cells 
examined, were calculated after the examination 
of 1000 cells from each culture.
R esults
The relevant mitotic indices obtained from 
both the micro- and macromethods with PHA 
are outlined in Table I. No mitotic figures were 
seen in any of the control cultures without PHA.
The differences in mitotic indices in both the 
micro- and macromethods between the new­
borns and mothers were highly significant (0.02 
> P > 0 .01  and 0 .02> P> 0.01  respectively).
Dividing cells were obtained from all the 
microcultures from the newborn infants, whereas 
such cultures from the mothers failed to give any 
readable results. With the macromethods the 
mitotic indices were very much lower than those 
of the microcultures both in newborns and 
mothers.
Although the range of mitotic indices were 
approximately the same in all the cultures in both 
groups of subjects (see Table), there is a 
considerable difference in their means. However, 
in the newborns, there was a greater uniformity 
in the distribution of the results obtained both in 
the micro- and macrocultures.
D iscussion
The cord bloods responded to PHA stimula­
tion with a higher degree of transformation than 
did the adult venous bloods. This observation 
lends support to the belief that cellular immunity 
is evident in early postnatal life (Elves, 1966).
Cord blood lymphocytes responded to PHA in 
all the newborns, whereas several of the mothers’ 
bloods failed to respond to PHA stimulation 
in both the micro- and macromethods. Lindahl- 
Kiessling and Book (1964), and Meuwissen et al. 
(1968) have previously reported that fetal 
lymphocytes respond to PHA stimulation in the 
same manner as adult lymphocytes. However, 
our results and those of Jones (1969) do not 
support this observation.
T a b l e  I
Results from both micro- and macromethods in 
mothers and newborns
Mothers Newborns
Micromethods
Range ..  1-17 per cent 1-16 per cent
Mean ..  2-11 per cent 5-40 per cent
S.D. . .  ± 2 -3 ± 2 -8
Macromethods
Range ..  1-15 per cent 1-19 per cent
Mean ..  0-34 per cent 2-43 per cent
S.D. . .  ± 2 -1 ± 2 -2
It has been suggested that a mixed cell 
population in the fetus, caused by transference 
of circulating maternal cells via the placenta 
could cause a high degree of spontaneous 
transformation of blast cells (Jones, 1969). The 
transference of cells via the human placenta is a 
problem yet to be clarified, although it has been 
demonstrated that in the mouse the admixture of 
maternal and fetal cells is possible and could 
lead to an enhanced PHA response (Tuffrey 
et al., 1969a and b, and personal observation).
Pulvertaft and Pulvertaft (1966) observed a 
high degree of spontaneous transformation of 
lymphocytes in cord bloods; but this was not 
verified by either Jones (1969) or by us. No 
mitotic figures were observed in any of the 
cultures without PHA and it can be assumed that 
the degree of transformation was negligible.
This increased response of cord blood to PHA 
stimulation can be explained on several grounds. 
The use of whole blood (micromethods) might 
introduce added stimulatory factors which are 
present in the newborns but absent in adult 
females.
The fact that fetal lymphocytes have not been 
exposed to any exogenous agents, having been 
protected by the maternal environment, might 
explain their more vigorous response on their 
first exposure to an antigenic stimulus. The fact 
that cord blood showed no impairment of 
response to PHA stimulation suggests that 
infants are born with an intact immunological 
system.
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SUMMARY
During the past half century there has been a substantial increase in the number 
and extent of usage of drugs, food additives, pesticides and other environmental 
chemicals. As a result, mutation-induced susceptibility to disease, once largely self- 
eradicating, is now being conserved and even propagated. In addition, we have over 
the same time period, added to our internal and external environments, numerous 
synthetic chemicals, the cytogenetic properties of some of which have been reviewed, 
and to which man’s metabolism has not necessarily been conditioned and adapted, 
and which may have the potential to augment the number of mutations of each suc­
ceeding generation.
We need to know far more about what we are doing to ourselves and our planet, 
and the foetuses of our unborn children, and to the genetic heritage of these children, 
by the permissive use of the chemical wonders of our age. It would surely be impracti­
cable that one should wait for time to reveal harmful mutations before we try to research 
out and eliminate the chemical mutagens.
Chromosomal studies and evaluation of mutagenic potential of all new and 
established drugs, food additives and environmental chemicals should therefore be 
integral aspects of the current practices of safety evaluation of these materials, and 
the same stringent principles should be applied to the numerous chemicals met with 
as solvents and intermediates in industrial processes. Persons exposed to high risk, 
such as those working in chemical industries, or patients on continuous chemotherapy, 
should be offered routine chromosomal monitoring, and the appearance of adverse 
effects and abnormalities notified and correlated.
INTRODUCTION
It is well established that radiation and radioactive substances can cause 
Abbreviations: FSH, follicle-stimulating hormone; ppm, parts per million.
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damage to genetic material and consequently the need for appropriate measures for 
detection and control are now recommended and widely accepted1. Present informa­
tion would indicate that many of the chemicals to which we are exposed may be just 
as dangerous, in terms of genetic defects, as radiation and may constitute a far greater 
risk. Such chemicals include medicinal agents, food additives, industrial chemicals, 
pesticides and environmental pollutants. Induction of mutagenesis has long been a 
subject evoking considerable scientific and medical interest as well as public emotion­
alism. However, recent technical advances, notably in tissue culture and other 
chromosomal techniques, have increased the number of cytogenetic investigations of 
these chemicals and have permitted a more critical evaluation of their overall muta­
genic potential to be made.
Chromosomal damage induced by chemicals is similar, in the type of aber­
rations, to that induced by radiation and viruses2. As the latter has been directly 
linked with the development of a variety of neoplastic conditions, it seems not 
unreasonable to suppose that once chromosomal damage has been inflicted, whatever 
the agency, the potential exists for the development of some form of .malignancy, 
assuming that the damaged cells survive and proliferate3,4. In an in vivo system it 
would be possible to monitor the survival of chromosomal aberrations, through 
periodic studies over prolonged periods, in order to assess the survival time of the 
inflicted cells. It might perhaps then be possible to correlate chromosomal damage, 
‘incubation time’ and the development and the progression of neoplasia, associated 
with all of these agents.
The problem of evaluating and limiting the use of potential mutagenic chemicals 
has been neglected largely because of the inability to develop valid test systems that 
are relevant to man. It is, however, relatively easy to test the effectiveness of suspected 
mutagens in producing chromosome breaks by conducting cytological observations 
on cultured cells. Lymphocyte cell cultures can readily be obtained from the peripheral 
blood of animals or man suspected of exposure to a mutagen1, and diploid cell lines 
from human skin fibroblasts are also available.
Many drugs used in cancer therapy are known to cause gross chromosomal 
damage and since the majority of cancers for which these cytotoxic agents are employed 
cause fatal disease, the risk of mutagenesis due to the drugs is justified1. In contrast, 
where drugs are used for the treatment of psychiatric disorders and other non-fatal 
diseases, the justification of exposure of patients to medicines that are known to be 
mutagenic may be questioned, particularly if less mutagenic ones, as therapeutically 
effective, are available. Hence, it becomes of paramount importance to study and 
evaluate, for chromosomal damage and mutagenicity, those commonly used drugs 
and other chemicals to which man is constantly exposed and to document and cor­
relate such information.
METHODOLOGY
The need for developing improved systems for determining mutagenicity is 
now well appreciated5, but before results can be realistically applied to man, tech­
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niques utilising mammalian systems and preferably also human cell cultures should be 
employed. These mammalian systems should include in vivo and in vitro cytogenetic 
testing, dominant lethal tests and the host-mediated assay5 (WHO Report, 1971). 
Cytogenetic studies in man involve the relatively simple procedure in which chromo­
somal damage resulting from the exposure of human subjects to toxic chemicals can 
be observed periodically by culturing circulating lymphocytes6, or alternatively 
human lymphocyte cultures may be exposed to the chemicals in vitro. When a more 
comprehensive examination is necessary the chemical is administered to laboratory 
animals, such as rats and mice, in which case germ cells as well as somatic cells can 
be examined. The host-mediated assay facilitates the study, in a rapidly dividing 
unicellular population, of the mutagenic effects of not only the chemicals administered 
but also of their mammalian and microbial metabolites. This is a flexible technique 
which allows mutation frequency to be measured in a variety of micro-organisms and 
mammalian hosts. The dominant lethal test system, is a simple technique which gives 
an indication of the genetic changes that are incompatible with the survival of the 
conceptus and is mainly carried out in mammalian systems. A mutagenic index is then 
calculated to relate pre-implantation loss and early deaths in the treated to a non­
treated control group.
Several factors mediate against the extrapolation of mutagenic data from simple 
unicellular systems to mammalian organisms, and from the latter to man. The pharma­
cokinetics of absorption, distribution and excretion of the mutagenic chemical 
administered, the nature and amounts of its metabolites, and the mutagenic activity 
of these metabolites, may all profoundly affect the extent and character of mutation 
and chromosomal damage. Microbial systems will provide information only on the 
extent and nature of the lesion produced by the mutagen itself and by its microbial 
metabolites, and as these latter are likely to differ considerably, in amounts even if 
not in chemical nature, from metabolites produced in mammalian systems, studies 
in vivo in laboratory animals are essential to any evaluation of the mutagenic potential 
of chemicals which is to be meaningful to man. In this respect, the host-mediated 
assay, in which micro-organisms are exposed to both the original chemical and to its 
mammalian and microbial metabolites, is of particular usefulness, especially as 
human cell-line cultures, because of loss of biochemical differentiation, may not 
metabolize the administered mutagenic chemicals in the manner in which they are 
metabolized in vivo. The carcinogenic chemicals, cycasin and nitrosamines, which were 
shown not to be mutagenic per se to micro-organisms have now been shown to be 
mutagenic, as well as carcinogenic, in higher organisms by virtue of their metabo­
lites4,7.
In addition to tissue culture systems, bone marrow, regenerating liver (which 
necessitates hepatectomies), and dividing cells from the testis are other useful animal 
systems normally utilised. However, they all have their limitations; the bone marrow 
cell population is heterogeneous and may have varying sensitivities with respect to 
individual cell types, liver which also contains a heterogeneous cell population is, 
moreover, more exposed to numerous xenobiotics, and the testis does not yield 
suitable metaphases in sufficiently high numbers.
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The report of the WHO scientific group recommended that all mutagenic tests 
of drugs should be done primarily on mammals, although systems utilising sub­
mammalian species such as viruses, micro-organisms, Drosophila, fishes, birds, etc., 
should also be studied. The report stresses that submammalian test systems and in 
vitro cell cultures, even human, should only be regarded as ancillary procedures 
although the results obtained from them may help considerably in explaining the 
basic molecular mechanisms involved in mutation. In selecting the test system to be 
used for evaluating chromosome breakage potential of a drug, it is necessary to be 
aware of the shortcomings of the different systems involved. The ideal method, of 
course, would be to examine cells of human subjects before and after exposure of the 
subjects to chemicals, but in so many cases this is impractible so the experimentalist 
is forced to resort either to tissue cultures or animal systems. The compromise solution 
would be to complement studies in the experimental animal with human tissue culture 
systems, since substances which might produce a detectable increase in mutation 
frequency in a human cell culture system may be innocuous to mammals in vivo 
because of metabolic transformations in the whole animal, or because the chromo­
somal effect may be intrinsic to the cell culture test system. The fact that compounds 
may be effective only in vivo, e.g. cyclophosphamide, perhaps because only 
metabolites are mutagenic, is sufficient reason for not dispensing with the animal 
system, especially the host-mediated assay. On the other hand, because of species 
differences in metabolic deactivation of potentially mutagenic drugs, the human cell 
culture system may detect cell damage which might not become manifest in any one 
species of experimental animal, especially if this species had a highly effective meta­
bolic defense system, and thus a positive response may not necessarily constitute a 
false alarm.
In the final assessment of the results one must be cautious when extrapolating 
the results obtained from experimental animals and in vivo culture systems to human 
situations. Furthermore, one must be aware that a negative result obtained from a 
certain dose level and period of exposure does not necessarily indicate that the poten­
tial mutagenic agent is harmless at and below this threshold. There is sufficient evi­
dence available to suggest that point mutations may continue to occur at very low 
dose levels8, and it is strongly suggested that point mutations may be highly correlated 
with visible chromosomal damage9. The present review, therefore, deals with some 
of the cytogenetic information available on various commonly used chemicals which 
for diverse reasons, and by various means, eventually reach the tissue of human organs 
in vivo.
MEDICINES
Anticancer drugs
Almost all of these drugs caused chromosomal damage. Nevertheless, in view 
of the high probability of the eventual fatal outcome of this disease, it may often be 
considered justified to institute this type of therapy. However, unless these drugs are 
carefully investigated and their biological effects documented one can never be certain
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of the actual benefits or risk to the patients receiving this type of drug. The list of 
anticancer drugs is extensive and a few members of some of the more important classes 
are now considered.
Triaziquone (2,3,5-tris[ethyleneimino]benzoquinone; Trenimon). This is a 
strong alkylating agent used in the treatment of cancer which gives rise to side-effects 
of leucopenia and thrombocytopenia. This drug has been reported to cause chromo­
some aberrations in vivo10 in Chinese and Syrian hamsters, mouse, rat and guinea pig. 
In a report by A r a k a k i a n d  S ch m id 11, who used fibroblast cells of Chinese hamster 
and human lymphocytes, it was shown that much higher concentrations of drug were 
required in the human lymphocyte system than in the hamster cells to cause chromo­
somal damage; it was also found that control hamster cells showed a higher incidence 
of spontaneous chromosome breakage than human controls. Using Chinese hamster 
bone marrow as an in vivo system Schm id et al.8 showed that Trenimon predominantly 
induced chromosome breaks in preference to other types of chromosome damage; 
abnormal metaphases were found at 6-8 h after intraperitoneal injection of Trenimon 
(2 x0.25 mg/kg) and the damage gradually decreased as the time after the final injec­
tion increased.
Triethylenemelamine (2,4,6-tris[ethylenimino]-.y-triazine; TEM or Tretamine), 
is an alkylating, antineoplastic drug with side-effects of bone-marrow depression, 
which can induce a significant increase in chromosome aberrations when added to a 
culture of human male leucocytes. This is a powerful mutagen and at a concentration 
of 5 • 10"6 M  it can induce 79 % abnormal cells12.
Apholate (2,2,4,4,6,6-hexabis[ethylenimino]hexahydro-l,3,5,2,4,6-triazatriphos- 
phorine), can also induce chromosomal aberrations and at a concentration of 
1 • 10-4 M  it produces 89% of abnormal cells.
Cyclophosphamide. This is an alkylating antineoplastic and immunosuppressive 
agent used in the treatment of lymphomas and certain leukaemias which has also 
been used in the treatment of severe skin conditions such as psoriasis. It does not 
cause chromosomal damage in human leucocyte cultures12 when added directly, but 
plasma taken from rats previously injected with the drug and added to the cultures 
produced many chromosomal aberrations including chromatid and isochromatid 
breaks, minute fragments and chromatid interchanges. This is indicative that cyclo­
phosphamide is effective in vivo but not in vitro13. It has also been shown to cause 
chromosome breaks in Chinese hamster bone marrow cells in vivo, with the number 
of breaks decreasing with time after the cessation of treatment. This drug has been 
reported to have chromosome breaking properties on cancer cells in vitro, and as a 
result it has been postulated that excess phosphatase in the cancer cell is responsible 
for activating the cyclophosphamide in vitro14.
Floxuridine (fluorodeoxyuridine), is an antiviral as well as an antineoplastic 
drug. It causes chromosomal damage of the kind similar to cyclophosphamide but 
fewer chromatid exchanges are found with this drug12.
Methotrexate (amethopterin). This is also an antineoplastic drug, which can 
produce chromosomal damage when added directly to human peripheral blood cell 
cultures (personal observations). Furthermore, Jen sen  e> al.15 have shown that bone
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marrow cells of patients treated with this drug show a significant increase in chromo­
somal aberrations consisting of chromatid breaks and acentric fragments. Metho­
trexate is commonly used for the treatment of acute leukaemia, and has also been 
used in the treatment of severe psoriasis.
6-Mercaptopurine, is another antineoplastic agent which has been shown to 
cause chromosome breakage in animal tissue cultures. Breakages and an increase in 
aneuploidy and tetraploidy have been found in a skin biopsy from a person under 
treatment with the drug16.
Azathioprine. This is an S-substituted nitroimidazoly1 derivative of 6-mercap- 
topurine and is widely used in the treatment of auto-immune disease and psoriasis. 
This drug has been found to cause widespread chromosomal damage in human bone 
marrow cells without causing an increase in aneuploidy15.
Prednisone. This is an anti-inflammatory and anti-leukaemia drug and does 
not produce any alteration in chromosome number or structure15 but after prolonged 
treatment of patients can cause an impairment of the DNA synthesis mechanism14.
Cytosine arabinoside, is an analogue of the natural nucleoside, cytidine, which 
is used for the treatment of disseminated malignant disease, and severe herpes viral 
infections and has the ability to cause severe chromosomal damage to cultures of 
human leucocytes173. It has also been shown to cause chromosomal abnormalities in 
patients under treatment, with morphological changes being seen in the bone marrow 
cells as early as 6 h after administration of the drug17. These changes are known to 
increase in severity in 5 days, but within 2 weeks after discontinuation of therapy the 
changes disappear. Some of the other important chromosomal abnormalities include 
breaks, despiralised and sticky chromosomes, and extensive fragmentation.
Damomycin. This is a nitrogenous glycosidic antibiotic of the rhodomycin 
group which since 1963 has been used regularly for the treatment of childhood 
leukaemias18. It has a narrow effective dose range which causes chromosomal damage 
for above this range mitosis is inhibited. The frequency of aberrations varies from 
subject to subject and appears to depend on the genetic background of those under 
investigation. Using human leucocytes, V ig  et al.19 ascertained that 0.015 pgjm\ of 
daunomycin produced chromosome breaking which was specific in nature and non- 
random along the chromosomes. There was also no change in the specificity of the 
drug either with respect to sex or to the addition of arginine (0.01 %). Daunomycin 
has a specific chromosome breaking effect when cells are treated in the G1 phase and 
it is not possible to relate the chromosome breaking to the early or late DNA syn­
thesis of the chromosomes.
Mitomycin C, is an antineoplastic antibiotic derived from Streptomyces which 
is known to disrupt DNA synthesis and to result in cross-linking of the complementary 
strands of DNA. It has been shown to result in extensive chromosome damage and 
possible translocations21,22.
Drugs o f abuse
Lysergic acid diethylamide (LSD). In 1957 C o h en  et al.23 reported that minute 
amounts of LSD caused extensive damage to the chromosomes of human leucocytes
CHROMOSOME DAMAGE INDUCED BY CHEMICALS 381
in vitro and studies in vivo have confirmed these findings. Investigations of children 
whose mothers had taken LSD during pregnancy indicated that the drug could cross 
the placental barrier and so affect the chromosomes in the blood and tissues of the 
foetus with the potential danger of teratogenesis. Injection of LSD into pregnant 
hamsters24 led to severe malformations and stunting in the offspring and there are at 
least two reports of congenital malformation in human infants, both of whose parents 
had taken LSD24, but considerable controversy exists, and S a to  et al. found no 
effect of a 100 ^g/kg single oral dose on rat embryo or bone-marrow cells25. The 
differences in results may be due to differences in level and frequency of dosage, and 
in the case of studies with human addicts, to the simultaneous administration of other 
psychotogenic drugs. C o h en  et al.23 found that the frequency of chromatid gaps was 
significantly higher in those patients which had been treated with LSD than in the 
control group. Damage to chromosomes in the germ cells had been considered as 
perhaps the most important hazard of LSD. Hsu26 and others found chromosome 
abnormalities in a newborn female whose parents had both been taking LSD before 
conception. This abnormality was similar to D-trisomy and it is possible that LSD 
damaged the maternal germ cell before conception, inducing chromosomal rear­
rangements. However, the mother took many other drugs during pregnancy including 
marihuana, barbiturates and methedrine.
G ilm o u r  and others27 have looked at the chromosomes of patients receiving 
some other psychoactive drugs and he divided these into five categories namely those 
taking: (a) marihuana in small amounts, (b) marihuana in large amounts, (c) 
phenothiazines, (d) amphetamines and (e) heroin. Each of the groups of drug users, 
except those taking small amounts of marihuana, showed an increase in the occurrence 
of chromosomal damage as compared with the controls. Dicentrics or an increase in 
chromatid exchanges were not found but chromatid breaks and centromere breaks 
were evident.
Nicotine. The active carcinogenic agent of cigarette smoke, which may also be 
mutagenic, has been postulated to be either cotinine or nicotine-1-oxide, metabolites 
of nicotine. An extensive amount of work has also been undertaken in an attempt to 
assess the active principle in cigarette smoke which is responsible for women giving 
birth to children of low birth weight28-.
We have studied the effects of adding nicotine to human peripheral blood 
cultures and also after injections into rats. The results show that, at high concen­
trations, the drug is toxic to the human peripheral blood cultures but does not induce 
any chromosomal abnormalities. However, experiments with rats in vivo showed a 
high degree of chromosomal abnormalities which included an increased frequency of 
aneuploid cells and metacentric chromosomes, thus confirming that the mutagenic 
agent may be a metabolite of nicotine29.
Other drugs
Oral contraceptive steroids. C a r r 30 exam ined the chrom osom es o f  the abortuses 
o f  w om en  w ho had “ taken the p ill” and found  a striking increase in  trip loidy in  the 
abortuses from  w om en  conceiv ing  w ithin 6 m onths o f  d iscontinu ing oral con tracep­
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tives. This was thought to be the result of temporary hormonal imbalance in these 
women, such imbalance affecting cell division in the ovum. It was further suggested 
that if cell division could be suppressed while still allowing normal chromosome 
division to occur it could result in either triploidy or tetraploidy. Triploidy would 
result at the time of the first or second meiotic divisions, and tetraploidy would occur 
if the zygote were affected at the first cleavage division. With these considerations in 
mind S in g h  a n d  C a r r 31 tested the effects of a series of hormones in an in vitro system 
but found that none of the hormones except FSH caused mitotic inhibition. However, 
cells in tissue cultures are not comparable to germ cells because formation of the 
latter involves partitioning of the chromosomes to produce a haploid number. 
Nevertheless, the mechanism of the second meiotic division is similar to that of mitosis 
in somatic cells. They also failed to find any increase in polyploid cells in leucocytes 
cultured in vitro when they were treated with various hormones, which probably 
implies that there was no direct effect of these agents on cell division. It therefore 
seemed likely that the increase in triploidy from the women taking oral contraceptives 
was due to an indirect effect on germ cell maturation or on the timing of fertilisation.
In a recent study undertaken in the Marie Curie Laboratories, leucocytes from 
the blood of babies and their mothers, some of whom had taken an oral contraceptive 
and some who had not, were cultured for 3 days, harvested, preparations made and 
25 chromosome spreads counted. Altogether 940 subjects (mothers and babies) were 
studied in the survey, and nearly two thousand cells were counted from mothers who 
had “been on the pill” ; two thousand more were from control mothers and a thousand 
more from the babies’ blood cultures (test and control). A comparison of abnormali­
ties in the cells showed that 2.16% have more than 46 chromosomes in test mothers 
compared to 2.45% in control mothers; and in babies there was 1.79% abnormal 
cells in test babies compared to 1.97 % in control babies. Thus no significant differen­
ces were found. Other abnormalities studied were structural alterations including 
gaps, breaks and rearrangements of chromosomes, and again, no significant differen­
ces were found between the test and control groups.
Acetylsalicyclic acid. J a r v ik  a n d  K a t o 32 investigating the chromosome break­
ing effects of aspirin, have shown that this drug produced a significantly high percen­
tage of breaks in human leucocyte cultures, but this work has not been substantiated 
by M a u e r  and his colleagues33. Obviously with a commonly used drug like aspirin, 
a great deal more work is required.
Diazepam. This tranquilizer/muscle relaxant has been studied by N ie ls e n  
et al.34', who performed chromosome analyses on the leucocytes of 23 patients using 
the drug and of 8 controls, by further exposure of the cell cultures to the drug over 
0.5-36 months. One patient showed chromosomal breakage in 15.3% of the cells 
examined, but 6 months after having stopped diazepam the breakage rate returned to 
the control level. These results disagree with those of C o h en  et al.35 who found no 
increase in chromosomal damage in vivo. Similarly S ta ig e r 36 who exposed leucocytes 
to concentrations of 0.5-1 % of the drug, found no evidence to suggest that diazepam 
possesses chromosome breaking properties.
Chlorpromazine, In a study of the chromosomes of leucocyte cultures from
CHROMOSOME DAMAGE INDUCED BY CHEMICALS 383
patients treated with chlorpromazine, or the other psychotropic drugs, perphenazine 
and lysergide, significant inductions of chromosomal abnormalities were seen. 
Patients treated with chlorpromazine (13), perphenazine (15) or lysergide (19) showed 
significant increases in the induction of gaps and breaks and in the frequency of 
hypodiploid cells. The frequency of gaps and breaks showed a correlation with the 
duration of treatment and amount of drug administered for perphenazine but not for 
chlorpromazine. Moreover, with perphenazine and lysergide, but not chlorpromazine,. 
there were significantly higher total frequencies of chromosome fragments, dicentric 
chromosomes and ring chromosomes34.
Chlorimipramine. W ilk ie  a n d  D e lh a n t y 37 added 10 //g/ml of chlorimipramine 
to cell cultures of human skin fibroblasts and found this substance leads to the arrest 
of cell division in metaphase, prevents oxygen uptake and eventually causes cell death. 
The effect of this drug appears to vary with the cell strain used, and S.V.-40 trans­
formed cells are considered to be very sensitive to this compound. However, in in vivo 
studies carried out in the Marie Curie Laboratories no chromosomal abnormalities 
have been observed on treating rats with a derivative of this compound.
Chloramphenicol. This antibiotic, once widely used in the treatment of a wide 
variety of bacterial infections in man and domestic animals, is now restricted in use to 
the treatment of B. typhosum infections because of its high toxicity. Bone marrow 
toxicity of this antibiotic is of particular significance and toxic damage may extend 
to development of marrow aplasia and acute leukaemia. Previous observations38 have 
shown the presence of nuclear and cytoplasmic vacuolations in haemopoietic cells of 
patients on prolonged chloramphenicol therapy. More recently, chromosome breaks 
and fragmentations have been discovered by M itu s  a n d  C o le m a n 39 who carried out 
experiments to determine whether similar lesions could be produced in vitro by this 
drug. Addition of chloramphenicol (10 /ig/ml) to short-term cultures of leucocytes 
produced gaps, breaks, fragments, secondary constrictions, and ring chromosomes, 
with significant differences between controls and tests. The nature of the biochemical 
effect of this drug on bacteria has been studied and levels of 10 /^g/ml inhibit protein 
synthesis by interfering with the attachment of mRNA to ribosomes; a similar effect 
is not apparent in mammalian cells37. The presence of the ring chromosome is of 
interest because it may indicate that chromosomal damage by chloramphenicol is 
liable to produce rearrangements. The development of new abnormal cell lines after 
exposure to this once widely used antibiotic may be of future significance in under­
standing the evolution of neoplasia.
Colchicine. This is an alkaloid still widely used in the treatment of gout and has 
been extensively studied for its chromosomal damaging effects. Addition of colchicine 
(10“ 6 M ) to cultures of 11-day-old chick embryo breast muscle resulted in fragmen­
tation of the elongated myotubules into rounded cytoplasmic sacs containing various 
numbers of nuclei16. Comparison of the dose-response relationship between myotu- 
bule fragmentation and metaphase arrest suggests that the underlying mechanism may 
be similar in both cases. The effects of colchicine on the mitotic spindles of mammalian 
cells can be readily reversed by washing the cells free of drug and then growing them 
in fresh media. This has been shown by K a t o  a n d  Y o sh id a 40 using a Chinese hamster
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cell line with a modal chromosome number of 22; colchicine was added to the cultures 
and cells were washed free of drug 30 min, 2 and 4 h after addition of colchicine. 
Deviation from the modal chromosome number became greater with increasing dura­
tion of the colchicine block and it thus appeared that the damage to the spindle fibres 
was not completely repaired. From studies of the stability of “colchicine-reversal” 
cells with abnormal chromosome numbers it was found that cells with lower chromo- 
. some numbers than controls disappeared rapidly from the population as incubation 
time increased and those with a larger chromosome number persisted rather steadily 
until the end of the cultivation periods. These observations suggest that the viability 
of the cells which suffered chromosome losses was impaired and their survival time 
greatly curtailed.
We have also carried out studies on the induction of chromosomal abnor­
malities by reversal of colchicine inhibition41 using human peripheral blood leucocyte 
cultures12. The test cultures had 71 % of cells with 45 chromosomes or less and there 
was also a marked increase in endo-reduplication (the chromosomes reduplicate 
themselves and can be seen lying side by side). Our observations also support those 
of K a t o  a n d  Y o sh id a 40 in that the colchicine inhibition effect is not completely 
abolished by washing the cells.
Phenylbutazone. In a study of fifty patients who had been taking phenylbutazone, 
a widely used anti-rheumatoid drug, for at least 3 months it was found that the fre­
quency of chromosomal damage in lymphocytes was significantly greater (2.0 %) than 
in controls (0.5%); the frequency of dicentric chromosomes was also increased42. 
Evidence was obtained that the drug does not act directly on DNA, and it is likely 
that individual susceptibility occurs. M u l l e r  a n d  S tr a s s e 43 investigated the effects 
of oral administration of this drug (400 mg/kg) on Chinese hamster bone marrow 
cells; results showed only 1 % of chromosome breakage, with an average of 4.5 chro­
matid gaps per animal in the test group as compared with 3.8 in the controls. In this 
species phenylbutazone only infrequently caused chromatid breaks and chromatid 
gaps. In view of the possible widespread usage of this drug and the equivocal findings 
further long-term studies ought to be undertaken with phenylbutazone, oxyphen- 
butazone and related drugs.
Lithium carbonate, is used in the treatment of manic depression. Cultures of 
leucocytes from patients taking lithium carbonate failed to show a significant dif­
ference from controls in either breaks or hypodiploidy3. However, these results do 
not agree with the findings of F r ie d r ic h  a n d  N ie ls e n 44 who observed chromosomal 
breaks in a patient who had been on the drug for only 2 months.
FOOD CHEMICALS
Caffeine occurs in coffee and tea and so a great number of people are exposed 
to regular dosage with caffeine. It has been suggested that because of its purine nature 
it may have a mutagenic potential, and there is a large amount of conflicting evidence 
of its effects on chromosomes. T h a y e r  and colleagues45 exposed HeLa cells to caf­
feine and found no significant increase in aberrations at a dose of 20 /zg/ml over 29 to
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48 cell divisions. Other workers (L ee S u n g 46 and personal observations) found that 
caffeine caused aberrations both in HeLa cells and other plant and animal cells. 
L ee S u n g 46 carried out studies on the effects of caffeine on human leucocytes and 
human embryonic cells in cultures containing 0.005-0.10% of caffeine. A significant 
increase in chromosomal abnormalities especially chromatid gaps, isochromatid gaps, 
chromatid breaks and acentric fragments were found, but no exchanges were seen. 
K ih lm a n  and others47 treated Vicia faba root tips, tree onions and Chinese hamster 
cells for 2 h with 2 • 10“ 2 M  caffeine and obtained various chromosomal aberrations. 
“Sub-chromatid” and chromatid exchanges were most apparent in the plant cells but 
chromatid breaks were more abundant in the Chinese hamster cells.
Studies were also made by W a lk e r  a n d  R eid 48 who administered caffeine to 
mouse L-cells, previously exposed to UV light, and found that the caffeine potentiated 
the lethal action of UV light. They showed that the action of methyl methanesulpho- 
nate and other alkylating agents on mouse L-cells was increased after subsequent 
incubation in 2 mM  caffeine for 48 h. HeLa cells cultured for 4 weeks in a medium 
supplemented with caffeine-at concentrations some 10 times the maximum levels of 
caffeine ingested by man, showed a significant increase in chromosomal breaks and 
rearrangements49.
K ih lm a n  et al.*1 also exposed the same cells to 8-ethoxycaffeine and found 
that this substance was much more active than caffeine. After exposure to concen­
trations of 10“ 2 M for 45 min many aberrations similar to those produced by caffeine 
were seen in all cell types, and a high proportion of isolocus breaks focalised in the 
nuclear constriction in the Vicia faba root tip cells were also found.
6-Methylcoumarin. K ih lm a n  and others47 further found that 6-methylcoumarin 
in Vicia faba root tip cells, onion tree cells and Chinese hamster produces the same 
sort of chromosomal aberrations as 8-ethoxycaffeine and caffeine.
Cyclamate and other sweeteners. The artificial sweetener, sodium cyclamate, in 
relatively high concentrations produces chromosome breakages in plant cells and in 
human leucocytes. S a x  a n d  S a x 50 and S to n e  et al.51 showed that chromosomal 
breaks in cultures of human leucocyte cultures supplemented with cyclamate (250- 
500 fig/ml) ranged from 0-35 % of the cells, averaging 11 %, whereas for the control 
cultures this was only 0-12% cells; with lower concentrations of cyclamate (50-100 
fig/ml) there was no clear effect on chromosome breaks.
Some work has also been carried out by C a t t a n a c h 52 with cyclohexylamine, 
a metabolite of cyclamate; at concentrations of 50-100 mg/kg cyclohexylamine does 
not induce dominant lethal mutations or chromosomal translocations in rats.
S to n e 51 studied the supplementation of leucocyte cultures with saccharin and 
showed that even at the high concentration of 500 fig/ml there was no evidence for 
chromosome breakage. Again, in a second series of experiments using human skin 
monolayer cultures and varying concentrations of cyclamate, no increase in chromo­
some breaks was found.
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Hydroxylamine
B r o g g e r 53 investigating the effect of this chemical (25-100 /ig/ml) on human 
leucocyte cultures found that it induced chromosomal damage and that the extent of 
the damage was proportional to the dose and length of exposure. A wide range of 
chromosomal damage was observed and the aberrations included isolocus constric­
tions, gaps and breaks.
Trimethylphosphate
This chemical is used in industry as a methylating agent and also as a solvent 
for paints. Work done by A d le r  et al.5A has shown that this chemical produces the 
greatest number of chromosome breaks in rat bone marrow cells after 48 h. After 
12 h chromosomal gaps were prevalent but with longer periods of treatment cells 
with chromatid exchanges became very frequent.
Ethanol
Ethanol at concentrations of 0.2-2 % has been reported to cause breaks in the 
chromosomes of Vicia faba and onion roots55. At a concentration of 1.2% in human 
fibroblast cultures treated for 48 h, the number of chromosome breaks increased about 
five-fold. However, human leucocyte cultures exposed to 0.3% ethanol for 48 h 
showed no significant increase in the number of breaks compared to controls, but 
when the dose is increased to 1.2% the frequency of breaks increased with a corre­
sponding increase in the frequency of gaps.
Benzene
Benzene is a solvent which despite its known toxicity to the bone marrow still 
has widespread use in industry, particularly the rubber industry. The first case of 
leukaemia attributed to benzol vapour was reported in 1928 and many cases have 
been reported subsequently. Benzene is metabolized in the body to phenol via the 
arene oxide, which is probably the radiomimetic toxic entity.
T o u g h  a n d  C o u r t  B r o w n 56 carried out a survey in 1964 and 1965 on men 
exposed to benzene for periods up to 20 years, and examination of blood cultures 
from these men showed that there was an unusual number of cells with chromosomal 
aberrations. F o r n i a n d  M o r e o 57 in 1967 investigated a woman who had been work­
ing with benzene for 22 years and suffering initially from anaemia later developed 
acute myeloblastic leukaemia. Cultures of peripheral blood cells from this subject 
showed a high rate of chromosomal aberrations and many cells with 47 chromosomes 
were found in bone marrow cells. They suggested that cells with different chromo­
some aberrations induced by benzene may give rise to abnormal clones which may in 
turn cause leukaemia. F o r n i a n d  M o r e o 57 in 1969 carried out chromosomal studies 
on a patient suffering from acute erythroleukaemia after having been exposed to 
benzene for 7 years; 2 chromosomes from group G were absent and 2 small marker 
chromosomes were present in all metaphases observed. T o u g h  et al.59 in 1970
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examined the chromosomes of individuals exposed to atmospheric benzene and they 
also found a higher percentage than normal of cells with “unstable” chromosomal 
aberrations. P h ilip s  a n d  J en sen 58 looked at the effects of benzene on rat bone marrow 
cells and found that benzene (2 ml/kg) given subcutaneously produced chromatid 
breaks within 12 h but recovery had occurred 36 h after injection and no breaks were 
then seen.
OTHER ENVIRONMENTAL AGENTS
Pesticides
Captan. This is a general fungicide used for soil treatment, mildews etc., which 
is highly mutagenic in E. coli and other cell cultures. It is also a potent teratogen in 
the chick embryo9.
DDT. This is the most common and one of the most effective of all pesticides, 
and is widely used in most parts of the world in spite of its acknowledged toxicity to 
mammals. It has been shown recently to be mutagenic in rats and in human cell cul­
tures in vitro9. More recently it has been shown also to cause chromosomal damage 
to cultured mammalian cells60.
2,4-Dichlorophenoxyacetic acid (2,4-D). 2,4-D is a plant hormone with herbicidal 
properties which does not appear to have any toxic effect on cultures of pea callus 
below a concentration of 50 mg/161. As the concentration is increased the rate of 
polyploid dividing cells decreased with the age of the culture, and at a higher concen­
tration mitosis in the cells was impaired.
Gases
Chlorine is used to purify water supplies and in various manufacturing proces­
ses62. Addition of chlorine to human lymphocyte cultures at concentrations above 
20 ppm produced an increase in the number of chromosome breaks, gaps, trans­
locations and dicentrics62, but no effects were observed at concentrations below this. 
This concentration is higher than that found in most water supplies although the 
chlorine concentration of water supplies may vary considerably.
Ozone. This is a gas used in certain industrial processes and is found naturally 
in the upper atmosphere. Inhalation of ozone by Chinese hamsters caused chromo­
somal aberrations63 in bone marrow cells and subsequent X-irradiation produced an 
increased number of breaks. Further investigations showed that ozone can be either 
synergistic or antagonistic with other mutagenic agents. Ozone also causes breaks in 
monolayer cultures of human cells, and in view of the fact that there is constant expo­
sure to ozone more extensive work is necessary.
CONCLUSION
The human organism because of its ubiquity, can be said to have adapted itself 
successfully to its environment. Man is found in almost all of the diverse climatic 
conditions which exist on this planet, and his ability to constantly adapt to his
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changing environment has been due mainly to variations in physical traits such as 
pigmentation of skin and hair, and to chemical changes in enzyme activities and 
physiological functions. In the past decade, rapid and dramatic changes of the en­
vironment, imposed by the numerous products of modern chemical technology, have 
further tested man’s ability to adapt and survive. Day by day, everyone, almost 
everywhere is exposed to some pollutant in the air he breathes, the food he eats, or 
the water he drinks. The polar ice, like the fat depots in our own bodies, contains its 
quota of DDT and other environmental contaminants and the fact that some of 
these environmental agents can and do induce mutations and chromosomal aber­
rations has been known to geneticists for the past three decades. The public today is 
exposed to an enormous variety and number of chemicals whose long-term, low-dose 
effects are seldom known and only poorly understood. With regard to their potential 
genetic or chromosomal effect we are best informed about such potentially toxic 
substances as the nitrogen mustards, and other cytotoxic agents which are not widely 
encountered, but we are poorly informed about the effects of less toxic and more 
commonly used compounds, such as aspirin, caffeine and oral contraceptives.
A number of chemical agents have been shown to alter the chemical makeup 
of genes and chromosomes; the alterations may be in the DNA molecule or they may 
involve alterations of the linear structure along the chromosomes, this being a result 
of chromosome breakage and rearrangement. Chemicals may also interfere with cell 
division and may thus alter the chromosomal numbers. Although the molecular 
mechanism of chromosome damage is not precisely known, incorporation of nucleo­
tide analogues into, and alkylation of DNA, intercalation and cross-linking of DNA, 
free-radial formation by ionizing radiation and by radiomimetic chemicals, lysosomal 
damage with release of DNA- and RNA-hydrolases, and impaired synthesis of 
protein, enzymes and coenzymes, have been postulated. In reality, probably all of 
these mechanisms, and others, may be involved with different agents acting by dif­
ferent mechanisms.
The systematic screening of chemicals for mutagenicity has played a significant 
role in establishing the fundamental points of the chromosomal theory of carcino­
genesis1. Aflatoxin has been shown to be teratogenic and carcinogenic in addition to 
being mutagenic9. Cyclamate has been shown to produce bladder cancers in addition 
to producing cytogenetic abnormalities4; and Captan has been characterised as a 
highly mutagenic agent9, as well as being teratogenic. DDT is mutagenic, produces 
tumours in animals and also produces chromosomal abnormalities60.
According to the chromosomal theory of carcinogenesis, chromosomal aber­
rations are the common pathway through which carcinogenic factors induce cancer 
and M i l l e r  a n d  M i l l e r 64 have concluded that many and perhaps all carcinogens 
are mutagens, although not all mutagens are necessarily carcinogenic. The review 
has demonstrated that many exogenous chemicals including medicines, food additives, 
pesticides and industrial and environmental chemicals can cause chromosomal dam­
age. It is then logical to suppose that because of the chromosomal damage caused by 
these chemicals they may be a causal factor in the evolution of the neoplastic growth.
Recently, studies have been undertaken to establish correlations between the
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chromosomal damage produced by carcinogenic chemicals and the molecular aber­
rations that may be involved in the induction of the carcinogenic process. In a study 
of the mutagenic properties of vV-acetyl-2-aminofluorene and its metabolites in 
Drosophila, in relation to the molecular mechanisms of carcinogenesis, F ah m y a n d  
F ah m y65,66 have shown that a subtle correlation exists between the mutagenic 
selectivities and the carcinogenic potential of this series of compounds. The carcino­
genic parent amine, its IV-hydroxylamines and the acetoxy derivative were all initially 
specific for the bobbed (bb) loci, which is in accordance with the concept that the 
rRNA genes might be significant in the initiation of cancer. Mutation at any of the 
RNA-forming cistrons would result in the production of aberrant RNA molecules 
which would then manifest altered efficiencies in the transcriptional and translational 
phases of protein synthesis and thus lead to the metabolic consequences characteristic 
of the neoplastic cell. Although much similar information, concerning the molecular 
effects of carcinogenic chemicals that induce mutations, is available almost nothing 
is known of the molecular effects of environmental chemicals on chromosomal 
material. However, it does not follow that a chemical which is mutagenic and produces 
chromosomal abnormalities is necessarily carcinogenic, although there may be 
similarities in those interactions with DNA which lead either to chromosomal aber­
rations, mutagenicity or carcinogenicity. In short, far from finding a close correlation 
between mutagenesis and the development of cancer, one may conclude that almost 
any chemically reactive compound, if tested by a sufficiently wide range of methods 
is likely to prove mutagenic to some systems. Some agents which are mutagenic to 
bacteria and viruses may not be mutagenic to man and although laboratory mammals 
provide rather better test systems, the results obtained must on all occasions be 
extrapolated to man with great caution. No doubt an enormous amount of work 
needs to be done regarding the relationship of chromosome breaking and the devel­
opment of neoplasia.
The knowledge that certain psychoactive drugs, e.g. LSD, may lead to leukaemia 
and neonatal deformities has exemplified the need for careful screening of drugs for 
possible chromosome-breaking potentialities1. Several of the commonly used 
psychoactive drugs have been shown to produce chromosomal breaks and re-arrange- 
ments, abnormalities that may lead to malignant growth. An even greater potential 
hazard is the possible chromosomal damage of the germ cells and this has been shown 
to occur with LSD67. These mutations will not necessarily lead to clinical manifes­
tation in the carrier, and perhaps not even to effects in all the offspring, but may remain 
latent with the potential for morphological or metabolic aberrations becoming only 
fully apparent in subequent generations.
The past half century has seen substantial increases in both the life-expectancy 
of man and in the number and extent of usage of drugs, food additives, pesticides 
and other environmental chemicals. The successful treatment, both by drugs and diet 
therapy, of many diseases of infection and metabolic origin has resulted in an increase 
in longevity with a simultaneous decrease in the process of natural selection. Mutation- 
induced susceptibility to disease, once largely self-eradicating, is now being conserved 
and even propagated. In addition, we have over the same time period, added to our
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internal and external environments, numerous synthetic chemicals to which man’s 
metabolism has not necessarily been conditioned and adapted, and which may have 
the potential to augment the increasing legacy of mutations of each succeeding gene­
ration. Chromosomal studies and evaluation of mutagenic potential of all new and 
established drugs, food additives and environmental chemicals should therefore be 
integral aspects of the current practices of safety evaluation of these materials, and 
the same stringent principles should be applied to the numerous chemicals met with 
as solvents and intermediates in industrial processes. Persons exposed to high risk, 
such as those working in chemical industries, or patients on continuous chemotherapy, 
should be offered routine chromosomal monitoring, and the appearance of adverse 
effects and abnormalities notified and correlated.
The extent of the induction of mutations by radiation and viruses is reasonably 
known whereas the contribution provided by drugs and environmental chemicals can 
only be conjectured. A recent estimate of the ill-health that is of genetic origin has 
been given by L e d e r b e r g 68 as 25 % of our health-burden. In our advanced civilization 
the financial cost of this health burden is already reaching maximum permissible 
limits, so that there are pressing economic and social reasons, as well as medical 
needs, for limiting, and hopefully reducing, the mutagenic contribution from environ­
mental chemicals.
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